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 Heart disease (HD) is a primary public health concern, with HD being one of the leading causes 
of death every year in the United States. Many risk factors influence HD, including lipid levels, 
and studies have shown that higher levels of plasma high density lipoprotein (HDL) cholesterol 
have a protective effect against HD. Recent genome-wide linkage scans have associated a locus 
on chromosome 7, harboring CD36, as being involved in components of the metabolic 
syndrome, including HDL-C levels.  Therefore, identifying variation in this gene affecting HDL-
C levels is of great public health importance. The “common variant-common disease” hypothesis 
has been tested by a limited number of studies through common SNP genotyping with 
inconsistent results. To date, no studies to our knowledge have evaluated CD36 using the “rare 
variant-common disease” hypothesis. The aim of this study was to further evaluate the role of 
common and rare variation in CD36 by sequencing individuals having extremely low and high 
HDL-cholesterol levels in two populations, U.S. Non-Hispanic Whites (NHWs), and African 
Blacks. In our initial sequence analysis, 343 variants were identified in CD36, 168 of which were 
previously unreported in the SeattleSNPs database. According to preliminary analysis of the 
sequencing data, our findings support the associations of three SNPs with HDL-C levels reported 
in the literature. No striking difference was noticed between the distribution of rare variants 
between high and low HDL-C groups. We identified four common variants (MAF≥5%) in our 
sequencing data from our small sample that displayed statistically significant differences in MAF 
between the low and high HDL-C groups but have not been confirmed yet by genotyping in the 
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entire NHW and Black populations while thirteen common variants had p-values between 5-
10%, which may be statistically significant due to the small sample size. To date, screening data 
was compiled for the entire NHWs and Black samples for a total of nineteen common variants. 
None of these variants displayed a significant p-value in our entire NHW and Black samples. 
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1.0  BACKGROUND AND SIGNIFICANCE 
1.1 CARDIOVASCULAR DISEASE AND CHOLESTEROL LEVELS 
Over 16 million people in the United States are living with coronary heart disease (CHD), with a 
total of 80 million American adults living with one or more types of cardiovascular disease 
(CVD) (Lloyd-Jones et al., 2009). This translates to approximately 1 in 3 American adults living 
with CVD, with the estimated direct and indirect cost of CVD in the U.S for 2009 being $475.3 
billion (Lloyd-Jones et al., 2009). Mortality data from the National Center for Health Statistics 
(NCHS) indicates that CVD was the underlying cause of 1 out of every 2.8 deaths in 2005, and 
CVD has accounted for more deaths than any other major cause of death since 1900, aside from 
the year 1918 (NCHS, 2007). 
 Many risk factors have been identified that influence the risk to develop CHD. These risk 
factors include excessive alcohol consumption, abnormal serum cholesterol levels, body mass 
index, diabetes, smoking, lack of regular physical activity, consumption of less than five servings 
of fruits and vegetables per day, psychosocial index, and hypertension (Lloyd-Jones et al., 2009; 
American Heart Association, 2003). It is important to note that blood pressure and hypertension 
are particularly important factors in black populations because compared to whites, blacks 
develop hypertension earlier in life and their average blood pressures are much higher – resulting 
in a 1.5-times greater risk of CHD death (Lloyd-Jones et al., 2009).  
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 Genetic factors, such as genes influencing lipid metabolism, make a significant impact on 
the lipid profile of an individual. This can result in a risk factor for CHD if the lipid profile is 
abnormal. Studies have shown that family history of a parent or sibling with CVD increases the 
risk of CVD two-fold, and further data has found that anywhere from 50-80% of the variation of 
the lipid profile is under genetic control (Berg et al., 1987; Boes et al., 2009; Lloyd-Jones et al, 
2004; Murabito et al., 2005). This information serves to illustrate the importance of 
understanding the genetic influences on lipid metabolism.  
When considering the lipid profile, cholesterol levels are of particular importance due to 
the fact that the levels of both low-density lipoprotein (LDL) cholesterol and high-density 
lipoprotein (HDL) cholesterol have been found to impact the risk for CVD. According to the 
American Heart Association (2009), total cholesterol should ideally be less than 200mg/dL, with 
200-239 mg/dL being borderline high risk and over 240 mg/dL being high risk. LDL-C levels of 
129 mg/dL and less are considered optimal/near optimal, 130-189 mg/dL are considered 
borderline high/high, and anything above 190 mg/dL is considered very high. When measuring 
HDL-C, the average male range is from 40 to 50 mg/dL and the average female range is from 50 
to 60 mg/dL. Low levels (less than 40 mg/dL for men, less than 50 mg/dL for women) are a risk 
factor for CVD, and HDL-C of 60 mg/dL or higher gives some protection against CVD. 
Data from 2001–2004 showed the serum total crude mean cholesterol level in adults was 
201 mg/dL for men and 203 mg/dL for women, and the age-adjusted prevalence of high LDL 
cholesterol adults from 1999–2004 was 25.3% (Lloyd-Jones et al., 2009). As of 2006 the 
percentages of individuals with high LDL-C were 31% in non-Hispanic white (NHW) males,  
33.7% in NHW females, and 36.2 % in non-Hispanic black (NHB) males, and 27.4% in NHB 
females  (Lloyd-Jones et al., 2009). 
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According to the NCHS, the mean level of HDL-C for American adults from 2005-2006 
was 54.6 mg/dL (Lloyd-Jones et al., 2009). In individuals with HDL-C levels less than 40 
mg/dL, which is a known risk factor for CHD, the percentages was 24.9% for NHW males, 6.5% 
for NHW females, 13.5% for NHB males, and 6.1% for NHB females (Lloyd-Jones et al., 2009). 
It is important to note the difference between the sexes, with males having a significantly higher 
proportion of individuals with low HDL-C compared to females.  
In addition to the evidence supporting the role of a favorable LDL-C level to prevent 
CVD, studies also show the importance of HDL-C levels in influencing CVD and CHD risk in 
both men and women (Boes et al., 2009; Gordon et al., 1977). The Framingham Heart Study 
showed that HDL-C levels are inversely correlated with the risk for CVD, with high levels of 
HDL being preventative against CVD (Castelli et al., 1986). This inverse relationship has been 
quantified, with each 1 mg/dL increase in HDL-C being associated with a 2-3% decrease in the 
risk for developing CVD (Boes et al., 2009; Lewington et al., 2007).  
HDL-C is influenced by a number of environmental factors, which can either raise HDL 
levels or lower them. Factors that are associated with lower HDL-C levels are BMI and smoking. 
Factors that are associated with higher HDL-C levels include physical activity, healthy diet, and 
estrogen (evidenced by the fact that women have higher HDL-C levels than men). In addition to 
environmental factors, the many genes that are involved in the structure, metabolism, and 




1.2 HDL-CHOLESTEROL METABOLISM 
HDL is a mixture of lipoprotein particles that range in density from 1.063-1.21 g/mL based on 
the lipid composition (Tsompanidi et al., 2009). The particle is composed of an esterified 
cholesterol and triglyceride core, surrounded by an ampipathic layer of free cholesterol, 
apolipoproteins, and phospholipids (Boes et al., 2004). The main protein component of HDL is 
apolipoprotein A1 (apoA-1), which is involved in the biogenesis and function of HDL 
(Tsompanidi et al., 2009). Serum HDL-C levels are influenced by a complex set of interactions, 
and variation in the components in these interactions can have a major impact on HDL and its 
properties. Some of these components include apoprotein concentrations; function of enzymes, 
transport proteins, receptors; other lipoproteins and their clearance from plasma (Boes et al., 
2009; Cavelier et al., 2006; Tsompanidi et al., 2009).  
As described above, studies have found that the level of serum HDL-C can act as both a 
protection against and risk factor for CVD. The protective role of HDL-C has yet to be 
completely defined; however, it is clear that HDL-C particles exhibit multiple antiatherogenic 
effects (Kontush and Chapman, 2006). The first hypothesis is that reverse cholesterol transport is 
the bases of these antiatherogenic effects. Reverse cholesterol transport is a process in which 
HDL-C removes cholesterol from peripheral cells (such as macrophages) and delivers this 
cholesterol to the liver or other tissues in need of large amounts of cholesterol. This is an 
important process that relieves the peripheral cells from cholesterol burden and prevents the 
excess accumulation of cholesterol in the arterial wall (Tsompanidi et al., 2009). Reverse 
cholesterol transport is accomplished using three routes (Figure 1). In the first route, large HDL-
C particles with multiple copies of apoE can be taken up by the liver via the LDL-C receptor 
(Bruce et al., 1998). In the second route, accumulated cholesteryl esters from HDL-C are 
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selectively taken up by the liver via the SR-BI receptor that is expressed primarily in the liver 
and steroidogenic tissues (Acton et al., 1996). In the third route, cholesteryl esters are transferred 
by the cholesteryl ester transfer protein (CETP) from HDL-C to triglyceride-rich lipoproteins 




Figure 1. The three pathways of reverse cholesterol transport. Solid lines represent 
cholesterol movement, and dashed lines represent the regeneration of nascent HDL-C from 




Aside from reverse cholesterol transport, there are several other ways in which HDL is 
hypothesized to have antiatherogenic effects. HDL-C has been found to have anti-oxidative 
properties due to associated anti-oxidative enzymes, which provide direct or indirect protection 
against oxidation of LDL-C (Tsompanidi et al., 2009). HDL-C also protects against 
inflammation, a large component in the pathogenesis of atherosclerosis, by expressing anti-
inflammatory activity in different pathways (Boes et al., 2009; Tsompanidi et al., 2009). HDL-C 
has been reported to stimulate the activity of endothelial nitric oxide synthase (eNOS), which 
diminishes endothelial dysfunction that contributes to the development of atherogenesis (Nofer 
et al., 2004). Another property of HDL-C contributing to atheroprotection is its ability to 
stimulate SR-BI-dependent endothelial cell migration, which initiates recruitment of endothelial 
progenitor cells into the intimal layer of the artery at the site of endothelial injury (Tso and 
Martinic, 2009).  
1.3 GENETIC DETERMINANTS OF HDL-CHOLESTEROL LEVELS 
Studies on the heritability of the lipid profile, as well as the heritability of HDL-C itself, estimate 
that HDL-C is under considerable genetic control with heritability estimates of up to 80% (Boes 
et al., 2009). Many of the studies to identify what genetic components were related to HDL-C 
levels were performed using twin studies (which predict heritability of HDL-C to be 50%), 
family studies, and linkage analysis, with 50 genes being associated with HDL-C (Holleboom et 
al., 2008). Studies have also examined the heritability of other portions of the lipid profile, with 
the heritability estimate for LDL-C being ~40% and the heritability for triglycerides being ~36-
80% (Krauss, 2008; Shea et al., 2009). 
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However, the more recent development of genome-wide association (GWA) studies has 
allowed researchers to travel outside the hypothesis-driven search for genetic factors influencing 
the lipid profile, which were often based on limited knowledge of the processes involved in lipid 
metabolism (Boes et al., 2009). These GWA studies allowed the detection of new genes which 
may be involved in lipid metabolism. Prior to 2009, eight GWA studies on HDL-C levels have 
been available (Willer et al., 2008; Kathiresan et al., 2008b; Kooner et al., 2008; Wallace et al., 
2008; Heid et al., 2008; Kathiresan et al., 2007; Aulchenko et al., 2009; Chasman et al., 2008). 
These studies have implicated the following genes in the regulation of HDL-C levels, which had 
already been identified in prior functional and association studies: CETP, LPL, LIPC, LIPG, 
ABCA1, LCAT and the APOA1/C3/A4/A5 gene cluster (Boes et al., 2009). However, these 
association only account for about 8-10% of the variation seen in HDL-C levels, which indicates 
that the majority of the additional genetic factors involved in HDL-C levels have not yet been 
identified (Boes et al., 2009; Willer et al., 2008). Several other genes have been implicated in 
affecting HDL-C levels, including CD36. Since the focus of this study is CD36, the following 
sections provide a brief overview of the molecular, biological, and genetic aspects of CD36.  
1.4 MOLECULAR ASPECTS OF CD36 
The CD36 gene is located at 7q11.2, and consists of 15 exons spanning at least 32 kb (Figure 2) 
(Fernandez-Ruiz et al., 1993; Armesilla and Vega, 1994). The CD36 protein is a cell-surface 
glycoprotein, which is composed of a single polypeptide chain that ranges from 78-88 kDa 
depending on the cell type, which results in a 50 kDa chain after post-translational glycosylation 
at 10 potential N-linked glycosylation sites (Alession et al., 1991; Oquendo et al., 1989; Gruarin 
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et al., 1997). The CD36 glycoprotein is characterized by two hydrophobic transmembrane 
domains spanning amino acids 7-34 and 440-466, with one located at the N-terminus and the 
other located at the C-terminus (Oquendo et al., 1989; Gruarin et al., 1997; Daviet et al., 1995). 
CD36 is also predicted to include two short cystoplasmic tails as well, which extend from amino 
acids 1-6 and 467-472 (Oquendo et al., 1989). The highly glycosylated central hydrophilic 
domain, which is rich in N-glycan acceptor sites and monoclonal antibody epitopes, seems to lie 
extracellularly. However, the exact topology of the molecule is still unclear (Gruarin et al., 1997; 







Figure 2. Physical Map of the CD36 gene from the SeattleSNP database. The legend 
is located at the bottom of the figure, and exons are labeled above. 
 
There are ten cysteine amino acids in the CD36 sequence, with six of them (amino acids 
243, 272, 311, 313, 322 and 333) being clustered in the C-terminal portion of the extracellular 
domain. The remaining four cysteine amino acids are distributed equally at the N-terminus 
(amino acids 3 and 7) and the C-terminus (amino acids 464 and 466) (Gruarin et al., 1997). A 
total of 11 exons (4-13 and part of 14) are thought to encode this extracellular domain, and the 
large number of exons encoding this domain may be a consequence of the multiple interactions 
  1   2                                                                 3                              4          5        6            7                          8      9   10   11  12 13 




in which CD36 seems to be involved (4-20). The large amount of exons encoding the 
extracellular domain also suggests that the polypeptide chain may be organized into discrete 
portions that may act independently or in combination to create independent structural and/or 
functional domains (Armesilla and Vega, 1994).  
The CD36 protein also undergoes posttranslational modification. Intrachain disulphide 
bonds are formed in the endoplasmic reticulum, and these bonds appear to be essential for 
maturation, intracellular transport and structural biogenesis of the protein (Gruarin et al., 1997). 
Palmitoylation also occurs, which involves the covalent, post-translational attachment of the 16-
carbon saturated fatty acid palmitate through a thioester linkage to cysteine residues (Tao et al., 
1996). Four cysteine residues at the very N and C termini of the protein have been identified as 
the sites of palmitoylation. (Tao et al., 1996) The possible role of this lipid modification is in the 
function of CD36 as a lipid receptor, binding oxidized low density lipoprotein (oxLDL), fatty 
acids, and anionic phospholipids (Tao et al., 1996). 
1.5 BIOLOGICAL FUNCTION OF CD36 
CD36 is a class B scavenger receptor that is expressed by erythrocyte precursors, mature 
monocytes, platelets, microvascular endothelial cells, adipose tissue, liver tissue, and mammary 
epithelial cells (Thorne et al., 2000; Greenwalt et al., 1992). It is a receptor for thromposondin, 
collagen, apoptotic cells, P. falciparum-infected red blood cells, and can trigger the activation of 
monocytes and platelets (Endemann et al., 1993; Xiaowei et al., 2004).  
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CD36 is also known to act as a receptor for fatty acids (FA), LDL-C, HDL-C, and very 
low density lipoprotein (VLDL) (Calvo et al., 1998). CD36 has been identified as possibly being 
involved in scavenging OxLDL from the blood via Kuppfer cells in the liver (Endemann et al., 
1993).  Because CD36 has been found to be an OxLDL receptor that likely mediates a response 
in the initial stages of lipoprotein oxidation, CD36 may be implicated in atherogenesis due to its 
possible involvement in foam cell formation (Endemann et al., 2007). CD36 may also be 
involved in processes that result in the differentiation of monocytes and the accumulation and 
adhesion of macrophages, monocytes, endothelial cells, and platelets in atherosclerotic lesions 
(Nagy et al., 1998; Tontonoz et al., 1998; Masuda and Ross, 1990; Endemenn et al., 1993). Due 
to these properties of CD36, it has been hypothesized that a reduction in CD36 activity is 
protective against atherosclerosis.  
However, despite this hypothesis that CD36 may be protective against CVD, other 
research has linked CD36 to alterations in the lipid profile that have the potential to increase 
CVD risk. Studies have shown the common haplotypes in CD36 are associated with 
abnormalities in serum FA and triglyceride (TG) levels, and an increased risk for CAD (Ma et 
al., 2004).  Miyaoka et al. (2001) showed that complete CD36 deficiency may be associated with 
an abnormal lipid profile, including elevated fasting plasma TG and LDL-C levels, in 
combination with reduced HDL-C levels (Miyaoka et al., 2001 and Yanai et al., 2000). CD36 
activity has also been shown to correlate with HDL-C levels. Madden et al. (2008) showed that 
common CD36 polymorphisms impact HDL-C levels after fish oil supplementation, while Love-
Gregory et al. (2008) linked SNPs in the CD36 gene with HDL-C concentrations. 
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Physiological studies of CD36 have also implicated the gene in metabolic syndrome and 
diabetes. Love-Gregory et al. (2008) found that certain variants in the CD36 gene are associated 
with metabolic syndrome, a cluster of risk factors that increase susceptibility to CVD and type 2 
diabetes. In a Dutch population, a promoter SNP was more common in subjects who had 
diabetes, and other studies have linked CD36 with diabetes, insulin resistance, and low 
adiponectin in diabetic subjects (Corpeleijn et al., 2006; Leprêtre et.al, 2004).  
1.6 CD36 POLYMORPHISMS  
A total of 187 variants in the CD36 gene have been reported and are summarized in the Seattle 
SNP Database for populations of African (n=24) and European (n=23) descent. Twenty of these 
are insertion/deletion polymorphisms and 167 are substitutions, with 5 exonic and 182 intronic. 
Of these variants, 167 are present in the African population and 80 are present in the European 
population. The African population has 70 SNPs with a minor allele frequency less than 5% 
(MAF<5%), and the European population has 19 SNPs with a MAF<5%.  
Gelhaus et. al (2001) sequenced CD36 in 12 individuals from West Africa and identified 
24 variants, 21 of them being novel. They identified 5 variants in the promoter region of the gene 
( -220A>G, -144G>T, -53G>T, -50G>T, -2A>C), 12 variants in exonic regions (158C>A, 
656G>A, 809A>G, 985_986insAAT, 1101T>C, 1264T>G, 1712_1715delAGTA, 1910G>T, 
1934A>G, 2065C>T, 2512A>C, 2549G>A), and 7 variants in intronic regions 
(990+7_8insAGTA, 1107+29_30CT>TC, 1296-119T>C, 1414-13C>A, 1415-150A>C, 1489-
121A>T, 1489-5_6insAT).  These variants included three single-nucleotide substitutions causing 
non-conservative amino acid exchanges E123K, T174A, and I271T, and the E123K variant was 
 12 
located within the putative ligand-binding domain for oxidized low density lipoprotein, while the 
other substitutions resided outside any of the binding sites for reaction partners mapped on CD36 
so far. They also found a three base pair insertion resulting in the addition of an asparagine 
residue (N232-233ins). Five additional SNPs were located in the promoter region, with -144G--
>T, -53G-->T, and -2A-->G altering putative binding sites for the transcription factors purine 
factor (PuF), phorbol ester-responsive element AP-2, and CCAAT/enhancer-binding protein. A 
G-->T exchange at position -50 appears to introduce a new recognition site for PuF (Gelhaus et 
al., 2001) 
1.7 CD36 GENOTYPE ASSOCIATIONS WITH PLASMA HDL-CHOLESTEROL 
To date, GWA studies have not identified CD36 as a major gene associated with HDL levels. 
However, several genomewide linkage scans have linked a region of chromosome 7 (7q11.2–
7q21.11) with components of the MetS, including insulin resistance and dyslipidemia (Love-
Gregory et al., 2008). This region harbors the CD36 gene, which has prompted researchers to 
further investigate the relationship of common SNPs and haplotypes with the lipid profile and 
other components of MetS (Love-Gregory et al., 2008; Madden et al., 2008; Goyenechea et al., 
2008; Ma et al., 2004).  
To our knowledge, four studies have examined the association of CD36 SNPs with 
plasma HDL-C levels in non-diabetic Caucasians, healthy middle-aged male, African American, 
and Spanish populations. These studies examined 42 SNPs, and several SNPs revealed an 
association with HDL-C levels. Table 1 summarizes these associations with HDL-C and the p-
value identified, and information from these studies on associations with LDL-C and TG levels 
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is included as well. These studies only examined a select set of SNPs and did not examine the 
entire genetic variation of the CD36 gene in relationship to plasma lipid levels, which is why we 
undertook this comprehensive study. 
 







Total chol LDL-C HDL-C TG 
rs3211849 Love-Gregory (2008)   0.029  
rs3211913 Love-Gregory (2008)   0.039  
rs13246513 Love-Gregory (2008)   0.038  
rs3173798 Love-Gregory (2008)   0.033  
rs3211870 Love-Gregory (2008)   0.0079  
rs3211842 Love-Gregory (2008)   0.00074  
rs9784998 Love-Gregory (2008)   0.015  
rs3211810 Love-Gregory (2008)   0.044  
rs3211868 Love-Gregory (2008)   0.011  
-31118 Madden (2008)  <0.05 <0.05  
25444 Madden (2008)   <0.01  
30294 Madden (2008)   <0.01  
-33137 Madden (2008)   <0.001  







rs2151916 Goyenechea (2008)  0.03 0.02 0.01  
rs3211938 Love-Gregory (2008)   > 0.0002 0 .006 
rs10499859 Love-Gregory (2008)   0.00028  
rs13438282 Love-Gregory (2008)   0.0038  
rs1358337 Love-Gregory (2008)   0.00066  
rs1054516 Love-Gregory (2008)   0.003  
rs1049654 Love-Gregory (2008)   0.0028  
rs3211909 Love-Gregory (2008)   0.022  
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1.8 SPECIFIC AIMS 
Due to the importance of HDL-C to cardiovascular health and CHD, determining the sequence 
variation in the CD36 gene that affect HDL-C levels in the general population would increase 
our understanding of HDL-C levels and increase our ability to detect and predict individuals at 
an increased risk for CHD based on HDL-C levels. The objective of this study was to evaluate 
the genetic variation in the CD36 gene in relation to HDL-C levels in two well-characterized 
samples of 788 African blacks from Benin City, Nigeria and 624 U.S. Non-Hispanic Whites 
(NHWs) from Colorado. Sequencing of the CD36 gene in individuals from our population with 
extreme HDL-C levels (upper and lower fifth percentiles) will allow to test the “common trait-
rare variant” hypothesis, while screening common tagSNPs in our entire population will allow us 
to test the “common trait- common variant” hypothesis. 
1.8.1 Aim 1 
Resequence the CD36 gene in individuals with HDL-C in the upper 5th percentile (47 NHWs 
and 48 Blacks) and in the lower 5th percentile (48 NHWs and 47 Blacks) to identify common 
and rare variants.  
1.8.2 Aim 2 
Screen common CD36 tagSNPs in the entire NHW and Black population (individuals with 
varying levels of HDL-cholesterol) in order to determine the distribution of common variants 
throughout our population.  
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1.8.3 Aim 3 
Determine the association of both the rare and common CD36 variants identified in Aim 1 and 
Aim 2 with plasma HDL-C levels in our NHW and Blacks populations.  
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2.0  SUBJECTS AND METHODS 
2.1 SUBJECTS 
2.1.1 Study Samples 
Samples from the Non-Hispanic White (NHW) population were taken from the San Luis Valley 
Southern Colorado Diabetes Study. All subjects who were included in the current study were 
normoglycemic, and a more thorough description of the population can be found in Rewers et al. 
(1993) and Hamman et al. (1989). Samples from the African Black population were recruited in 
Benin City, Nigeria as a part of a study on CHD risk factors in Blacks. Subjects from Benin City 
were recruited from Junior and Senior staff in government (representing different salary grades). 
Demographic and health information was gathered from participants, and this detailed 
information about the study population can be found in Bunker et al. (1995, 1996).  
In order to measure the fasting total serum cholesterol, the esterase-oxidase method was 
used, and then HDL-C was determined enzymatically after dextran sulfate magnesium 
precipitation (Harris et al., 1998; Richmond et al., 1973). Table 2 summarizes the population 
characteristic data for the subjects used in this study. The DNA used for sequencing and TaqMan 
genotyping was extracted from clot sample (Blacks) and from buffy coat (NHWs) using standard 
DNA extraction procedures. 
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Table 2. Population characteristic data (mean SD) of entire NHW and Black 
populations (Harris et al., 1998) 
 
                                     
Variable    
        NHW (n=623)   
                                                       
        Men                Women 
                   Blacks (n=788) 
 
Men               Women 
Age (years)  
52.9 ± 0.6 
 













BMI (kg/m2)  
26.2 ± 0.20 
 
24.8 ± 0.2 
 










104.7 ± 0.1 
 




43.9 ± 0.6 
 
56.3 ± 0.7 
 
45.9 ± 0.6 
 




147.6 ± 4.1 
 
128.2 ± 2.9 
 
77.8 ± 1.7 
 




213.7 ± 2.2 
 
217.7 ± 2.1 
 
167.1 ± 1.6 
 









2.1.2 Subset of the Study Population used for Sequencing 
Subjects with serum HDL-C in the upper 5th percentile (47 NHW and 48 Black) and in the lower 
5th percentile (48 NHW and 47 Black) were selected to be screened for common and rare 
variants by re-sequencing of DNA samples for the entire CD36 gene. Of 95 NHW individuals, 
47 were females (23 with high HDL-C levels and 24 with low HDL-C levels) and 48 were males 
(24 with high HDL-C levels and 24 with low HDL-C levels). Of 95 Black individuals, 48 were 
females (24 with high HDL-C levels and 24 with low HDL-C levels) and 47 were males (24 with 
high HDL-C levels and 23 with low HDL-C levels). Table 3 shows a summary of the population 
characteristics including age, gender, BMI, LDL-C, HDL-C, total cholesterol, and triglyceride 
levels in NHWs and Blacks for both high HDL-C and low HDL-C subgroups.  
Table 3. Population characteristic data (mean SD) of Black and NHW samples used 
for DNA sequencing 
 
                                     
Variable    
         NHW (n=95)   
                                                       
High HDL(n=47)    Low HDL(n=48)         p-value  
                   Blacks (n=95) 
 
 High HDL(n=47)      Low HDL(n=48)        p-value 
Age (years)    
  55.45 ± 9.8 
 




  41.26 ± 8.72 
 
  40.87 ± 7.16 
 
       0.8 












BMI (kg/m2)  
23.17 ± 3.17 
 




22.06 ± 4.71 
 






126.84 ± 46.95 
 




112.55 ± 39.75 
 






77.68 ± 13.32 
 




76.05 ± 7.53 
 












61.98 ± 19.85 
 






227.34 ± 51.76 
 










2.2 DNA SEQUENCING 
We used publicly available information from the SeattleSNPs database 
(http://pga.mbt.washington.edu/) to order the M13-tagged sequencing primers which produced 
44 overlapping resequencing amplicons (Table 4). Due to polymerase chain reaction (PCR) 
related technical difficulties, we designed new primers for amplicons 14, 19, and 20 using 
Primer3 software (http://frodo.wi.mit.edu/primer3/). Uppercase letters in Table 4 indicate gene 
specific sequences, and lowercase letters indicate the M-13 sequence. The base pair length of 






































































































































































These amplicons produced a ~30 kb genomic fragment (accession number AY095373) 
harboring the entire CD36 gene as well as ~ 150bp of 5’ flanking region and ~ 1830 bps of 3’ 
flanking region. All amplicons were sequenced in both the forward and reverse directions. The 
PCR reaction and cycling conditions are listed in Table 5. 
 
Table 5. PCR reaction and cycling conditions 
 
PCR Reaction (total volume of 25 µL) 
 
PCR Conditions 
DNA 3.0 µL  
1. 95º C for 5 minutes 
 
2. 95º C for 45 seconds 
 
3. 58-60º C for 45 seconds 
 
4. 72º C for 1 minute 
 
- Repeat steps 2-4 for 40 
cycles 
 
5. 72º C for 10 minutes 
 
6. Cool to 4º C 
dH20 11.75-13.25 µL 
10x BufferGold 2.5 µL 
MgCl2 (25 mM) 1.5-3.0 µL 
dNTPs (1.25 mM) 3.8 µL 
Forward Primer (20 mM) 0.4µL 
Reverse Primer (20 mM) 0.4 µL 
TaqPolymerase (5U/ µL) 0.15 µL 
 
Gel electrophoreses was performed to confirm the successful amplification of PCR 
products prior to sequencing using the Invitrogen™ E-Gel® 96 2% with SYBR® Safe precaste 
gels. For samples that failed in the initial amplification, re-amplification and confirmation was 
performed using regular 2% agarose gels. The amplified samples were sent to a commercial lab 
for automated fluorescence-based cycle sequencing and capillary electrophoresis on ABI 
3730x1DNA Analyzers (Genomic Services of Agencourt Bioscience Corporation, Beverly, MD). 
Sequencher version 4.8 (Gene Codes Corporation, Ann Arbor, MI), and Variant Reporter version 
1.0 (Applied Biosystems, Foster City, CA) were used to analyze sequencing data.  
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2.3 GENOTYPING 
Premade Taqman SNP genotyping assays were ordered for 19 SNPs, of which 18 were common 
(MAF≥5%) in at least one population (NHWs or Blacks). The SNPs were primarily selected 
from the list provided in the paper by Love-Gregory et al. (2008) and/or the information 
available through HapMap (www.hapmap.org). We initially ordered only available SNPs in 
order to being genotyping while we waited for sequencing to be completed. Table 6 provides the 
assay IDs of the genotyped SNPs and study samples in which the SNPs were screened. We also 
selected some SNPs located within ~44 kb 5’ further upstream (*) or ~3kb 3’ further downstream 
(**) from our targeted region for sequencing, corresponding to the largest CD36 sequence 
available in Genbank (NC_000007.13) that harbors additional alternative noncoding exons. 
Figure 3 shows the full size of the CD36 gene, showing the targeted region for sequencing in our 
study and the areas not sequenced in our study but containing TaqMan SNPS that were 

















Location Assay ID Population 
rs3211822 3157 Pre-Made Intron C__30605020_10 Both 
rs3211842 7167 Pre-Made Intron C__26572331_10 Both 
rs3211881 13094 Pre-Made Intron C___1803783_10 Both 
rs1924 15932 Pre-Made Intron C__26572328_10 Both 
rs3211908 18463 Pre-Made Intron C__31374621_10 Both 
rs3173804 24426 Pre-Made Intron C___1803772_10 Both 
rs1527483 26076 Pre-Made Intron C___8315330_10 Both 
rs1405747 26512 Pre-Made Intron C__22275240_10 Both 
rs3211956 28375 Pre-Made Intron C__27519229_10 Both 
rs1334511  Pre-Made Intron* C___8314966_10 Both 
rs1537593  Pre-Made Intron* C___1803815_10 Both 
rs9641866  Pre-Made Intron C__30118565_10 Both 
rs1194182  Pre-Made Exon* C___8315074_10 Both 
rs17154155  Pre-Made Intron* C___1803841_10 Both 
rs10499858  Pre-Made Intron* C__29685580_20 Blacks 
rs1049654  Pre-Made Exon* C___8314408_1_ Both 
rs1194181  Pre-Made Intron* C___8315073_20 Both 
rs4731642  Pre-Made Intron* C__28030011_10 NHW 








Figure 3. CD36 and its splice forms 
Targeted region for sequencing 
Region not targeted for 
 sequencing, but containing 
 genotyped SNPs 
 
The entire CD36 gene 
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2.3.1 Taqman Analysis 
Genotyping of the sample populations was done using the TaqMan procedure, which involves 
the amplification of the product and endpoint reading using the ABI Prism 7900HT Sequence 
Detection System (Applied Biosystems). TaqMan Genotyping Master Mix and Assay is added to 
384-well plates containing dried whole genome amplified DNA. The Genotyping Assay contains 
sequence-specific forward and reverse primers, one TaqMan minor groove binder (MGB) probe 
labeled at the 5’ end with VIC dye and one TaqMan MGB probe labeled at the 5’ end with FAM 
dye to detect the alternative alleles. On the 3’ end of the probes, a nonfluorescent quencher 
(NFQ) is attached. PCR amplification is done using a PTC-200 MJThermal Cycler (Biorad) or a 
GeneAmp 9700 (Applied Biosystems), and the endpoint fluorescence reading is done on an ABI 
Prism 7900HT instrument. The cycling conditions are displayed in Table 7. 
 
Table 7. TaqMan thermal cycler conditions 
 
 
TaqMan Reaction (total volume of 5 µL) 
 
PCR Conditions 
dH20 2.74 µL  
1. 95º C for 10 minutes 
 
2. 95º C for 45 seconds 
 
3. 60º C for 1 minute 
     -repeat steps 2-3 49x 
 
 
Master Mix 2.5 µL 




Each TaqMan MGB probe anneals to the target sequence harboring the SNP of interest 
during the annealing step. Then, AmpliTaq Gold DNA polymerase cleaves the probes that 
hybridize to the target sequence. During this process, the reporter dye is separated from the 
quencher dye, releasing fluorescence. Fluorescence is suppressed if probes do not hybridize to 
the target sequence and the reporter dye does not separate from the quencher dye. Because of the 
selective annealing of the TaqMan MGB probes, discrimination of alleles is possible. This 
process is shown in Figure 4. 
 
 




2.4 STATISTICAL METHODS 
Allele frequencies, concordance of genotype distributions with Hardy-Weinberg equilibrium 
(HWE), and linkage disequilibrium (LD) patterns were determined using the Haploview version 
4.1 (http://www.broad.mit.edu/mpg/haploview/). χ2 test was used to compare the allele 
frequencies of the SNPs with a MAF≥5% between high and low HDL -C groups among the 
subjects included in sequencing. For those SNPs that were genotyped in the entire population, 
one-way analysis of variance (ANOVA) was performed separately for males and females within 
the NHW and Black populations to test for the effects of genotypes on the means of HDL-C 
levels. The HDL-C levels were transformed (using either log or square root transformation) to 
reduce the effects of non-normality. The significant covariates were identified using stepwise 
regression in both directions. The R statistical software package (version 2.3.1, http://www.r-
project.org) and Statistical Analysis Software (SAS) were used to perform all computations. Two 
genetic models were used for data analysis, the additive and dominant models. A p-value of less 
than 0.05 under one of these models was considered as suggestive evidence of association.  
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3.0  RESULTS 
3.1 DNA RESEQUENCING 
Resequencing of the CD36 gene from 190 NHW chromosomes (94 in high HDL group and 96 in 
low HDL group) and 190 African black chromosomes (94 in high HDL group and 96 in low 
HDL group) revealed a total of 343 variants. Of those 343 variants, 46 were insertion or 
deletions and the remaining 297 were single nucleotide substitutions. Out of 343 variants 
identified in our study, 1 was located in the promoter region, 305 were located in introns, 18 
were in exons, and 21 were in the 3’ flanking region. Of the 343 variants identified in this study, 
only 175 were previously reported in the SeattleSNPs database. Of the total 343 variants, 131 
were present in NHWs, 281 were present in Blacks, and 69 were shared by both populations. Of 
these shared variants, 8 had not been previously reported in the SeattleSNPs database.  
3.1.1 Non-Hispanic Whites 
A total of 131 variants were identified in the NHWs, of which 78 had been previously reported in 
the SeattleSNP database. 34 of these variants had a MAF>1%, 52 had a MAF of 1-5%, and 44 
had a MAF ≥5%. We identified 119 variants located in introns, 5 variants located in exons, and 7 
variants located in the 3’ flanking region. 15 of the variants were indels, with the number of 
bases affected in NHW ranging from 1-29. Two of these indels are located in exons; however 
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they are located in the 3’UTR and not in coding sequence. Of the other three exonic variants, one 
was located in exon 5 and resulted in a synonymous change, one was located in exon 11 and 
resulted in a glycinevaline change, and one was located in exon 12 and resulted in a 
tyrosinehistidine change. Table 8 is a summary of the CD36 variants identified in our NHW 
population sample, and the given locations are based on the DNA reference sequence provided in 
the SeattleSNPs database (accession number AY095373, total number of exons..13). The refSNP 
ID number is located in the table for those SNPs previously reported in the SeattleSNPs 

































861 T>C rs1527463 Intron 2 
 
0.016 1.000 
1024 A>G rs3211809 Intron 2 
 
0.016 1.000 
2389 delT rs3211815 Intron 2 
 
0.047 1.000 
2521 G>A rs3211816 Intron 2 
 
0.389 0.735 
















3094 G>A rs3211821 Intron 2 
 
0.453 0.946 
3157 G>A rs3211822 Intron 2 
 
0.404 0.753 
3304 C>G rs3212000 Intron 2 
 
0.043 0.288 
3349_3350 insA rs3211823 Intron 2 
 
0.011 1.000 
3691 G>A rs3211825 Intron 2 
 
0.016 1.000 








4134 T>G rs3211828 Intron 2 
 
0.047 1.000 
4249 C>T rs3211830 Intron 2 
 
0.053 1.000 








4648 C>A rs3211834 Intron 2 
 
0.405 0.677 
4990 C>T rs3211838 Intron 2 
 
0.043 1.000 


















7167 G>A rs3211842 Intron 2 
 
0.437 1.000 
7306 G>A rs3212001 Intron 2 
 
0.026 1.000 
7664 G>A rs3212002 Intron 2 
 
0.005 1.000 
7854 A>G rs3211849 Intron 2 
 
0.442 1.000 
7988 A>C rs3211851 Intron 2 
 
0.048 1.000 



















Table 8 Continued 
9473 C>T rs1054516 Intron 2 
 
0.452 0.864 
9534 C>T rs1054517 Intron 2 
 
0.436 1.000 
9600 A>G rs1133344 Intron 2 
 
0.065 0.630 
9616 T>C rs3212003 Intron 2 
 
0.018 1.000 


















10381 T>C rs3173798 Intron 2 
 
0.047 1.000 













11472 C>A rs3211867 Intron 3 
 
0.043 1.000 








11684 T>A rs3211869 Intron 3 
 
0.043 1.000 
11741 C>T rs3211870 Intron 3 
 
0.437 1.000 


















12145 G>A rs3211873 Intron 3 
 
0.039 1.000 
12272_12274 del3 rs3211874 Intron 3 
 
0.379 0.960 








12775 A>G rs3211876 Intron 3 
 
0.026 1.000 
























13528_13530 del3 rs3211882 Intron 3 
 
0.396 0.787 
13577 T>A rs3211883 Intron 3 
 
0.06 0.544 
13936 C>T rs3211885 Intron 3 
 
0.437 1.000 
13973 G>A rs3211886 Intron 3 
 
0.389 0.735 
14299 A>G rs3173799 Intron 3 
 
0.053 1.000 


















15833 C>T rs3212008 Intron 4 
 
0.005 1.000 








































18463 C>T rs3211908 Intron 6 
 
0.032 1.000 













18966 G>A rs3211912 Intron 6 
 
0.016 1.000 
19151 A>G rs3211913 Intron 6 
 
0.01 1.000 
19228 A>C rs3211914 Intron 6 
 
0.042 1.000 































21110 C>T rs3211922 Intron 7 
 
0.016 1.000 
22296 C>G rs3211928 Intron 7 
 
0.437 0.990 
22749 C>T rs3211931 Intron 7 
 
0.426 1.000 








23463 T>C rs3211932 Intron 7 
 
0.426 1.000 
23533 G>A rs3173802 Intron 7 
 
0.426 1.000 
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26076 G>A rs1527483 Intron 10 
 
0.037 1.000 





























28314_28329 del 16 rs3212018 Exon- 3'UTR 
 
0.163 0.487 





















29225 A>G rs3211960 3' flanking 
 
0.426 1.000 














A total of 281 variants were identified in the Black population. Out of these variants, 143 had 
been previously reported in the SeattleSNPs database. 68 of these variants had a MAF<1%, 110 
had a MAF of 1-5%, and 103 had a MAF ≥5%. We identified 1 variant located in the 5’ flanking 
region, 250 variants located in introns, 13 variants located in exons, and 18 variants located in 
the 3’ flanking region. 43 of the variants were indels, with the number of bases affected in 
Blacks ranging from 1-665. Four of these indels are located in exons; one of them is located in 
exon 3 and causes a frameshift, one causes a deletion of exon 4, and the other two are located in 
the 3’UTR and not in coding sequence. The following is a list of the remaining nine exonic 
variants: tryptophanstop codon in exon 3, tyrosinestop codon in exon 5, tyrosinestop 
codon in exon 9, cysteinephenylalanine in exon 9, tyrosineaspartic acid in exon 10, 
tyrosinephenylalanine in exon 10, argininetryptophan in exon 11, and two substitutions 
located in the non-coding 3’ UTR region. Table 9 is a summary of the CD36 variants identified 
in our Black population sample, and the given locations are based on the DNA reference 
sequence provided in the SeattleSNPs database (accession number AY095373, total number of 
exons..13). The refSNP ID number is located in the table for those SNPs previously reported in 







Table 9. CD36 Variants identified in our study for the Black population 
 
CD36 
Variant Base Change 
refSNP 
ID Location Amino Acid Change MAF 
HWE  
(p-value) 





















1021 T>C rs3211808 Intron 2 
 
0.068 0.609 





























2162 A>G rs3211812 Intron 2 
 
0.058 0.528 








2306 A>G rs3211814 Intron 2 
 
0.037 1.000 
2389 delT rs3211815 Intron 2 
 
0.205 0.819 
2521 G>A rs3211816 Intron 2 
 
0.100 0.737 
2638 T>G rs3211817 Intron 2 
 
0.105 0.655 





















3094 A>G rs3211821 Intron 2 
 
0.295 1.000 
3157 G>A rs3211822 Intron 2 
 
0.400 1.000 
3350 delA rs3211823 Intron 2 
 
0.196 0.028 







































4134 T>G rs3211828 Intron 2 
 
0.221 0.050 
4249 C>T rs3211830 Intron 2 
 
0.116 0.506 














Table 9 Continued 
4366 A>T rs997906 Intron 2 
 
0.095 0.823 
4648 C>A rs3211834 Intron 2 
 
0.305 1.000 
4752 C>A rs3211835 Intron 2 
 
0.016 1.000 
4879 G>C rs3211836 Intron 2 
 
0.094 0.869 
4990 C>T rs3211838 Intron 2 
 
0.200 0.164 



























































7167 G>A rs3211842 Intron 2 
 
0.289 0.023 
7175 A>G rs3211843 Intron 2 
 
0.106 0.536 













7430 C>A rs3211845 Intron 2 
 
0.054 0.450 
7486 C>A rs3211846 Intron 2 
 
0.021 1.000 
7663 C>T rs3211848 Intron 2 
 
0.038 1.000 
7854 A>G rs3211849 Intron 2 
 
0.489 0.436 
7947 G>A rs3211850 Intron 2 
 
0.063 1.000 
7988 A>C rs3211851 Intron 2 
 
0.191 0.196 


















8583 C>T rs3211854 Intron 2 
 
0.043 1.000 
8595 T>A rs3211855 Intron 2 
 
0.210 0.777 


























9473 T>C rs1054516 Intron 2 
 
0.277 0.192 
9474 G>A rs3211858 Intron 2 
 
0.056 1.000 
9505 T>A rs3211859 Intron 2 
 
0.054 1.000 
9534 C>T rs1054517 Intron 2 
 
0.261 0.139 



































10381 T>C rs3173798 Intron 2 
 
0.189 0.204 
10423_10424 del2 rs3211861 Exon 3 Frameshift 0.016 1.000 
10465 G>A 
 
Exon 3 (Nonsense) 
Tryptophan> 














11137 delG rs3211865 Intron 3 
 
0.069 1.000 
11155 C>T rs3211866 Intron 3 
 
0.021 1.000 
11472 C>A rs3211867 Intron 3 
 
0.300 0.143 








11684 T>A rs3211869 Intron 3 
 
0.188 0.230 
11741 C>T rs3211870 Intron 3 
 
0.371 0.601 


























12145 G>A rs3211873 Intron 3 
 
0.162 0.745 
12272_12274 del3 rs3211874 Intron 3 
 
0.090 1.000 


















12919 G>A rs1358337 Intron 3 
 
0.463 0.532 
12998 C>A rs3211878 Intron 3 
 
0.058 0.528 
13094 T>A rs3211879 Intron 3 
 
0.058 1.000 
13346 T>C rs3211880 Intron 3 
 
0.034 1.000 
















13577 A>T rs3211883 Intron 3 
 
0.363 0.284 
13758 T>C rs3211884 Intron 3 
 
0.060 0.544 
13936 C>T rs3211885 Intron 3 
 
0.311 0.082 








14076 G>A rs3211887 Intron 3 
 
0.011 1.000 
14081 C>A rs3211888 Intron 3 
 
0.058 0.528 
14190 T>C rs3211889 Intron 3 
 
0.016 1.000 
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14455 A>T rs3173800 Intron 3 
 
0.105 0.655 










Intron 3-Intron 4 Del Exon 4 0.005 1.000 
14882 T>C rs3211891 Intron 3 
 
0.063 0.619 
14903 G>A rs3211892 Intron 3 
 
0.321 0.582 























15932 G>A rs1924 Intron 4 
 
0.237 1.000 
15975 A>G rs3211895 Intron 4 
 
0.068 0.712 
















16565 T>G rs3211898 Intron 4 
 
0.011 1.000 










Exon 5  
(Nonsense) 
Tyrosine> 
Stop 0.011 1.000 





















17462 delT rs3211904 Intron 5 
 
0.042 1.000 
17743 A>G rs3211905 Intron 5 
 
0.080 1.000 













18364_18367 del4 rs3211907 Intron 6 
 
0.042 1.000 







































18911 T>G rs3211911 Intron 6 
 
0.084 1.000 
18966 G>A rs3211912 Intron 6 
 
0.011 1.000 









































































































21891 G>A rs3211926 Intron 7 
 
0.011 1.000 








22296 C>G rs3211928 Intron 7 
 
0.174 0.875 
22338 A>G rs3211929 Intron 7 
 
0.011 1.000 































23463 T>C rs3211932 Intron 7 
 
0.165 1.000 
23533 G>A rs3173802 Intron 7 
 
0.069 1.000 


















24165 C>T rs3211933 Intron 8 
 
0.033 0.163 
24166 G>A rs3211934 Intron 8 
 
0.054 1.000 
24186 C>G rs3211935 Intron 8 
 
0.011 1.000 
24426 T>A rs3173804 Intron 8 
 
0.168 0.973 


















25025 T>G rs3211938 















Phenylalanine 0.005 1.000 








25550 G>A rs3211940 Intron 9 
 
0.037 0.219 
25580 T>C rs3173805 Intron 9 
 
0.060 1.000 














Phenylalanine 0.016 1.000 








26076 G>A rs1527483 Intron 10 
 
0.011 1.000 
















26305 G>A rs3211946 Intron 10 
 
0.011 1.000 


























26776 T>C rs3211949 Intron 11 
 
0.011 1.000 
26927 A>G rs3211951 Intron 11 
 
0.016 1.000 
26948_26984 del37 rs3211950 Intron 11 
 
0.011 1.000 
27003 C>T rs3211952 Intron 11 
 
0.111 0.614 

























Exon- 3' UTR 
 
0.016 1.000 
28302 A>G rs8956 Exon- 3' UTR 
 
0.037 1.000 
28314_28329 del16 rs3212018 Exon- 3' UTR 
 
0.037 1.000 













































Table 9 Continued 




















































3.1.3 CD36 Annotated Sequence  
Figure 5 depicts the variants identified in CD36 within a color FASTA representation of the 
annotated reference sequence adapted from the SeattleSNPs database 
(http://pga.mbt.washington.edu/) and modified by including additional variants identified in our 
study. The variants identified in this study as well as in the SeattleSNPs database are shown in 
black font with the nucleotide change, refSNP ID number, and SeattleSNP database location on 
the right side of the sequence. Variants reported in the SeattleSNPs database but not identified in 
our study are depicted in green font, and those variants identified only in this study are shown in 
red font, of which there are 183. One possible reason for these variants that are unique to either 
the SeattleSNPs database or our study could be that the SeattleSNPs sample was unselected with 
regards to HDL-C levels. The insertions identified only in this study are indicated by the flanking 
bases being highlighted in yellow. Large deletions found only in our study were highlighted in 
light blue. The suspicious variants with low sequence quality are marked with an *. The color 
code used in SeattleSNPs for the reference sequence is as follows: light grey for flanking regions 
and introns, green for UTR, dark blue for exons, purple for repeat regions, and light blue for 
regions not covered for SeattleSNPs database. Among the two large gaps present in the 
SeattleSNPs database, only one was also present in our study (21350-21672). It is important to 
note that our intron/exon numbering differs from the SeattleSNPs numbering after exon 3 due to 
the fact that the SeattleSNPs database separated exon 3 into two separate exons (exon 3 and exon 
4).  It also seems that SeattleSNPs did not highlight an alternative exon, and if we took this 
alternative exon into consideration then all of our exons and introns would be numbered one 
higher (exon 3 would be exon 4, etc.). In general, the literature has inconsistent numbering of 
introns and exons for CD36, and the numbering scheme used would be based on the reference 
 43 
sequence used. The RNA form that seems to be must representative of the exon structure in 
SeattleSNPs is NM_001127443.1. This form includes all 12 coding exons and the non-coding 






















ATGTCTTGCT GTTGATTTGT GAATAAGGTA TCGTAAATAA AACATCTGTT 50  
ACCATACTTG CTTATCATTT AATGGAAAAC ACATCAGTCA ACCCACATTC 100  
TGTTCGCAGG AGAGCTCCAG AAGGGGTGTG GAAGGTTGTG TTGGGTGGAG 150 | [G/T]_rs3211805 (106)  
AAACCAGATA GTGAGGATGC AACTAAGTTG CTGAGACAAG GGAAGAGAGA 200 | Exon 1 | UTR  
TGAGGGTGAG AGTTCTCCTT AGATAAGATT TCAATATGTT AATCATGTGT 250  
AGAAAGAAAA TTAAAAAGGA GGAATATGAA GAAATTCAGA TATGACATTA 300 [GGA/-] (271_273) 
TTAGTTCTGC CACTGGTAGG CATTAGAAGC AAGAAAAGGG AGACGGACCG 350  
AGGAAGCCAC TTTGGTGAAA CAAAAAGAAA AGCATTTGTT TATTTAGAAC 400 [C/T] (400) 
GGGCAAAATG ATACGTTTCA GTGGGTGTTT TCTTTGTACT TTGATCTTTT 450  
TGTACTGATA TTTAAGCTTC TGTTTTATGA TCTCTTTCTA ATGATAGAAC 500 | Exon 2 | UTR  
CAGAGCTTGT AGAAACCACT TTAATCATAT CCAGGAGTTT GCAAGAAACA 550  
GGTGCTTAAC ACTAATTCAC CTCCTGAACA AGAAAAATGG GCTGTGACCG 600  
                                        M   G  C  D  R 5 
GAACTGTGGG CTCATCGCTG GGGCTGTCAT TGGTGCTGTC CTGGCTGTGT 650  
  N  C  G   L  I  A   G  A  V  I   G  A  V   L  A  V   21 
TTGGAGGTAT TCTAATGCCA GTTGGAGACC TGCTTATCCA GAAGACAATT 700  
F  G  G  I   L  M  P   V  G  D   L  L  I  Q   K  T  I  38 
AAAAAGGTAC AAGTAGTCCA AAGAATATGC CTTCTCATTT TGATTGATTC 750  
 K  K                                                  40 
TAACTTCTCT TTTTTTGCTT TGTATTTACC TGCTTTATAT TTCATGGTAA 800 | [C/A]_rs3211806 (757) 
CTGCTAATTT TGTATCTTTG ACATAAAGGT AATTATGAAC CACTGCAACT 850     
CTATATGATG TGACTTTATG TGAAATGTTA TAAGTATAAT GTATATTTAA 900 | [T/C]_rs1527463 (861)  
CATGACTCCA TTGCTGTCTT AAATATAAAT ACCAAATTCT ATTAAAAGCT 950 | [AG/-] (947_948) | [-/A] (949_950) 
GTCTACAGGT ATGCATGTTA GTAGAAATAA TTGTTTTAAG TTATGTCCAA 1000  
AGAGCATGTT GGCATGCTTT TGAATAGGAA ATAAGTGAGT ATATTTTGTA 1050 | [T/C]_rs3211808(1021)| 
[A/G]_rs3211809 (1024)  
AAAGCACATT TATAAAAGAA GTTGCACTTT AGTTAATACT GAGAAAAGTA 1100  
AAACTGTGTG TGTGTGTGTG TGTGTGTGTA ATGTGTTTAA TATTGAAACA 1150 |  
TAAATCCTTA TTAAATTGTA GGTAAACTTG TTTGGTAATA CACTGTTTAG 1200  
TAATCCACTA TTTTTATATA TGTGTAATAA TCTCATCTCA TAAATATTTT 1250  
CTATTTGTGA AGCTTCATAT TGGAATCTTA GAAAATACTT TCAGAAATAT 1300 | [G/A]_rs3211999 (1272)  
GCAGAACATG TCTTAGTATA AAACAAATTG ACTGTAGTGT GAAAAAACAG 1350  
AATGATTGAA TAGATGGGCT TTGCACAACA ACCTAGAATT CATCTCCCAC 1400  
CCTAGCTTAT TCGAATTAGC TACACACTCA CTCATCAGAA ACGTTGATTG 1450  
ATAGGGGGAA GAAGAGAATA AAGGGAAGCA GTTCTGCTGA AGTTCTAAAT 1500 | [G/T] 1466 
CAGGGATGGC AAATTCAAAT GGCTGCAGGA GTTTGGATAC AGGGGTTAAA 1550 | [G/A] 1529 | [T/G]_rs3211810 (1547)  
CAAAATTTAA GGTGCCAAGA ACAAGATAAA ATGAAGAACA GGAACTGCTG 1600  
TGAACTAGAC TGTGTGTTTA CTGCCTGAAG GCATAAATGT TCATTTTATT 1650  
AAACATAATA CTGGCCAAAT AAAACGAGTT CTGCCTTCAA CTCTCTACCT 1700 | [C/A] (1675) 
GGTTAGGATG GCAATGACCT AGACAAAGGG TTAGTAAGCA TAGTGCACGA 1750  
TGGAGAACAG GAGGAATTGA ATTTTTATTA AATTTTTATT GCTATATTGT 1800  
TAGTATTTTT AATATTTTTG ATCCACAGTT GGTTGAATCT GCAGATGTGG 1850 | REPEAT | [T/C]_rs3211811 (1848) 
AACCCATGAA TACAGAGGGC TGACTGTATT GTGTTTATTG CTAACATATT 1900  
GCAGAACTTC AGCCTCATGC ATTTAACTGA AAAAACATAT GTAAATTAGT 1950  
ATCCCCTGCC TTGGAATTCT TAGTTTTCTT GATAGTATTT TTAATACAGG 2000  
CCAATGGAAA CAGACAGGTA ATAGTGAGGT GTGGGGCTTA TCTAATAGTG 2050  
GGATGGAGTG GCCATTGATC TGACATCCTT CCTACTCATA AACTATGTTC 2100 | [A/G] (2092) 
TCACCCAGAT CTTATGCAGA GAAAGTACAA GATCAGTGTC TGTGTTAACG 2150  
TACAGACTAC AACATCATTT GGAAAAGTTT TCCAAATTCA AAAATCACAA 2200 | [A/G]_rs3211812 (2162) 
TAATCTTCCA ATGCACAGCG ATTTAGACTA CTTTTTTTTG CTGACACATA 2250  
ATTATTGGTC AATAACTGAG TATTGATGAT TTAATTTTTT TCTTTGTCAT 2300 | [T/G]_rs3211813 (2273) | [C/A] 
(2298) 
GCAACAAAAC TGGTACATGT AGATTCTTTT GAATAGCATG TGAGGTGCTA 2350 | [A/G]_rs3211814 (2306)  
GCATTTATTT TAATTCTTTA ATATTTATCT TTATGCTTTA TAATAGTTAA 2400 | [T/-]_rs3211815 (2389)  
CCATGAGAAA GTAAGTTTTC TGACATCAAA ATGTGCTTTT GTATAATGAC 2450  
TAAGAGAATA ATATAATCTC ATCTATTGTA AGCTATAACC AGGGGAAGAT 2500  
ATATTATAAT AAAAAATACC GAGACCTATG AGACTCTAGA ATTGAATTGG 2550 | [G/A]_rs3211816 (2521) 
AAAAGTAAAT GCTGTAATAC TTTGAAAGAG AAATCTCTCA GAGTATTCAA 2600  
GAAACTTCAG GAAAAAGGTA GGACTTGATT CAGATTTTAA AGAAGTGTAG 2650 | [T/G]_rs3211817 (2638)  
AATTTTGAAA GTCTCAAATA ACTGCAGTAA CCATATTAAA GGACTGATTG 2700 | [A/C]_rs3211818 (2652) | [A/G] 
(2688) 
ATAGTATGAA AAACCCTGTG AAAATGCTAC CAAATGCAGT GAAGATGGAA 2750 | [T/C] (2702) 
GGAAGAAGGT AGAGAATGTG CCCATAATAC TGGATTAACA GCAGAAAAGA 2800  
TTAGAAGTTA ACATGGGGTT AGAGTTAGGA AGCAAGCTTA GAACATCAGG 2850  
CAGAAAAATA CTTAATTGAT GATACAATAC ACAATAGTCG TCGGTATGTT 2900 | [A/G] (2856) | [G/A]_rs3211819 
(2890)  
TTTCAGCAAG TGTAAGATAT GATAAAACCT GAATTTAGAG ATTAGATGGC 2950  
TAACATTTAA TTCTTACTAA GAGTTTCCTA TATACTAGTT CACTTCATCT 3000 | REPEAT | [C/A]_rs3211820 (2996)  
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TCAAAAATAT CTGTGAGAAG TTGCTGTTAT TTTACTCATC TTACAGGCGC 3050 | [G/A] (3049) 
AAGTCCTTAA ATCAACTTGC CAACTCACCT AGCCAATAGG GAAAGAAGTC 3100 | [C/G] (3079) | [A/G]_rs3211821 
(3094)  
ATTCTCCAAA TGTAAGCAAT CTGTAGGAAG AGCCTAGATG AAAAACCTGG 3150  
CCTTGTGTAC TACTCTACAG CAGAAAGGTT GCAAAGTGAG GATACCAGAG 3200 | [G/A]_rs3211822 (3157)  
ATAGGAAAAC AAACAAACAA AAAACTGTAG GATATGACCA CTTTCAAGGA 3250  
GAATATAAGA TTCCCTTTTA GAAAGATATT TGCATAATCT GCACATTATA 3300  
TAACAAAAGG CACACTGGTC TGGCATGGTT GAGTATATAG AAAAAAAAAA 3350 | [C/G]_rs3212000(3304) | [-
/A]_rs3211823 (3350)  
CTGATAGATA ATAGGATGAA ATGGAAGCTT GGAGAGACAG ATTAAATTAG 3400  
AGGAGTAAAA GCATCAAACT CAAGATGTCC AGTGAGTTAT TGATAGAAGG 3450 | [C/T]_rs3211824 (3412)  
TATGTATATA CCTTACAAAG TAAAACAGAG GTTTTATAAG TGATGTTTTA 3500  
TGAACATCAG TCTGTGTTTC AAAGGTCAGA GTTCAAATAG ATTTGATCAT 3550 | [C/G] (3505) 
TGCTATAAAG ATTAAAAATA AAACTAAACA GTAGATTTAC TTTTAGAGAG 3600  
TTTTAATGGA GAGAGGAAAA AGCAGAAGAA TTATTACAGA ATTTGTAATA 3650  
ATTCAGAGGC AGGAAGACAA AAGTAGAAAA GGAAAAGAAT GATCTTATAT 3700 | [G/A]_rs3211825 (3691)  
GAAGAAACAA ACAAAGAGTA CAATCCTAGA AGTTAATAGG AGGCCAGAAC 3750 | [AA/-]_rs3211826 (3714)  
TCAAGGAAAG AAAGCATAAA ATGTTCTCAG GCAGATGAAA ATTAAGAAAA 3800  
TAATGATTAG AACATGGTCA CCAATAATTT TGAAAGTATA CTTTGAGTAG 3850 | [A/-] (3835) 
GGTAATAAAG AAGGGGGAAT TAAATCAATG GAGTGCTTTT CCTTCTTGTT 3900 | [G/A] (3852) 
TTTGAAATAA GAATTATCCG TGCAATCTTT TACAAGGAAA AGAGAAGATT 3950  
CAGACTTCCT AGTGTAGATT CAAACTCAAG GAGGTGGTAC AACAGAGACT 4000 | [A/C]_rs3211827 (3991)  
CATAAAAACT GTCAAATGAC AGTGCACATT GTAAGCCCCC TACATGTCCA 4050 | [C/T] (4039) | [G/T] (3046) 
TAGACTAAGA CTCATCATCA GAATCCTTAT ATTGGTCAAG ATGTATGGTA 4100  
CATTTAAGGC TAAGCTTCTT TTTGCTCTCA GATTCCTACA CAACCATGTT 4150 | [G/A] (4108) | [T/G] (4133) | 
[T/G]_rs3211828 (4134)  
GACCTTGTTA ATTTAGTCAT ATGAAGTAGG TGGAATATTG TTTGAATAGA 4200 | [G/A]_rs3211829 (4180)  
CTGTTTCTTT TTTCTTCAGT TTACAGACTA TTTTTTAAAT GATATTGGCG 4250 | [C/T]_rs3211830 (4249)  
TATGTATATC TTTGGCATAG AGTAGGAGTC AAATATTTGA ATTTTGTGTA 4300 | [T/C]_rs3211831 (4259) | [C/T] 
(4266) 
AACCTAGAGA GCCAAGTGTC TTACTGCTGC CTCAGAAATA CTTAGAGTAA 4350 | [A/G] (4308) 
TGCTATTTCA CAAACATATG GGTTTTGGTA CTGTTGACTT CTTATTTGTG 4400 | [A/T]_rs997906 (4366)  
TACCATTAAA ACTCATTTAA TATTACTTTG TTTAGCTGAC TAATAGCAAA 4450 | [T/A]_rs3211833 (4423)  
TTAAGAAAGC TATTGTATAC AAGTGATATT TGGAAAAAAA TAATTAAACT 4500  
TCTTAATTGA GAATGATGAG AAAATCATTT CATATTTAGT GTAGAGTTGC 4550  
AGTGCTGTGA TACCTTCCAA TTCTGAAAGA TGTCATTACC ATTTGAAGTA 4600 | [G/A] (4595) 
GTCTAAAACA GTTTAGCAAG CTTATTTGTA CTTTATTTTT GCTCTTTCTT 4650 | [C/A]_rs3211834 (4648)  
TTCAAGGGAT GTCTCTGGTA TCCTCATGCT TTTTATGGAT TATAGCTGCA 4700  
ATCTTTCTTA CCAGTATTTT TGACCGTGAT TCTTAATAGA GTTGTGTGCA 4750  
GCCAGCAAGT TTATGCAGTC TTTCAAAAAA AAAAAAAAAA CTAAAAATCA 4800 | [C/A]_rs3211835 (4752)  
ATAGCAAGAG CTGCCATGAA AGTAGAAACT ACCAAAGCAC TGTGGAAAAG 4850  
GGTCAAAATT CTACCACCAT TTACAAAAGA TAATTTATCA CTTGACATTA 4900 | [G/C]_rs3211836 (4879) 
TTAATGTCAG TTGATAAAAA GTTTAGTGAA TATTGTATAA CATAACATAG 4950 | [A/G]_rs3211837 (4949)  
GTAGTTGTAT GCTAAGCAGA TTAATGCAGG AACAGAAAAC CAAATACCAC 5000 | REPEAT | [C/T]_rs3211838 (4990) | 
[A/G]_rs3211839 (4993)  
ATGTTCTCAC TTGTAAGTAG GAGCTAAATA TTGAATACAC GTGGATATAA 5050  
AGAAGGGAAC AATAGACACC TGGGGCTAAT CGAGGGTGGG AAGGGGGAGG 5100 | [C/T] (5081) 
AGAGCGGAGG ATCAAAAAAC TACCTATCAG GTACTATGCT TATTACCTGC 5150  
GTGAAGAAAT AATCCGTACA CCAAACCTCC ATGACACACA ATTTACCTAT 5200  
ATAACAAACT TGCACATGTA CCTCTGACCC TAAAATAAAA GTTGGAAGAA 5250 | [G/C]_rs3211840 (5241)  
AAAAATAAAA TTTAAATAAG TTCTATAGTT CTAACTATAG AACACCAAAA 5300 | [G/A] (5290) 
AAGGAATTAT AGGTTTCTTT GTTCCTGTTA GAGAACTAAT ATTAAATATC 5350  
ATCATTCAAT TATACCATTT TTCCTTCTCC CATTCTTGAA AACAATGATC 5400  
CTTCTGTAGC TTGTAAGAAA TGCCTTCAGA CAAAATAAAT TGAAATCATG 5450  
ATTCATTAAA ATGGTTATAC ATGGCTGGGC ATGGTGGCTC ATGCCTATAA 5500 | REPEAT [A/G] (5497) 
TCCTAGTACT TCGGGAGGCT GAGACGGGTG GATCACTTGA GCTCAGGAGT 5550 | [T/A] (5504) 
TTGAGACCAG CCTGGGCAAC ATGGCAAAAC CCCATCTCTA CGAATAATAC 5600  
AAAAAAATTA GCTGGATATG GTTACACATG CCTGTAGTCC TAGCTTTTGT 5650  
GGGGCTGAAG TGGGAGGATC CCTTGAGCCC AGGAGGTTGA GGCTGCAGTG 5700  
AGCTAAGGTC GCGCCTCTGT ACTTCAGCCT GGGTGACAAA GTGAGACCCT 5750  
GTCTCCCCCC GCAAAAAATT ATGTTTGAAT TAATAGTCCA TATTTTAAAC 5800  
ATATAATTTG TTTATATTAC CTTTATAATG TATGCTTCTA GTATTTCCAG 5850  
ATATAATAAA ATAATTTGTA CTTTTTCATA GTATCTAAAA GCTCAAAAAT 5900  
AAATGACTAA AAATATTAAA GATGGTAAAG TTTGTTTTAT ATTTAATAAC 5950 | [A/-] (5913)* | [C/T] (5950) 
GTAAGAACAA CCCAAAATAT TTAAATTAAA ATAGCAGTAT AAAAACGAAT 6000  
TAAACACTAT GTATATGTGC ATATAGCTGT AATAACAAAT GTCACTTAAA 6050 | [C/T]_rs3211841 (6007)  
GACAATGTTT CAAGAAATAG ACAAGCATAT ATGTTTCTTC TACTAGTCCA 6100  
ATTTAATATC AACATAGTTT ACTTTTCATG CCAAACACAA CATAGTTTAC 6150 | [T/C] (6146) 
TTTTCATACC ATTTTAGGTA CTTACATAAA TTCTTGGAGG CTAATTTCTA 6200  
GGTTTCAGAA ACATATTAAA GCTTACTACT CCAATACATT TCACCTAATT 6250 | [A/G] (6238) 
TTATTCTGGG TTTTAGTTGA TGATGATGTT CTGAAACTAA AGCCATTTTC 6300  
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AGATTCTCTG CATAACTGTC ACTACAATTC TAATTCATTC TCAACTTACA 6350  
CACACTTGCA TAATGCAAAA ACATTAGAAT TTCTTTTAAC ATGGGGAAAT 6400  
GATTCGTTTT AGGCCCAATT ACAAGCAAAT GGTAGCAGCT AGTGGGAAGG 6450  
ATGGAAGTAT GCTTCTGGTT TTTAAGAAAG TTTTTACTTT ACTAGAAAGA 6500  
GAAATATTAA AATGATTAAA TAACAGAAAA ATAATTGTCA CAGGATATTA 6550  
TATAAGTTAT TGGCACATGA CTGGCTTAGA CAGTAAATGC TATGAACCAA 6600 |  
GCAATTAAAG CAGAATGGAG AAGTAAATGG TATTAGAGTT CTTCCTCTAA 6650 | [G/T] (6638) 
AGGATGGATA GAATTTGTAA AATACTAATA GCTGACATTT ATTGAATGTC 6700 | REPEAT [G/T] (6652) 
TGGTTTGTAC TAACACTGTT CTAAGTGTTC ACGTTTATTG ATCCCCATAA 6750  
CAACCTATGA GGATAAATAT TTAAGCCACA TGAAAATGCC AAAATTCAAC 6800 | REPEAT  
TTTTTTTGAT TTTCAAAAAT ACTAAGTCTA TATGGTTCAA TCTAACATTA 6850 | REPEAT  
CTGTTATAAT TTCACAGATA AGGAAAGTGA GGTACAAAGA AATTAAATAA 6900 | [G/A] (6877) 
TCTGCTCAAA CTTCAATGAT GATGATTATT ATTAAGTGAT CAAACTCATA 6950  
GCATCTAATT TCATTGTTGG CCACTTCAGT CTATGCTTTA GGGAAGAAGC 7000  
CACTATACCT TGTTAGGGTG GGGATAGGGT AAAAAAATCT AACTCGTAGA 7050 | [-/A] (7037_7038) | [G/C] (7046) 
TTAAAATCTG CTAAACATAC TTCTGTCTCT TGGTAGAAAT GTGTAAAGTC 7100  
CTTGAAAAGT GAAACAAAAT ATTTTCTACA TTTGTACTCT ACTCCATGCG 7150  
TAGCAAAGTA TGAAGGGCAT TTTAATAATG AAAGTTGTCA GTTATGTAGA 7200 | [G/A]_rs3211842 (7167)| 
[A/G]_rs3211843 (7175)  
TGATTATTGC TGTTGCATGA AAACAGTATT CAAGTGAGTG CATGACTACA 7250  
TATAGGATAT TAAGGTCCCA ACAAGCATCT GTTTTCAAAT TAATGTAGCA 7300 | [G/T]_rs3211844 (7265)  
GAATAGAAGT TTCAAGGTCA GTGCTTTCAA CCCAGCTATA GAACATGCTA 7350 | [G/A]_rs3212001 (7306)  
TGTGAGAGTC ACCAGGTTGA AATCCAGTTG TTGTTGGGGC TTGGTAGTCT 7400 | [T/A] (7351) 
GCATGCTTAG AGTCAGGGAC AAATACACAC ATACACATTA GCCAAGTGAG 7450 | [C/T] (7414)| [C/A]_rs3211845 
(7430)  
AAAATCTTAT ATCACTTTTT CTGTGTACAT ACTTACCAGC TTTGTACTTC 7500 | [C/A]_rs3211846 (7486)  
AAATTTAGTA AAATATTTGC AAAATAGTCT AGACAGTCCA AATTCAATTT 7550  
AAAATCAAGT TCTTTTAAAT TCACAAAGGA CATAACATCT TTTGTTTCTT 7600  
GTGACATATT TAGTCTTGGT ATTCAAGGAG TGACTACAAT TTAATACATA 7650  
TAGTAGTGGT AGCGTCAGAA GCATATTATT ACTACTTCGA CTACTTCAAT 7700 | [G/C]_rs3211847 (7662) | 
[C/T]_rs3211848 (7663) | [G/A]_rs3212002 (7664)  
ATTTTTCTCT ATGTCTCTAA ACAAATCATG ATGCTATGGA AACTATATAA 7750  
AATTGAAGTG AAAGGACCTG ATTTTTCTAT TATCTGCTAG TAAATTTGTC 7800 | REPEAT  
ACATAACATT GAGTCAGACA TCTCTTTTCT CTAGAACCCA TTTTCCACCT 7850  
CTAGAAAAAT GGACGGGGTT AGATAGTCCT GATTCTAACA GTTGATAATT 7900 | [G/A]_rs3211849 (7854)  
CAACACATTC ATTTCAACCC TGTGTTTCAC GTTTGCCTTA TTTGTCGCTA 7950 | [G/A]_rs3211850 (7947)  
GAGATATTTT TTAAGGGAAA AGTGATTTGT GGCCTTTAGA AAAAAAGGTC 8000 | [A/C]_rs3211851 (7988)  
TCATACACGT ACAATGTCTT TTGGTGTTTA GATGGACACT CATTGTAGAG 8050  
TTAGGAAGGC ATTCAATCCT GTCAAGCACA TTCTGTCACA GACTCTCTTC 8100  
AATTCTATAA GAGTTTGTTG AGTTTCTTTC ATTAAGAGAT ATTAGGTCGG 8150 | REPEAT  
TGCAAAAGTA ATTGTGATTT TTGTCATTAA AATCGCAAAA ACCGTAATTA 8200 | [G/A]_rs3211852 (8152)  
CTTGTGTACA AACCTAATAT GTACCTTGAG AGGCACTTGA TGAATAACAG 8250 | [G/A] (8228) 
GTATTGTTTT TGAGCATTAA GATTCTAATA GTGTGAGGAG AATAATGTTT 8300  
GTGTTTGTGT GTTCTCCCTT GTTAAGTCTC TTGAAATGGA GAAATCAACC 8350  
GTTTTCAGCT TCTATTTAGC TTTGAGCTTC AACATCCTCA CCAAACATAT 8400  
TTACATTTAG AAGAATATCC ATAATGCTTT AAGCAATTTT GTCTTAATAT 8450 | [A/T] (8414)* | [G/T]_rs3211853 
(8426) | [C/A] (8427)* 
TAGACTTAGT ATGGAAATAA GCCTTTTTGG GAGCAAATAA AAAGTTTTTC 8500  
AAGGACAATT TGTTGTAAAA AGTAATAAAG ATTCCATCAC TCTAGCAGGT 8550  
CCAATGTACC CCGTATAAGT GGATTACAGC AGCGTAGGAT TTTGTAATTC 8600 | [C/T]_rs3211854 (8583) | 
[T/A]_rs3211855 (8595)  
CATTTTAACT TGGTGCCCAG TTCTTCTCTA AGGAATTCGC TTATTCCCTA 8650 | [G/A] (8639)* 
CATTAAGCAA TAAGTAAAAT ATCATGAAGA TATGAAACTT AATTTGACTT 8700  
CTACCAACTA AGTGCAGAGG GTGACGGAAA AAAAAAAAAA AAAGACAGTC 8750 |  
ATAGCATGGT GTAAAGGAGG ACTAGTCTAA GGGTCATGGA TGAGGATTTT 8800 | REPEAT | [A/G]_rs3211856 (8796)  
TGTCATGAAT TCACTACTGT TTGCCTAGGC TGTCCTTGGG CCAGCCACCT 8850  
GGTTTCTCAG AGCCTCAGTG TGATCCACTG GAAAATGTGA TCATGTTCAA 8900 | [A/G] (8873) 
TGTCCTTTCC TAATCTGTCA TTCTGTGAAG TGGTGCTTCC AGGTCAAGGA 8950  
AACAAATAGG TCAGAATGTT CCTGTGGTCA TTGTTCTCTT TAGGCTCATT 9000  
TTCCATGAAA TAGTTGTATT CCTCTTCCTG TAGCACACTC AGGTTAAGTT 9050 | [T/A] (9045)  
GGAGCTCTTT AACCTGGGCA TTCTTCCCAA TACTTCATTA GAAATACCGC 9100  
CTGCTTCAAA ATCACCTTTG TTTGCACTAT CTACTACAGC GTAATAGACT 9150 | [T/G] (9117)| [A/T] (9136) 
TCTGGCTCAG AGAGTGAAAG CTGTGGAAGA AAACTAGAAG AATATTTATG 9200 | [C/-]_rs3211857 (9152) | REPEAT  
TTAACTCCCT TATTTTACAG CTAATGAAGT TGACCCTAGG GAGGTTTGAT 9250  
GACTCTCCAC CCAGTCCCAA AGCTCCTAAA GCAAGGAATC GAGTTCCTAA 9300 | [G/A] (9291)* 
TGTAGGATTT TTAATTCTCT TATTGGTGTA TTTTCCACTT GTCTATCTTT 9350 | [C/G] (9347) 
ACCAAAGGAG CATCAGTGAT TTTTAGTGGA TTTCACAAAG GAGTAATAGG 9400  
ACAGCTTCCT TGTCCTGTTT TTTTCTTTAA AAACTACAAC CCAATAATGA 9450   
TGAGTGAGGC TGTTGTAATT TTTGGAAACA TGATAATGGG TTGTTGCAAA 9500 | [T/C]_rs1054516 (9473) | 
[G/A]_rs3211858 (9474)  
TATATTGAAA GTTAGGGGCT GTGTGCAGTG GCTCACACCT GTAATTCCAG 9550 | [T/A]_rs3211859 (9505) | REPEAT | 
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[C/T]_rs1054517 (9534)  
CCTTTTGGGA GTCCAGGTCA GGTGGATTGC TTCAGCTCAG GAGTTCAAGA 9600 | [A/G]_rs1133344 (9600)  
TCAGCCTGAC CAATATGGTG AAATCCTGTT TCTACTAAAA CTACAAAAAC 9650 | [T/C]_rs3212003 (9616)  
TAGGTGGGCA TGGTGGCACA GGTGAGAGGA TCACTTGAGC CTGGGAGGTC 9700 | [G/A]_rs3212004 (9663) | [T/C] 
(9699) 
AAGGCTGCAA GGAGCCAAGA TTGTACCACT GTACTCCAGC CTGGGTGACA 9750  
GAGCAATATC TTGTCTCAAA AAAAAAAAAA AGAAAAGAAA AAGAAAAAGG 9800 | [A/-] (9786) | [AAAAAG/-] 
(9794_9799) 
TTAGGGAAGC CAGATTGAGC AGGATTTTGA AGACACGGTG TCAAATTTGT 9850  
GTTCTTCATG TAGATATTTT TATTTTCTTA ATGTAGTGAG TGTTAAGTAC 9900  
CATCCTCTGA AGTGTCCAAC TCTTGAAGGA AAAGAAAAAG CTTCCAATAC 9950  
CATTAGATTT TTCACTCAGT TTTTGTGTTT TGTTTCATCA GTCCAACTTA 10000  
GGGGCAGAGA AGAAGTTCAA CTCAGTAAGA ACTTTTTTGA ACTTCGGTAA 10050 | [C/T] (10045) 
AATTTGCTTA ATAAATTATG TTGACTGTTG CAATATTTTC AAAGCGTCAC 10100  
TCTAAAGCTT GCCGAAGGGT CACTTTAAAG TTTGCCTTAA AATCAACAGT 10150 | [T/C] (10103) 
CGTGTCTTCA GTATTACACA CTGATTCTCT TTGTAAAAGG CTAAAAAGAC 10200 |  
TGCTGTAATA ATAATTTGTT GAAAACATTT CTGCTGCAAG TGTATGGTAA 10250  
GGTTGCAAAG GTTCTCATGA ATGAGGTACT TGGGCTTGGT CCTTTTATTC 10300 | [C/T] (10279) 
TGGCTGACTC AAGGCTGCAA ACAATCTTCC AGAAGTGCCT GTACTTACTA 10350 | [T/C] (10342) 
CAAAGACATA ACCCAAACTT ATTTTCTTTT TCATAGCAAG TTGTCCTCGA 10400 | [T/C]_rs3173798 (10381) | Exon 3  
                                        Q   V  V  L  E 45 
AGAAGGTACA ATTGCTTTTA AAAAGTTGGG TTAAAACAGG CACAGAAGTT 10450 | [AA/-]_rs3211861(10423_10424) | 
[G/-]_rs3211862 (10425) |  
  E  G  T   I  A  F   K  N                                 W      V     K     T     G 
     T     E     V   61 
TACAGACAGT TTTGGATCTT TGATGTGCAA AATCCACAGG AAGTGATGAT 10500 | [G/A] (10465) 
 Y  R  Q   F  W  I  F   D  V  Q   N  P  Q   E  V  M  M 78 
GAACAGCAGC AACATTCAAG TTAAGCAAAG AGGTCCTTAT ACGTACAGGT 10550  
  N  S  S   N  I  Q   V  K  Q  R   G  P  Y   T  Y  R   94 
GAGTGAGTCC CCACAAATAT GAGACACTCT TACCTTGACC ATGTATTTCT 10600  
GAGAAGTCTT CTACTTGGCA AATGTCATTG TATTGAAATG TACTTATTAT 10650 | [A/G]_rs3211863 (10613)  
TTTCTTGCCA AAAATATACT TTAAAATATT TTTCCTGTCT GTATAGAATC 10700 | [C/A] (10654) 
CTAATCTAAG AATTTAATGA TTATAAGGTA TTTATTTTGA AAAAAGTGGA 10750  
AGATATATAC ATTATCCAAA TATTTATTAG ACAATATATA GAAAAGATAA 10800  
ACAGATTTTA TTATAAACTT ACCAGTATCA AATAACTTCC CTATGTTTAT 10850  
GAAGTTAGTG TTTTGTTATT GTGGCATATA TTCTCAACAA CTCTGAAATA 10900 | [A/G]_rs3211864 (10876)  
TTCCTGCTGA GGAAAAAAAA ATCAGTTTTC ACATCTTAAA ATTTAAAGCA 10950  
TATTTTAACA GTGGTTCTCA AAGTGTAGCT GGGCCACAGC AAAGTGCTGG 11000 | REPEAT | [G/A] (10975) 
GCCAGCTGCA TCAGCATTAA CAGGGAATTG GGAAACATGC AAATCCCTCC 11050  
ACCCCATCCC AGACCAAATG AATGAAAGAG TTGAGGCCCA CTAAAGAGTT 11100  
TTACAAATCC TGGGTGATTT GAATACACAA TTTTGAGAAC CACCGTGCTA 11150 | [G/-]_rs3211865 (11137)  
AATTCATTTT TCCTAACTGC GGTACCTACT CAAGATTTAT ATTCAAATTA 11200 | [C/T]_rs3211866 (11155) 
ACTTCTGGGT CATATAGATG TTTACATTGA TCTATTTTAG TTTCACTCTT 11250 | [T/G] (11249) 
ATATTTCCTC TAGTGTTGAG ACAATATTTT ATATCTTTCC TCTGCCTTCC 11300  
CTGATAGTTT AACACACTTT TGAACAGAAT CTTAGAGTAT TAGAACTAGA 11350 | REPEAT  
GGAAATGATC AGCCAGAATC TGTCATTTTG TGAGTTAAAA ATGCCTGATC 11400  
CAGTGGATGT GAGGTCACTT GTCCATGTTC ACACAGATGT AGGTACTGGT 11450 | [T/C] (11440) 
AGCTCCTAGA TTTTTGTATA CCTTTTCTTC CATTTCAATT ATAGACACTC 11500 | [C/A]_rs3211867 (11472)  
TGTCTTTTTC ACTAAAAAGG GAAAAAAGGG GGAGATTGAG GTGCCAAAAA 11550  
CACTACCTTA ACCAAGGATT AGGAATATAT TTATGGTATC CATATGGAAA 11600 | [T/C]_rs3211868 (11554)  
CATAGTTATG TTCTGCTATA GAATTTGTTA CCTAAATGTG TATTTTCCCT 11650 | [A/G] (11618) | [G/A] (11640) 
CATGGATAAT CACAACTAGT TATACACCAT GATTAGTTCT CATCACAAAG 11700 | [T/A]_rs3211869 (11684)  
TTTTGTATTT CTAATGATTT TTTATAATTT GTAGTTTTAG CATCTTATCT 11750 | [C/T]_rs3211870 (11741)  
GTTTTGGTTA TCGGATGATT GTATAATTTT CCTTCTTCCC CAAAGCATTA 11800  
CTATGCTTCC AGATTGAAAA TTCACACCCA AAATAAAATG AAATAACAGG 11850  
CATGGTGAGG GTGGTGCCTA CTACCATAGC ACATGACATA TAAGCCCCAG 11900 | [A/G]_rs3211871 (11890)  
AGGGCCTTGG TGCATGTCCT GTCTTAGCAG TTTTACCCGA ATCGGGTGTC 11950 | [G/C] (11904) | [C/T] (11943) 
TCTGTGCGCA TCTGTGACAA TTCATAATTT TGTCAATGAA GACTTAGTTT 12000  
TTATGGGTAC AAAAACATCT TACCTTAGAA TTTTCTTCAT GGTCTTAAAG 12050  
TTTTTATATT ATTAGCAAGA GTCTATACAA GTATCTTGTT GCAAAGAATG 12100  
TTGTTAGGTG TACCATATAT ATATACACAC ATATATATAT ATATGTATTC 12150 | [T/C]_rs3211872 (12124) | [-/TA] 
(12125_12126) |[T/C] (12132) | [AT/-] (12143_12144)* | [G/A]_rs3211873 (12145) 
ATAGGTGTAT ATATACTTAT GAAAATCTAG AATTCACATA TGACCTAAGG 12200  
AGAGTATCAG CATAATTGTT TAAGAAATAG AACCTAAGTG AACTGAGTAA 12250  
GTGTGAGGAA AGAAAATAGT TGTTAGAATT TGAGAACTCA TCATGATTTT 12300 | [GTT/-]_rs3211874 (12272_12274)  
TTTTGTTTGT TTGGGGGAAG TTATATTTTT CACTTCTGTT TTTAATTTTG 12350 | REPEAT  
TTTATTTTTT GAGGCAAGGT CTTGTTCTGT CACCCACTCT AGAGTGCAGT 12400  
GGCACGATCA CAGTTCACTG CATCCTCAAC CTCCTAGGCT CAAGTGATCC 12450 | [C/G]_rs3211875 (12403)  
TCCCACCTCA GCCTCCTGAG TAGCTGGGAC CACAGGCGCA TGCCACTATA 12500  
CCCAGCTAAT TTTTATGGGT TTTGTTTTGT AGACAAGGTT TCGCCATGTT 12550  
GCTCATGCTG GCCTCAAACT CCTGGGCTCA AGCAATCTAT GTGCCTTGGC 12600  
 48 
CTCGCAAAGT GTTGGGATTA CAGGTGTGAC CCACCATGCC CGACCATATT 12650 |  [G/C] (12609) | [G/A] (12642) 
TTTCACTTTT AAATATATTA TTTGGGATAT GAGAAAACAT ATTATTGAAA 12700 |  [A/T] (12691) 
TAGTTCTCCT CTGGTAGTTG ACAGCTGATC TATATTTTAT TCTTAAAGCC 12750 |  [A/C] (12745) 
TTTAACCTAT CTCTCTAAGG GACAAAAAGG GGATGTGTTA GATATATTTG 12800 | [A/G]_rs3211876 (12775)  
GTTTGCTTAG AGAGGCAATG GAGCAAAGAC TGGAGAAGAA CAGTTGCATT 12850  
TACAGCTAAA TTTTAGAATC CATAAATAGC TCTTTCTGTA ACAATTTTAA 12900  
AGGGATTCCT GATTATCTAT AGGTCATCTT GTCTCAGCAT GTCACCAAAA 12950 | [A/G]_rs1358337 (12919) | [A/T] 
(12936) 
TAGTCTTTTA TTGTTTGCCT GAGTGCCTTA AATAATGGAA AAACAACCAG 13000 | [C/A]_rs3211878 (12998)  
TACCTTTTAG AAAAAAAATT AACACTTTGA TAGTGCATGT GTTGAGCTAA 13050  
ACATGCTTTT TCATAACTAA TTATACCCTA AATCCATCTG ACATTGGAAG 13100 | [T/A]_rs3211879 (13094)  
TATGTGAGAA TGTCCCTCCT CAAACAGAAC CACAGGCTGT ATTTGGCCAT 13150 | [T/G](13140)* 
TGTCTGCTAA AGTAAGCTTG ATTACACTTT GACAAGATAT GACCTGAATC 13200  
AAAGCACGAA ATTGCTTGGG TTGAGATCTT ATGTGTGTTT CTACCTACAC 13250  
CATCTCTATG AAGATGCTGT AATTCCTTCA GAATATTCTT AGATCTGTAA 13300 | [C/T] (13279) 
TTCATTTTTT GAGTTACTTT GCTTTGGAAA GAATATAAAA AGTAATCTTG 13350 | [T/C]_rs3211880 (13346)  
AGAAAAGCAT AAATTCCTTC CCTTGACCTT ATAAACAAAC ACGTTCCAAA 13400 | [A/G]_rs3211881 (13388)  
ACTTCCATAC AGTCTAACTT TTAAACAAAA AATTCAGTAA TTATGTTCCC 13450  
TTTTTAAAAC AACATTCTAA AGGCAGGGCT GTTTTAAGGA TTTTTCTTCT 13500 |  [C/G] (13479) 
AGTGACTGCC ATCTACTGGT ATAATGTTGT CAGTACACTT TAGGTAACGT 13550 | [TGT/-]_rs3211882 (13528) |  [C/T] 
(13548) 
GACAATTATG TTGCTATTGT TTTAATTTAT GGGCATATTT CTGAAAATTG 13600 | [T/A]_rs3211883 (13577)  
AAGTACTTTG ATTTGAAATA TTAGTAATAT GCACACTAAT TTAAAATACA 13650  
ATTGTCCTGA GTGCTGTTTC AGATTTTTAT ATTCTTTGTG TGTCTGCAGT 13700  
ACTTCAAGAA TAGTAGTTTT AATAAAATTA TATTAAAAAT ATATTTCTAG 13750  
CCAACTTTGA ATCCTCTTTT TAAAGAATCT GAGACATTTG TTTAGTAAAT 13800 | [T/C]_rs3211884 (13758) | REPEAT |  
[A/G] (13799) 
ACATTTACTG AGAACTCATT ATATACCAGG CATGATGCTT AGAGATACAA 13850 | [A/G]_rs3212005 (13823)  
AACACTCATA AACCCCTACC CTGTAGGAAT TTACATTTTT ATTATAATGG 13900  
AATAAAATGG GTTTTTAAAA AATTCAGTCC AATTGCTTAA GTCTTTACCT 13950 | [C/T]_rs3211885 (13936)  
TGGCTATCTA CTCACTTCAC AGGCATTCAA ATATGACAGT GCAATTATGA 14000 | [G/A]_rs3211886 (13973)  
TATATATCTT ATTTCTTCTC AGTGAATATC TTCCACTTGT GAAATGTATT 14050 | [T/C]_rs3212006 (14003)  
TTTCCTGTAA TAATCACCCT TCACCGCGTT CCTAAAATGT AGTTGGTACT 14100 |  [C/T] (14075) | [G/A]_rs3211887 
(14076) | [C/A]_rs3211888 (14081)  
TTGCAGCCTA GATATGTTAG AGTCAGGAGA TTAGAACTAG CAAAAGTATT 14150  
CAATATACTT GAGGGGCTGG GGAAGTTAGT CTATAACCCT TAAAAATGGA 14200 | [T/C]_rs3211889 (14190)  
AATTATATTC TTATCTCTAA TTCTCATTAA AGAAGTCCTG AAAAAGGGAA 14250  
AAAGCAGTGC TGGATAGGCC TTGTATTTTG ATCATTCTTT CTAATATAAG 14300 | [A/G]_rs3173799 (14299)  
AAAATGTGCT CTAAATATTC CCCTGCTGAA GCCCCTGTAC TTTTTCCTCC 14350  
TTATCCTCAG GATAAAGTCT CGTTTGAGTA TTAGATGCAA CTCTTTTATG 14400  
TTTGAGATCT TACTTGTTTC AATAACTTTA TTTCCACTAC TCTCCTCACC 14450  
TCTTACTCTG TAATCCAACC ACACTCAAAT ATCTGCATTT CCCAAAACAT 14500 | [A/T]_rs3173800 (14455) | 
[T/G]_rs3211890 (14482) |  [T/C] (14500) 
ATTATGTTCG TTCTTATGCA TGCTACCATC TGCCGTACTT TACCTAACTA 14550 | [G/A] (14510) 
AACTTGTATT TGTTACATAG ACCATTTATG TAGACTTGTA CTAAAAAGTG 14600  
TTTTAACCCT CACCCCTACC CTGACCATTC TAAATCTGGA TCTGGATCTG 14650  
TTTTGTGTTT TCCCATGGAG TCTCCATTAT AACAATATTC CTTCTCTCTC 14700  
ACTATTTTAA TTTCCAGTTT GCCAGTTTAA GACCCCTTCT CGTTAGTTTG 14750 | [592bp/-] 14071_15292 
CTAGAGACCC TGGCTGATTT CTCATTTTAA CACCATTGCT TACATACTAT 14800 | REPEAT  
CTATCTGGCA TATTCTGTGT GTTCAAAAAT CATTTGTTGA ATGAATGACA 14850  
TTTGAGATCT AATGTTCACA TATGACAAAT GTTTTGAATT TTGTTTACTG 14900 | [T/C]_rs3211891 (14882)  
CTGTTTCTTT AGAGTTCGTT TTCTAGCCAA GGAAAATGTA ACCCAGGACG 14950 | [G/A]_rs3211892 (14903) | Exon 4  
               V  R   F  L  A  K   E  N  V   T  Q  D   106 
CTGAGGACAA CACAGTCTCT TTCCTGCAGC CCAATGGTGC CATCTTCGAA 15000  
A  E  D  N   T  V  S   F  L  Q   P  N  G  A   I  F  E  123 
CCTTCACTAT CAGTTGGAAC AGAGGCTGAC AACTTCACAG TTCTCAATCT 15050  
 P  S  L   S  V  G  T   E  A  D   N  F  T   V  L  N  L 140 
GGCTGTGGCA GTGAGTAGAC AAACAACAAA GTTATCTATT TTAAAATACT 15100 | [T/C]_rs3211893 (15062) | [A/G] 
(15075) 
  A  V  A                                              143 
CTAGAACTCA TGTAATTAAT CCTATCATTA GAATTATTAG GTTTTACTTG 15150  
TTTTTCCATT TTTATCAAAA CGTATTCCTA TATCATTATT TTGAATGGAG 15200  
GCATGGTCAT TTGGAAAGTG ACAAAATCAT AAGAATCGAC TGCATTAGAA 15250  
GACCACTTTA TTTTTTTCAT TATTTTTTGT CGAAACATTC TCTATATTTA 15300  
ATTTCAATTT TATAACAGAT TACAGGAAGA TGCTTAAGAA ACAAGTACAA 15350  
CATTTGTTTC AGTATGTCTT TAAATGAAAG ACTTTTAAGT ATGTAAGCAA 15400  
CTATATAATA AAAGGTTTCC AAACGCAGCC TGTAAGAAAT CAGGCAAATT 15450 | [A/G] (15405) | [G/A] (15425) 
TTACTATAAG CAATAAACCA TTCCGAGCTT TCCAGACAGT GTACCAGTAG 15500  
CTGTACCAGT GGGCAATAAC CTTTAACCAA ACAAAAACAA ACAAACAAAC 15550 | [C/T]_rs3212007 (15521)  
AAACAAAAGC ACTTTGCAAT TTGTTGCTGC AAAATGGGGA GAAAAAAAGA 15600 | [CCA/-] (15554_15557) 
GTATATAAAC TTGATGGAAT CACAACTGTC AATATAATTT AAGGGAAAAT 15650  
 49 
AAAGTCGATA AGGTTGATGG TGTCTATTGT TTGGAAAGTC GAATTCGGCT 15700 | [A/G] (15676) 
ATTTGCTTGG GGCTCTAGAG ACCACACCAC TGAATAAACA AAACTCTGCA 15750  
GAGTCTAGCT ATCCGCCAAC AGGGGGTGCC GTCCAAATTC ATGGCAAATA 15800  
AAGGGCATTT GGTGCTCACC ATTCACAACA GGCGGGCATT TATGTGGATG 15850 | [C/T]_rs3212008 (15833)  
AAGTACAATT TCTTCAGCAA GCTCAGCAAA AACTCTTAAG GGGCAAATAT 15900  
GAACTCTGCA TTTTAAGAAA AATAGAAAAC GGAAACACAA AATCCTAAAA 15950 | [G/A]_rs1924 (15932)  
AGTATATGAA GGCTCTGCAT TAGCACACTG GCATCAAACC ACACATCCAC 16000 | [A/G]_rs3211895 (15975)  
AGCACATCCT AATTCTATGG GAAACAATCC TTGCTTATCG GAGGTGCATA 16050 | [G/T]_rs3211896 (16040)  
TCTAAATTCA ATAGCTTACC AATATATTCT TGGGAGTAGG CCAAAAGGAA 16100 | [T/C] (16051) 
ACAGAAAACC CACATTAAAA AAAGAAGTTT CTTTTCCTAA ACATTTTCCT 16150  
GAAGCTGAAA TTGAAGTGGA GAGGAAGTCA GTTGTCCTCG TCGAAATCGT 16200 | [G/A]_rs3211897 (16163)  
AGTCCTCCTC ATCCTCCCCA ACCTGGGACA CCGGGGTCTT CACCCTGGAG 16250  
ATGCTGTACT GAGACCTGTT GGAGCTTGTG GCCAGCATTT CATCCGCACC 16300 | [C/T] (16295)  
ATTGGTCAGG TCACTGGCAG AGAGCCTCGT GCCGTTAGAC GTGGAACCTG 16350  
CCGTTGTGAT GAACACGCCT GCAACAATTG TCTGCGCCAT TTCTGTCACG 16400 | | [A/G] (16377) [C/T]_rs3212009 
(16385)  
TGTGGCTCCA GCGCCTTTGG GACCAGACTT ATGGCTTTTT TTTTTTTTAA 16450 | REPEAT  
GTTCTGGGAT ACATGTGCTG AATGTGCAGG ATTGTTACAT AGGTATACAT 16500  
GTGCCATGGT GCTTTGCTGC ACCTATCAAA CCATCATCTA GGTTTTAAGC 16550  
CCCGTATGCC TTAATGCATT AGATATTTGA GAAGACCACT TTAAGTGTAT 16600 | [T/G]_rs3211898 (16565)| 
[A/G]_rs3211899 (16568)  
CGTTAAATAA ATAGAGCTTA ACTTGGAATG TCGTCTTCTT GTGGCTGGCA 16650  
CTGAGGCAAA GAAATGTAAT CATCTAGGAA TTAGACGAAT TGCATTTTGA 16700  
GTTTTGGCAG GATCTGGCAG TAATTTTAAA GATAAGCTTT AAAAAGTTTT 16750 | [A/G] (16741) 
GTATTAAGCT CAATATTAGC ATTTAATCCA TTTATTTGTT AAAATCTAAT 16800  
ATTGTATTCT TGTCTTAAAC AGTGACTTTG TTTTTGTAGG CTGCATCCCA 16850 | [C/T]_rs3211900 (16809) | [G/T] 
(16824)| [A/G]_rs3211901 (16838) | Exon 5  
                                            A  A  S  H 147 
TATCTATCAA AATCAATTTG TTCAAATGAT CCTCAATTCA CTTATTAACA 16900  
  I  Y  Q   N  Q  F   V  Q  M  I   L  N  S   L  I  N   163 
AGTCAAAATC TTCTATGTTC CAAGTCAGAA CTTTGAGAGA ACTGTTATGG 16950  
K  S  K  S   S  M  F   Q  V  R   T  L  R  E   L  L  W  180 
GGCTATAGGG ATCCATTTTT GAGTTTGGTT CCGTACCCTG TTACTACCAC 17000 | [G/A]_rs5956 (16983) | [C/T] 
(16986) 
 G  Y  R   D  P  F  L   S  L  V   P  Y  P   V  T  T  T 197 
AGTTGGTCTG TTTTATCCTG TAAGTACCAA ATATGAATGG CAATATTATT 17050  
  V  G  L   F  Y  P                                    203 
ACATTTTAAT TTAATTAATT CAATGGCATT GGCAAGGCAT AATTTTATAA 17100 | [T/A]_rs3173801 (17093)  
TTTAGCTCAT TAGTCTTATT GCTGATCTGG AGACATATAT CCTAACTTTT 17150  
TAAAAAGTCC ACTTCTCATT ATAGCTTCAG CTTTCCTAGT TGGGAAATTC 17200  
ATCTGAATTT AACAATTAAA TTTAAACCTG AAGAATAGAT TTAATAAGGT 17250  
TTCTACTCAT TTATAAATAC ACAATTTTTT TTAAATTAGC CGGTAAGCTA 17300 | [A/T] (17274) | [-/T] 
(17282_17283)| [T/A]_rs3211902 (17282) | [G/A] (17292) 
GTCTGTAAAT CTTTGAGCAC TGTTTTTGGC TTTTATTTCC CTATTCACAT 17350  
AATCAAGTTT AATACCATAT TTTTATTTGT TTTAAATATA CTCCTCATTC 17400  
CTCCTTTTCT AGACCTCTTA CAATTTTAAT TTATATTTAA AAGTTAGCCT 17450 | [TTACAATTTTAAT/-]_rs3211903 
(17421_17433) | [T/C] (17437) 
AATGTTCACA TTCTCAATAC TGATAAGGTA ATAGACTTCA TTTTAATGGG 17500 | [T/-]_rs3211904 (17462)  
ATTTGTAAAT AAGAATTTTT AGTAGTCCAT AATGTCATGA AATGGCAGCT 17550  
TGAAGATTAA GGAAAATGTG AACTTGATGG TGTACTTGAT TACCGCTTAA 17600  
TGTTTTGAAT TACAAATAGG ATAAGCTAAC TACTGAATTG GAAGTTGGAC 17650 | [G/A] (17641) 
TATGACTTCA TTTGGCACTA TATGTGAATA TTATGTTCTC TAGTTCATTG 17700  
TTTTACTTTT AGATACTGTT AGGATTACAA GGTTATATAT CAATTATAAA 17750 | [A/G]_rs3211905 (17743)  
TGAATGTAGA AAGCCATAAT GAATCAAATT CATTCTGATT TTAACTCAAT 17800 | [TACTCAT/-]_rs3211906 
(17807_17813)  
ACTCATTACT CATAGCTCTT TCTTTGGCTA ATGCTTTAAC TTTTGGATGT 17850  
CTAATTTTTA TCATTTTAGT AACCACTTAT TATCATTTTA GTAACCACTT 17900  
ATTAATGACT GTAACATTTA GAATACCCCT AGAAATCATT GTTCTTATAG 17950  
GTTTGTTCAA TGTCCCTCAC CTCAACATAG TAAGAATAGT GATCAAAATG 18000  
CCCTCATTGG CTTAATTATG ACAGAGTGCT AGAGTTCACA TCATGTCAGC 18050  
TTCTGATATG TATCTTCTTT GTCACAGCAT CTAGCACTTA TTTCTAGGCA 18100  
CCTTTCACAA TTTTTAAGGC CAATAATTTA AAAAAAATGT ATTGCAGATG 18150 | [G/A] (18119)| [A/-] (18137) 
TATTTCAAGT CATTTGAGTA ACCAGTGATT GAGAAATGTG AAAGTGAGTT 18200  
ATGTATTGTA CAACTTTGAA AAAATGACTT GTAGAAGTAA CATTTTCCCA 18250  
TACATATATT TCAGTACAAC AATACTGCAG ATGGAGTTTA TAAAGTTTTC 18300 | Exon 6  
                Y  N   N  T  A   D  G  V  Y   K  V  F  215 
AATGGAAAAG ATAACATAAG TAAAGTTGCC ATAATCGACA CATATAAAGG 18350  
 N  G  K   D  N  I  S   K  V  A   I  I  D   T  Y  K  G 232 
TAAAAGGTAA GTAAGTATTC TGGTAAAATG TGCATGTATG TTACTAGGGT 18400 | [AGTA/-]_rs3211907 (18364_18367)  
  K  R                                                 234 
ACTCTTAAGC AGGAATAGTA TTCATTTAAC ATCTCATAAG ACATAGGCAT 18450  
 50 
CAACCTATAG AACAGACCTG GTTATAATTC AGCTCTGGAA ACTCCTGTTC 18500 | [A/G]_rs3212011 (18457)| 
[C/T]_rs3211908 (18463)  
TGCTAGGTAT TAACTCTTTA GTTGTGGTAA CTGGTGAGTT CACACCAGTG 18550  
CATAGCTGCT GACTATCAGC TCCACTTTAA GGTTTGGTTC ACCTTTCTGC 18600 | [-/T] (18596) 
ACAGGTTATG GTTGTGTTAC ATAAATCCCC AAAGGGACTA TTTTTTCATC 18650 | [-/ATC] (18650_18651) 
TCTGCTACTT ATCCAGCATT ACAGTATAAT TATTCTTACA ATTAGATAAC 18700 | [T/C] (18659)| [T/C]_rs3211909 
(18662)  
CATAAATGAA AAGGTAAAAA AAAAAAAAAC AACACATCAA CTGATTGTGT 18750 | [A/C] (18724) | [A/G] (18726) 
AGTAGATGGA AACTTTTTTT TTACTTTTTA AATCGAGCAT ATCGAATTCC 18800 | [C/T] (18784)| [G/A]_rs3211910 
(18785)  
ATATTCCAGT GGCATGACCT AAATGTGTCT ATAAAGATGG AAGCTTAATG 18850 | [AAATGTGTCTATA/-] (18821_18833)| 
[G/A] (18825) 
AATCCAGGCA ACTGCTTTCA TGACCTTCCC CCTGCAAATA GTCTTTAATA 18900  
ATTTTCCATA TTGATAACTC AGCTTTTTTA ACTTTATCAA TGCAAAAATA 18950 | [T/G]_rs3211911 (18911)  
GAATGAATAT TTCAAGTGCA GTTCTACAAT GTAAATACAA AATGTGAAAA 19000 | [G/A]_rs3211912 (18966)  
TGAAGACTTT GCCAACTTTA AAGTGGTAAA ATAACAAATC AGCTTCCTAA 19050  
GCCATTATTT CCTTTTTTTT TTTCTAGCTC CAGCCTATTC ACCTAAAGAA 19100  
TTTATAATTT ATCATATATG TAAACTAGGA AGAACCCTAA TAAATATCAG 19150  
AGGAACAAGC TTTCTTCTCC ATAAAATTAA CAATTGTGTG TTTGACTAGT 19200 | [A/G]_rs3211913 (19151)  
TTTTTTCTGA AAAAGAATAA AGTGATCAAA ACCAAAAGAG ATGAAATGTT 19250 | [A/C]_rs3211914 (19228)  
TTTATTAATA TAAAGTAACC CCTACCTCAA ACTGAGTCTA TCTAATGATT 19300 | [-/AATA] (19260_19261)| 
[TCAAACTGAGTCTATCTAATGATTGCTTT/-]_rs3211915 (19307_19335)  
GCTTTTCAAA CTGAGTCTAT CTAATGATTG CTTTTAACAG CTAAATATTA 19350  
CTAGTGGAGT ACTTTTTCTT CTAAAGAGTC CACAGTTACA TATTTTTATA 19400 | [T/C]_rs3211916 (19386)  
GAAAAAGTCA GTAGAGGGAA AAAAACACTT CTAAGTATTC ACTTAAAAGG 19450 | [C/T] (19426) 
AAATCACAGC AATTTTTTAT ATTGAGAAAT AACGAGCATT TCACTCTAAT 19500  
ATTACAGAGA GATGTGGAGG GGAGTTGCAA AGCACTCCTA GTTAGAGTAA 19550  
GAATTTCACA TCATTTTAAG ATTGTAAGGT TGATTTAACT CATGGCAAGA 19600 | NOT SCANNED  
CTGAACATGA TTAACCACTT ATTTTGTTTA AGCAATGGCT TGTCTTGACA 19650  
TGTCACTGTC AGGAGTGGAA AAAAAGTTTT TCCATCACCA AAAAGTGAGG 19700 | [A/T] (19673)| [T/G] (19678) 
ATGCAGGGAA ACTATTACTA TTGTTTTTAT CACTTCCAGA TATATATAGC 19750 | [A/G] (19742) 
TTATTTAGAC AGCAAAGTAT AAGTTAGTAA ACTCTTTCCT ACTTTAACGC 19800  
CAGTCCATGG GAGAATTAAA GGGAGGAAGG GGCAAGAATA TAAATTAATC 19850 | [G/A] (19810) 
ATCTACATGT TTTGAATGTT TGCTGATCCA AACATCTGCT TCTTTCCTCT 19900 | [T/C]_rs3211917 (19877)  
TCCCTGCTTC TCTCTTCTGC CTGCCTTGTA CTTAGCTTAT ATCAGTTACC 19950  
CACTTAACAC TTTCCTTCTA TTCATTCTGA ACACTTATAC TACTGAGTAA 20000  
TTCATGTATC CCATTGGAAA AAAAAAAATT TCCCCTAAGT AGAGATCTAA 20050 | [A/-]_rs3211918 (20028)  
GTTTCTGATA AATGTTTTTA ATTTTTTTCT TATTCCAAGA TGTTTCTAAT 20100  
TAACACCTGG CAGTTTTTAT TTTATGATCT GGCTACCTAA TGGCATCAGG 20150 | [T/G] (20108)| [-
/TAATTAACACCTGGCAGTTTTTA] (20119_20120) | [T/A] (20141) 
TACATTGCAA TAAGATAAAA GGTTCAAACA AAACATAAAC AGAATTGAAC 20200  
ATTTCTTAAA CTTAGTACTT GTCACATTTA AATGCATCAT ATTAACAGAA 20250  
GTATTGAATT ATAATAGAAA AAGTAATGTA AGAAAGGTAT TCTTTAAATA 20300 | [T/C]_rs3212012 (20277)  
AGAATGTTTA TTCATTGTCT TTTTCTATTC CTAGGAATCT GTCCTATTGG 20350 | Exon 7  
                                       N  L   S  Y  W  239 
GAAAGTCACT GCGACATGAT TAATGGTACA GGTAAGAATA TTTGTTTTGT 20400  
 E  S  H   C  D  M  I   N  G  T                        249 
GGTCATCACA GTTAATCCAC CTCCCTTTCC CACAAATCCA CCGTTGTACT 20450 | [A/G]_rs3211919 (20440)  
GACAGTGTTC TGAAAGTTGA GGGTGTGTGT TTACTTGCCT TTATATCCCC 20500  
ACAACAAAAT TCAGAGTCAC TATTTGTATA TAGGCTAAAG GTCTGTTCAA 20550  
TGTGATGGGA TTTGTAAAGA TTAATCATAA AAAATTAGCC CTTACTGCAT 20600 | [A/T] (20584) 
GATTCAGAGA AATGTTTGCT TTGTAAAAAC TTTACTGCCA TCCTGGCAAC 20650 | [C/T]_rs3212013 (20630) | 
[T/G]_rs3211920 (20644)  
AGAAGTAAAT GGTAAAAAAC AAACAACAAC ACAAAACACT TTAGTTACAT 20700  
TTCAAATATT TTATAAATAG TATACAGATA AGTTAGAATT GAAAGAATTA 20750  
AAAAAAGCTA ATTACAAAAT AGAAAACATA TCTAAGCAAG GCTTATAGCT 20800 | [C/G] (20758) | [T/C] (20759) 
GAGATAGAAT AAAGTTGCAA GACAGAACCA TCCATTTTTG GATAAGGTGG 20850 | [T/C] (20843) 
TCAGAATGAG AGAGAAAACA ATAACAAAGT CAGATGTCTT CTTAACTGTG 20900  
AAAAATATAT GTAAAAAATG AGCATTCATA AACTTAGATT TAAGGTATGG 20950  
TTAGATCAGG CTTATTCTCC TTCAGGAAAA GCAAAGTACA GATATGCCTA 21000  
TTAGTTTAAG AATTAAGATT TTTAAAAAGC AATGGGAGGC TGGTCACAGT 21050 | [T/A]_rs3211921 (21005) | [G/A] 
(21034)| REPEAT  
GGCTCATGTC TATAATCCCA GCACTTTGGG AGACCAAGGC AGGTAGACTA 21100 | [C/T] (21084) 
CTTGTGCCCC GGAGGTTGAG ACCAGCCTGG GCAACATGGC AAAATCCCAT 21150 | [C/T]_rs3211922 (21110) | 
[G/A]_rs3211923 (21111) | [G/A] (21138) 
CTCTACAAAA AAAATACAAA TATTAGCTGG GTGTGCTGGC ACACGCTTTT 21200 | [T/C] (21174) 
AGTTCCGGCT ACTTGGGAGG CTGAGGCAGG AGGATCACTT GATTCCAGGA 21250  
GGTGGAGGCT GCAGTGAGCT ATAATTGTGC CTCTGCACTC TAGCCTGGGC 21300  
AATAGTGTGA GACCCTGTCT CAAAAAAAAA AAAAAAAAAA AAAGTGGTGG 21350 | [-/GTCT] (21320_21321) 
GAATCGAATA CCATGAAGTA ATTAATATCC AGAGGCAAGC TTTCAACTAC 21400 | NOT SCANNED  
TAGGAAACAA AAGCATGAAG TTTAGAAAAT TAGGGAATAT CCCATAGGAA 21450  
 51 
AATGATATAA CAAAGATAAA GACACTTAAG TAAAAATGAA GTACAGAGAA 21500  
TGTTTACTTT GCCAAAGGTA TGATTATTGA CTTCGTATGC GTACTTGATT 21550  
CTATCATTGC CTTGTAGGAA ATGATAAACA AAAAAAGCAA ACAAAAAAAA 21600  
CAGCAAAAAC ACTGTTGGAT TTGCAGGGGT TTTCTTTTGT TTTTTTTTTT 21650 | REPEAT  
TTTTTTTTTT GAGACATAGT CTGGCTCTGT TGCAGGCTGG AGTGCAGTGG 21700  
TGCGATCTCG GCTCACTGCA ACCTCTGCCT GCCTGGGGTT CAAGTGATTC 21750 | [C/T]_rs3211924 (21703) | [C/T] 
(21728)| [GCCT/-]_rs3211925 (21731)  
TCCTACCTCA ATCTCATGAG TAGTTGGGAC TACAGGCATG TGCCACCACA 21800  
CCCAGCTAAT TTTTGTATTT TTAGTAGAGA CGGTTTCACC ATGTTGGCCA 21850  
GGATGGTCTT GATCTCTTGA CCTTGTGATC CGCCCCCCTC GGCCTCCCAA 21900 | [G/A] (21882)| [G/A]_rs3211926 
(21891)  
AGTGCTGGGA TTACAGGCTT GAGCCACCAC ACCTGGCCAA GGCTTTGCAG 21950 | [C/T]_rs3211927 (21927)  
GGTTTTGAGC CATAGGAGTG GGCAAATAAG CTATTTTCTA AGTAAAGCAT 22000 | [T/C] (21984) 
TTCTGGAAAT AAATTTTCAA GTCCTCAATA CTACCAATGC TAGTAGTTGT 22050  
ATAAGCGGAA TACTTAGTCC TTAGATGCAG AGATAAATAT ACTGTGTTAA 22100  
TCCTAGTAAA GGATTCTTTA AGGAGAAAAA TCTTTAAAAA GAAGATTCAT 22150  
TGACAATAAT AGAAATGCAT GAGCATCAGG CATGATGTTA AAAATATCTA 22200  
TGGGGAAAAT AGGGCTGATA CAAACTAGGA AAAGAGGGAA TTTGGACAGA 22250  
GCAGGGGATG ATCCCTGTGA GAGAGATTCT TGCTTATGGC ACTAGCGAAA 22300 | [C/G]_rs3211928 (22296)  
AGAAAGTAAT AAAACAGTAA GGTTCTAATG TGTTTTCATC GTAATTTAGA 22350 | [A/G]_rs3211929 (22338)  
AGTGCATCCT CTTTACCTTC TTCAGTAAGT TTGAAAAGAC TTAAAATGAA 22400 | [A/C]_rs3211930 (22351)  
AGTATTGGTA TACATTTAGA ATGTTTCTTT TGGGAGGACA GAAAAAAAGC 22450 | [G/A]_rs3212014 (22434)  
TCTGCAAATA TCAACTATGT TGCAGTCATT GTCCATGGTA GTTGCTGGGT 22500  
ATAATTAGGA CATAATCTTC AATGATATTT TAGATAATGA TCTTAAAAGC 22550  
TTTTCAATGC ATTTTTCTTT AATTATTAAG GAAATGGAAA AGCAGTTGTT 22600  
GTCAATGTCC ATATGGGGGC TTATATTTTA CTTGTCACAA GAGTGTAAAC 22650 | [T/C] (22614) 
TAATGAAAAC AAGGTCACAA GGTTGACACA CTTGCCAGAG AAAGAACCTA 22700  
CAATGCATAA TCAAAGATGA GACTTACCAT TTAAAACTCA TTCAATGACG 22750 | [C/T]_rs3211931 (22749)  
GCTCGTATTA GTGATATTCA TGTGAGAAGT ACATGGAGGA GTTAACTATT 22800  
TCTTCATATA TCCAATGTTT GCCATGGATC ATAGCTGTAG CAAAAAGTAA 22850 | [C/T]_rs3212015 (22830)  
ATTCAATAAA TGACTTTTTT ATACACTTTC AAAGCATTTG AAGTTCTGTT 22900  
TAGTGAGAGA ACTTTAGTAA ATATTTTTAG AAGTAGTAAT CAGCCATTAG 22950 | [G/C] (22907) 
GACAAATGAG AAAAAAAATC ACTACAAATA AATGTGGACA TGGCAGGAGA 23000  
TCCAAATGAA CTTCACTGGA AGAAAAGTGC CACTCTACTG GTGGGGTAGG 23050 | [G/C] (23008) 
GCATTTCAAA AAACAAACAC AATGTTAGCC TTAACATTTC ATGTTTAAGT 23100  
TTCTTTTATT TTGTACCATT AAATATGTAT AGTATGTAGA TTTGTTGTTG 23150  
ACAATAGCAG CCGCCAGCCA TATGTAACTG TTAAGGACTC AAAATCTGGC 23200 | REPEAT  
TAGTATGATT TGAAATGTGC TGTAAATATA AAATGCACAG TAGATTTTGA 23250 | [G/A] (23219) 
GACTTTAAGA ATTTAAAATA TTTTATAATG GTTACATGTT AAAATATTTT 23300  
GGATATTAAT AAGTTAAATA TAGTTTTGTT TTGTTTGAGA CAAAGTTTTC 23350 | [G/C] (23345)| REPEAT  
CACTTGTCGC CCAGGCTGGA GTGCAATGGC ATGATCTTGG CTCACTGCAG 23400  
TATCCGCCTC CTGGGTGCAA GCAATTATCC TGCCTCAGGA TAGCTGGGAT 23450  
TACGAGCGCC TATCTCAGGA TAGCTGAGGC AGGCCTATCC TGCCTCAGGA 23500 | [30bp/-] (23459_23488)| [A/G] 
(23463)| [T/C]_rs3211932 (23463) | REPEAT  
TAGCTGCCTC CCAAGTAGCT GGGATTACAA GCGCCTACCA CCACACCCAG 23550 | [G/A]_rs3173802 (23533)  
CTAATTTTGT GTATTTTTAG TAGAGATGGG GTTTCACCAT GTAGGCCAGG 23600  
CTGGTCTCAA ACCCCTGACC TCAGGTGATC CACCCGCCTT GGCCTTCCAA 23650  
AGTGCTGGGC TTGCAGGCAT GAGCCAGCAT GCCTGGCCGG TTATTTCTTT 23700 | [G/A]_rs3173803 (23689) | REPEAT  
TTACCTTTTA AAAATGTGGC TGCTAGATAA ATTACTTAGG CAGTTTGCAT 23750  
TACATTTCTA TGGACTACAC TGGAGGAGAG ATTTCTAGGT TTTTTTCTAG 23800 | [G/A] (23780) 
AACACACATT ACATCTAATC ATTTGCCACT CGATTTTTAA ACAGATGCAG 23850 | Exon 8  
                                                D  A   251 
CCTCATTTCC ACCTTTTGTT GAGAAAAGCC AGGTATTGCA GTTCTTTTCT 23900  
A  S  F  P   P  F  V   E  K  S   Q  V  L  H            265 
TCTGATATTT GCAGGTAAGA CAGATACTGA AGTATAAGTA TGTCTGAGTC 23950  
AGACCCCAGG TGACAAAATG CAGACCAAGA AACTTAAACA CAGCATAGGA 24000  
AATTCATCAT GTTTATTAAC TAACTCTTTG CAAAATGTTC TTCTGCATCT 24050  
TCCAATTTTT AATAGTACAA ATTTTTTTTT TTTTTGCCAT TTCTATCTAA 24100 | [A/T] (24071) | [T/C] (24080) 
GCAAGAACCA TTTTGCCTTT TAAAAACTAA ACTAGTAGTC TATTAACGAT 24150 | [A/G] (24104)* 
CAAGTCCAGA AGGGCGTGCC CAATCTTTCT AAAGACATAC AGAGAAGATG 24200 | [C/T]_rs3211933 (24165) | 
[G/A]_rs3211934 (24166)| [C/G]_rs3211935 (24186)  
ATGCAAATGT AACAGAACTG TGTTAATGTG CTCTGCTCAG ATTTGTGGGG 24250 | REPEAT  
CCCAGTAGAT AACACACAAG CACTGGAGCC TTTACCACTA CCCTTGAGCC 24300  
CAAGCTCTGT CCCTAAAGAC TGTATGCTTG TGGGTAGGCA TTTAACATCT 24350 | [T/C] (24331) 
CTGAATTTTT TTCTTATCTG TACAATTTAA GACAGCAGTA TTTCTTCATA 24400  
TACGTGTATC TGGGGATAAG AAAAATATGT GTATTGAACC CTATGATAGA 24450 | [T/A]_rs3173804 (24426) | 
[A/T]_rs3211936 (24427)  
CACTTGGTAA ACGATGGAAA TGTACCAGGT ATATATCCAG CATGTATATG 24500 | [A/G] (24496) 
CATACACTCC AGTGAGTGGT CTTTCTTTCC AGGATTAATT AAGCCGTGAA 24550 | [C/T] (24545) 
AGAAACTATT TCATTTAAAC TGATCACAAA TAAAGTATTT GAAGGAAGTC 24600 |  
CTATAAATAT TTACTCTATT GGATAAATTG CCTGTGAGAA GTAACTTGAG 24650  
 52 
TATAAATAAA CATGGTACTT CACAAACAAG AATAGTTCAT GCTTGGCTAT 24700 | [T/C] (24657)| [G/A]_rs3211937 
(24685)  
TGAGTTTTAG TATGTGTTAA AATTTCCCAA TCACTTTTTT TCTAAGAATG 24750  
AAACAAGAAT TTAAAAGAGT ATATGATGTT TCTAAGTTAA AACAAGAATA 24800  
AGAAAAAATG AATCTCCAGA ATGTAAGTTC AGGTTCCTGG AATGCAGCTC 24850 | Exon 9 
                                                     S 266 
TTTTTTCTCT GTATTTAGGT CAATCTATGC TGTATTTGAA TCCGACGTTA 24900  
  F  F  S   V  F  R   S  I  Y  A   V  F  E   S  D  V   282 
ATCTGAAAGG AATCCCTGTG TATAGATTTG TTCTTCCATC CAAGGCCTTT 24950  
N  L  K  G   I  P  V   Y  R  F   V  L  P  S   K  A  F  299 
GCCTCTCCAG TTGAAAACCC AGACAACTAT TGTTTCTGCA CAGAAAAAAT 25000  
 A  S  P   V  E  N  P   D  N  Y   C  F  C   T  E  K  I 316 
TATCTCAAAA AATTGTACAT CATATGGTGT GCTAGACATC AGCAAATGCA 25050 | [T/G]_rs3211938 (25025) | [G/T] 
(25048) 
  I  S  K   N  C  T   S  Y  G  V   L  D  I   S  K  C   332 
AAGAAGGTGA GTAAATAACC TCAGTAGCAC AGTCCATACC ATAATTTGTG 25100 | [AAG/-]_rs3212016 (25054)  
K  E                                                   334 
ATATTCTTTA AGATGAGAAC TTTACCATAA TCCTTTAGCA ACCAAAATTT 25150  
AAAATATATC ATAATTTGTG ATATTCTTTA AAATGAGAAC TTTACCATAA 25200  
TCCTTTAGCA ACCAAAATTT AAAATTAAAG TAAGAAAGTA ATTAGGGCAG 25250  
AAGAAAGAAT GGTGGCAGAA AATTTTAGTG CTGATTTTGT ATTTTGGGAA 25300 | [T/C]_rs3211939 (25276) 
GATCCCACTT GTGTTTCAGT ATTACAAAAT TTAGTTAAAA CCACACCAGT 25350 | [C/T] (25305) 
ATTTCCTTGT GGCTGCTTTT AGATTTAGGG TGAAATGAAA ATAATTCCGA 25400  
GAACACATTA AACATCCTGT TATTCATCTG TCCTAACTTT TTTCACTAGA 25450  
AAATGGTACA GGTAAATGTA TTTTCAGTAT GTATCTAAAG CTAGAGTTAA 25500  
ACATAAAATT TGGAGACTAG CTTATCCTGT ACATATTTAT CATACTAACG 25550 | [G/A]_rs3211940 (25550)  
TGGGTGTGGA AGAAGAAAGA AAAAACTAGT GTTAAATAAA TTCTTAGTCC 25600 | [-/A] (25575_25576)| 
[T/C]_rs3173805 (25580) 
ATAGACATAT TACTGCCTGA AAGCTTTACA TATTGAAAAT TAATACTGAA 25650  
GGAGTTTATA GTAGAAATCA ACTGACATAA TTCTTCCCCA CCCATGTTAA 25700 | [T/C]_rs3211941 (25695)  
AAACCATGTA TTTTTTAATG CAAGAAGCTT TAGTTTTGTG GAAATATTTT 25750  
TTGAGTTATA TGTGAAATGA AGGAAGTTAT TAATTCCAAT TGACTCTTAA 25800 | [C/G]_rs3212017 (25794)  
AACTTGTCTT CAGGGAGACC TGTGTACATT TCACTTCCTC ATTTTCTGTA 25850 | Exon 10 | [T/G] (25849) | [A/T] 
(25850) 
              G  R  P   V  Y  I   S  L  P   H  F  L  Y 347 
TGCAAGTCCT GATGTTTCAG AACCTATTGA TGGATTAAAC CCAAATGAAG 25900  
  A  S  P   D  V  S   E  P  I  D   G  L  N   P  N  E   363 
AAGAACATAG GACATACTTG GATATTGAAC CTGTAAGAAA ACACCTTATT 25950 | [C/A]_rs3211942 (25945) 
E  E  H  R   T  Y  L   D  I  E   P                     374 
GATCTGATTT GGTTGATATT TTTAAAAATA CAATTGAAAT AAAAATAATC 26000  
TTGTCGATGA TTATTTATTC AATAAATAAT CATATTTATT GAATCACATT 26050 | [TATT/-] (26016_26019) 
CTTGAAAGTT ACTGAAACTT AGGTCGATTT CTTCCTATGG TTTATGAAGT 26100 | [G/A]_rs1527483 (26076) | 
[G/T]_rs3211944 (26089)  
GATTCTAATT GGCTTAAAAT AATTTTATAT AAATATTTAT GTTTAGATGA 26150  
GGAGTTATTG TATATTATGC AAAAGTCAAA GAGTATATGT GAGTTTGACT 26200 | [T/C] (26158)| [G/T]_rs3211945 
(26160)  
ATACTTATTG TCAAAATCTA TAAAATTGTT GTAGCGCAAC AGTTTTAATC 26250  
ATCTTTATTT TTGTATTTTC CTTTTCAAAA AGTAAATGAA ATTCTAGGAT 26300 | [T/C] (26262) 
TTTAGTAGTT ATGTTTTAGT TTAAACAATG ACACATGGAT TCTAACTGAA 26350 | [G/A]_rs3211946 (26305) | 
[C/T]_rs3211947 (26346)  
TATATATTTG ACCAGGAATT ATCTGAGATC TTATATTTTG TTGCTGATTT 26400  
TTGATTTTTT AAAAACCATT TCAAGTAACT CACAAATCTA ACTAACTAAA 26450 | [CTAA/-] (26446_26449) 
ACCTTGACAT TCGATTGGGC AAATAAATTG TGTGTATCTA TATGGATGCA 26500 | [G/A] (26484) 
TGTGTATATA ACTATAACTA TATATGCAGT TTTAAAAGTT TCAATTAGTC 26550 | [C/A]_rs1405747 (26512)  
CTGTTTAACC TTAAGTTACT ACCTTCTCTT CTGCTGTAAG AAAAATAAGT 26600  
TTTGAATAGT ATAAAATAAT GTTTTTAAAA GTTGGTAATT ATTTAGTTGT 26650  
TCTCTTTTTA GATAACTGGA TTCACTTTAC AATTTGCAAA ACGGCTGCAG 26700 | Exon 11 | [G/T] (26669) | [C/T] 
(26692) 
             I  T  G   F  T  L   Q  F  A  K   R  L  Q  387 
GTCAACCTAT TGGTCAAGCC ATCAGAAAAA ATTCAGTGAG TCTCTTGAAA 26750 | [G/C] (26740) 
 V  N  L   L  V  K  P   S  E  K   I  Q                 399 
ATGGTTATTT TGATATGATC TGTAGTATCG TAGTATCTTC TTGTAAGAAC 26800 | [T/C]_rs3211949 (26776)  
ATGAGTAAAT CTATGTAAGT AAGTGGAAAT AACATCTGAT ATCAACTTAT 26850 |[A/C] (26822) 
CTTTAGCTTA ATGTCACCAA TCATTATTAA ATGCTTATGA CTAATTTCAC 26900  
AGATTTTGGA ATGGTTTTAT GGTTTTATTT GAGCATTTGA TAGCATCATG 26950 | [A/G]_rs3211951 (26927) | 
[ATGGTTTTATGGTTTTATTTGAGCATTTGATAGCATC/-]_rs3211950 (26948_26984)  
GTTTTATGGT TTTATTTGAG CATTTGATAG CATCTCTTAT TTTGTTAGCT 27000  
GCCCAAATAT TTCTATGACA ATAATTAATT TTTGGAATTC ATATTTCAGT 27050 | [C/T]_rs3211952 (27003) | 
[A/G]_rs3211953 (27041)  
TCCCCGAGAA TTTATTGAAA GGAAAAATCC ACACTTGTGA AAAAAAATCA 27100  
ATGTGATTAG AAGACATATA AGAGCAAAGG AAGTCAAAAA CAACTATATT 27150  
 53 
AAAATTTAAA TGAGTCATTA CAGGAACAAA ATCAAATTAG CAACAGCAAC 27200 | [A/T] (27163) 
TAATTTATGA ACATTTATTT TAAAGTTTGT TATATATAAA TATTAGTTTA 27250 | [ATATAA/-] (27234_27239) 
TATGTTCATA ATTATTTTCA ACGTATATTA CAGAGTATTA AAGAATCTGA 27300 | Exon 12  
                                      V  L   K  N  L   404 
AGAGGAACTA TATTGTGCCT ATTCTTTGGC TTAATGAGGT TTGTATTTGC 27350 |[T/C] (27309) 
K  R  N  Y   I  V  P   I  L  W   L  N  E               417 
AGCTGTTAGT CATTAAAAAC AACCTTCTTT GTATATAAAC AAGCTCTTGA 27400  
TGTTTCAAAA GAATGTATAG TATTTAAAGC TATATGTATT TCCATTACCC 27450 |[G/T] (27411)| [T/C]_rs3211954 
(27418)  
ATATGGATGA GTATACATTT ATTTAACCTA TTTGAGATGA TCCAATTGAA 27500 | [A/G] (27494) 
CAAAAACATT TCCTATCATT TAAGATTTTC TTCAAAAATG CATCTATTAA 27550  
ACACATTTTC TTGTTGTAAC ATTTGTCTTC TATTGCCTGA CAAGGTATTT 27600  
TTACTATAAA TCCATGCATT GATAGCTATA AAAATAGGAA AAACATTGAA 27650  
TAAGTCTTTG GAGCAAATGA AACTGTTGAC CCTTTGATAG TTCTGAAGAG 27700  
CAAATGAATC CTAGTACATT GAAGAGTACC GTACTCTATC TGGCACTTAA 27750  
TTGCCTTTCT TGACTTGCAA AAGGAATTCC ATTAACTTGC CTTATAGATA 27800  
CTGATGACTA ACACCAATAG AGGTGTTAGA AAAAAGGGTG ATAGGCAATT 27850  
GAAGGGTTTA TTTTGTTTTA CTAACGTACC CAAATAATGT TGATTATTAA 27900  
CTTGATTACA GACTGGGACC ATTGGTGATG AGAAGGCAAA CATGTTCAGA 27950 | Exon 13  
             T  G  T   I  G  D   E  K  A  N   M  F  R  430 
AGTCAAGTAA CTGGAAAAAT AAACCTCCTT GGCCTGATAG AAATGATCTT 28000  
 S  Q  V   T  G  K  I   N  L  L   G  L  I   E  M  I  L 447 
ACTCAGTGTT GGTGTGGTGA TGTTTGTTGC TTTTATGATT TCATATTGTG 28050  
  L  S  V   G  V  V   M  F  V  A   F  M  I   S  Y  C   463 
CATGCAGATC GAAAACAATA AAATAAGTAA GTATGTACCA AAAAATATTG 28100 | UTR |[AGTA/-] (28080_28083) 
A  C  R  S   K  T  I   K                               471 
CTTCAATAAT ATTAGCTTAT ATATTACTTG TTTTCACTTT ATCAAAGAGA 28150  
AGTTACATAT TAGGCCATAT ATATTTCTAG ACATGTCTAG CCACTGATCA 28200  
TTTTTAAATA TAGGTAAATA AACCTATAAA TATTATCACG CAGATCACTA 28250  
AAGTATATCT TTAATTCTGG GAGAAATGAG ATAAAAGATG TACTTGTGAC 28300 | [G/T] (28278) 
CATTGTAACA ATAGCACAAA TAAAGCACTT GTGCCAAAGT TGTCCAAAAT 28350 | [A/G]_rs8956 (28302) | 
[GCACAAATAAAGCACT/-]_rs3212018 (28314_28329)  
TGACTGGTTC ATTTCTCAAT TATATAGCTA GTTATATATT ATCTGATACT 28400 | [T/G]_rs3211956 (28375)  
TAAAAATAAT TGACTAGGAA ATGGTTTCAT AAGACCAGGA TTGCTGCATG 28450 | [G/A] (28412)| [G/A]_rs3211957 
(28423)  
TAGACATGCT GGCCGTGCAT TTTCCAAATC CAGAAAAGTC CTGAACAAAA 28500  
ATTTGAATAT AATAGTATCA GGAAATAGGG GAAAATAGTG TTCAACATAG 28550 | [-/AAAA] (28507_28508) | [A/T] 
(28509) 
TAGAACCAAG TACTCAGAGT GGTGTACAAG AGTTTAGGCC TCTATGCTTT 28600  
AGATATTAGT GTCCATGCAC TCTTAAAGAT GAATGAATGC CTGACCTTTC 28650  
CTAAAGGAAA ACCTTTTTTT AGTTATCACA GGTAACATTG GTGTTGCCTG 28700 | [A/G]_rs3211958 (28685)  
TGGGGGAGAA TTTTTTACTT TCTCCCTATT TTTCTTCAGC CCACCTCAAG 28750 | [C/G] (28747) 
GCAATGTAAA TAAAAGCAGT ATGTGTGTTA TAATAACTTA TTTAGTTGTT 28800  
TACTGTGTGC CAGTACCATG CTAAAGAAAG ATTCTTTATC TCACATGATC 28850  
CCTAATACAA TTTCATGATT TTCCAATAGC CTGGATTCAT CAGCATCCAT 28900  
TCTATCTTCT AGAGATGTTC CATGAAATCA TACATTTTAA TTGTTTGTGA 28950 | [G/A]_rs3211959 (28947)  
CCAAAGCATA AATCAGTGAA AGTGGAATTT GGGGACCAAT AATTTCCTTT 29000 | [AAAGTG/-] (28969_28974) | [A/G] 
(28971) 
TGTGAGATGG AGAGCTTGTG TTTGAAAAGG CAACCTAATT TTTGGTTCTA 29050  
ATCACTTCTA CCACTATTTA GTCACCAAAA AGACAATAAT TCTGCATCCA 29100 | [G/A] (29082) 
AACTATTTGG ACAGAATGGC TTCAAAATGC TAGCCTAAAA TGTTCACATT 29150 |[C/G] (29112) 
ATAAAAAGTT AAATATTACC TTCAATACCT GTCAGTAGCC TACTGACAAA 29200 | [-/CAGT] (29186_29187) 
TTATGACTAA ACAAAGGTAT TTGTATGACT ATGTAATAGA TCATCCGCTG 29250 | [A/G]_rs3211960 (29225)  
AAAAGTAAAA CAAAATAACA AAAAAACTTG TCCTAATGGG AAAGCATGCT 29300 | [665bp/-] (29281_29945) 
TAATAAAAGG AAATGCAGAA GTTATAAACA TGTTTTGTAA GTAAGTATTC 29350 | [AGTA/-] (29344_29347) 
AGAATTAAAA TTATGTGATA CATTTTTATG ATTGCTTAAT GATCCTTGGA 29400  
TGTCAGATTC CTTGGGTCTA TTTATAGCTA AATTATAATG AAAAATTCAA 29450  
GGCTTGCTGG AGCAACTTTG TCAACAAATA TATTAGTTTT GCTTATATAT 29500  
TTGATTTTTA TGTGGAAAAA TTACTACCCT TTTTTACAAG CAGAGAATAA 29550  
ACTGTTGATT ACTTGATTTA CTAGATTTAG AAGAATCACA AAAGATATGT 29600  
AGATTTTCTT AAGCAAAATT CAGCTCTTAA TATCATAAAA ATTATATCTT 29650  
TGGGCAGATT TGTAAACAAT AGGAACAAGT AAGAAGACAG GTATGTAAGA 29700  
AGTAGCAAAG TGTAAGACGG TGGAGCTTTA ATGTGTGGTT TTACTCAGGG 29750 | [C/A] (29706) 
GGTCACAAGA AAATAACCCA ATGGTCCTTT TGAAAGTAGT ACATACACCT 29800  
TTAAATGGAA CTTGGTCTGA AGGGTGTGGA AATGCTGGTC CAGGGCAGAT 29850 | [G/A] (29815) 
GCACTTCAGC TACCGTTCCT TGCCTGGTGT GTGCTTGTCT TGAGGGTTGA
 








AGCACCCT TCTTATGTGC CTTTCTGGAA TGGGAATGTG TTTTGCCCTA 29950  
TTGGTGAAGT CCGTTAGAGA ACTTCTCTCT GCAGCTAGAG AAACTGAACT 30000 | [G/A] (29963) 
GATTAATAAA AAGTATGATA TCTAAGATAT ACTGCCACTC TACAGGTAGT 30050 | [C/G] (30040) 
AAATGATTCT TCACATTTGT GCGCCAGCTA CATCATGACC CTTGGTAATA 30100  
CCGACCAACA GGATGAAAAT TGGATATGCT TTACTTTTAC AAAGCACACC 30150  
TTATCTTTTA GTTGAAGAAA TGGTGGCACT 
 
Figure 5. CD36 annotated sequence. 
 
3.2 DISTRIBUTION OF CD36 VARIANTS IN HIGH AND LOW HDL GROUPS 
3.2.1 Non-Hispanic Whites 
Of the 131 variants identified in NHWs, 44 had a MAF ≥5%, 52 had a MAF 1-5%, and 35 had a 
MAF <1%. Of the variants identified in our study but not previously identified in the 
SeattleSNPs database the MAF range was 0.005-0.396%. Among the common variants (MAF 
≥5%), three variants had a statistically significant difference when comparing the allele 
frequencies between the high HDL-C and low HDL-C groups: 4249C>T(p=0.047), 
13094T>A(p=0.040), and 14299A>G(p=0.047). However, 13 of the common variants have a p-
value of between 5-10%, which may be statistically significant due to the small sample size.  
Of the relatively uncommon or rare variants (MAF<5%), 21 were present only in the low HDL-C 
group versus 25 present only in the high HDL-C group. For NHWs: 14 out of 47 (29.8%) 
individuals with high HDL-C had more than two rare variants versus 16 out of 48 (33.3%) 
individuals with low HDL-C; and 11 out of 47 (23.4%) individuals with high HDL-C had more 
than three rare variants versus 6 out of 48 (12.5%) individuals with low HDL-C:, and 8 out of 47 
(17.0%) individuals with high HDL-C had more than four rare variants versus 5 out of 48 
(10.4%) individuals with low HDL-C. Of five exonic variants identified, one was found only in 
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the low HDL-C group (27309T>C, p=0.321 ), one was found only in the high HDL-C group 
(26669G>T, p=0.311), and two of them were found in both the high and low HDL-C groups. 
Table 10 summarizes the distribution of common CD36 variants, and Table 11 summarized the 
distribution of relatively uncommon or rare CD36. Those variants highlighted in yellow are only 


















Table 10. Distribution of common CD36 variants in high and low HDL-C groups in 
NHWs. 
 









MAF (n=48) p-value 
2521 G>A rs3211816 Intron 2 0.389 0.340 0.438 0.170 
2996 C>A rs3211820 Intron 2 0.405 0.351 0.458 0.132 
3094 G>A rs3211821 Intron 2 0.453 0.426 0.479 0.458 
3157 G>A rs3211822 Intron 2 0.404 0.348 0.458 0.123 
3991 A>C rs3211827 Intron 2 0.389 0.340 0.438 0.170 
4249 C>T rs3211830 Intron 2 0.053 0.085 0.021 0.047 
4366 A>T rs997906 Intron 2 0.395 0.340 0.448 0.130 
4648 C>A rs3211834 Intron 2 0.405 0.351 0.458 0.132 
4993 G>A rs3211839 Intron 2 0.441 0.413 0.468 0.450 
7167 G>A rs3211842 Intron 2 0.437 0.415 0.458 0.546 
7854 A>G rs3211849 Intron 2 0.442 0.415 0.469 0.455 
9473 C>T rs1054516 Intron 2 0.452 0.426 0.479 0.464 
9534 C>T rs1054517 Intron 2 0.436 0.415 0.457 0.556 
9600 A>G rs1133344 Intron 2 0.065 0.085 0.043 0.248 
9794_9799 del6 
 
Intron 2 0.058 0.097 0.026 0.078 
10876 A>G rs3211864 Intron 3 0.063 0.096 0.031 0.068 
11741 C>T rs3211870 Intron 3 0.437 0.415 0.458 0.546 
11890 A>G rs3211871 Intron 3 0.388 0.337 0.438 0.157 
12132 T>C 
 
Intron 3 0.388 0.337 0.438 0.157 
12143_12144 del2 
 
Intron 3 0.389 0.330 0.446 0.110 
12272_12274 del3 rs3211874 Intron 3 0.379 0.321 0.433 0.129 
12919 G>A rs1358337 Intron 3 0.437 0.415 0.458 0.546 
13094 T>A rs3211879 Intron 3 0.068 0.106 0.031 0.040 
13388 A>G rs3211881 Intron 3 0.062 0.091 0.034 0.120 
13528_13530 del3 rs3211882 Intron 3 0.396 0.356 0.435 0.275 
13577 T>A rs3211883 Intron 3 0.06 0.089 0.032 0.103 
13936 C>T rs3211885 Intron 3 0.437 0.415 0.458 0.546 
13973 G>A rs3211886 Intron 3 0.389 0.340 0.438 0.170 
14299 A>G rs3173799 Intron 3 0.053 0.085 0.021 0.047 
14455 A>T rs3173800 Intron 3 0.389 0.340 0.438 0.170 
19307_19335 del29 rs3211915 Intron 6 0.468 0.447 0.490 0.555 
22296 C>G rs3211928 Intron 7 0.437 0.500 0.375 0.097 
22749 C>T rs3211931 Intron 7 0.426 0.468 0.385 0.249 
23463 T>C rs3211932 Intron 7 0.426 0.468 0.385 0.249 
 57 
Table 10 Continued 
23533 G>A rs3173802 Intron 7 0.426 0.468 0.385 0.249 
23689 G>A rs3173803 Intron 7 0.426 0.468 0.385 0.249 
24426 T>A rs3173804 Intron 8 0.426 0.468 0.385 0.249 
25580 T>C rs3173805 Intron 9 0.426 0.468 0.383 0.238 
26512 C>A rs1405747 Intron 10 0.426 0.468 0.385 0.249 
27003 C>T rs3211952 Intron 11 0.426 0.468 0.385 0.249 
28314_28329 del16 rs3212018 
Exon- 
3'UTR 0.163 0.181 0.146 0.514 
28685 A>G rs3211958 3' flanking 0.426 0.468 0.385 0.249 
29225 A>G rs3211960 3' flanking 0.426 0.468 0.385 0.249 

















Table 11. Distribution of relatively uncommon or rare CD36 variants in high and 
low HDL-C groups in NHWs. 
 











Intron 1 0.037 0.011 0.062 
861 T>C rs1527463 Intron 2 0.016 0.011 0.021 
1024 A>G rs3211809 Intron 2 0.016 0.011 0.021 
2389 delT rs3211815 Intron 2 0.047 0.074 0.021 
2638 T>G rs3211817 Intron 2 0.048 0.076 0.021 
2688 A>G 
 
Intron 2 0.005 0.011 0.000 
3049 G>A 
 
Intron 2 0.011 0.000 0.021 
3304 C>G rs3212000 Intron 2 0.043 0.043 0.042 
3349_3350 insA rs3211823 Intron 2 0.011 0.000 0.021 
3691 G>A rs3211825 Intron 2 0.016 0.032 0.000 
4108 G>A 
 
Intron 2 0.005 0.011 0.000 
4134 T>G rs3211828 Intron 2 0.047 0.074 0.021 
4595 G>A 
 
Intron 2 0.005 0.000 0.010 
4990 C>T rs3211838 Intron 2 0.043 0.067 0.021 
5497 A>G 
 
Intron 2 0.005 0.011 0.000 
6146 T>C 
 
Intron 2 0.005 0.011 0.000 
6652 G>T 
 
Intron 2 0.005 0.000 0.010 
7306 G>A rs3212001 Intron 2 0.026 0.011 0.042 
7664 G>A rs3212002 Intron 2 0.005 0.000 0.010 
7988 A>C rs3211851 Intron 2 0.048 0.076 0.021 
8595 T>A rs3211855 Intron 2 0.016 0.011 0.021 
8639 G>A 
 
Intron 2 0.005 0.000 0.011 
9136 A>T 
 
Intron 2 0.005 0.011 0.000 
9347 C>G 
 
Intron 2 0.005 0.011 0.000 
9616 T>C rs3212003 Intron 2 0.018 0.017 0.019 
9663 G>A rs3212004 Intron 2 0.005 0.011 0.000 
9786 delA 
 
Intron 2 0.036 0.065 0.013 
10279 C>T 
 
Intron 2 0.005 0.000 0.010 
10381 T>C rs3173798 Intron 2 0.047 0.074 0.021 
11249 T>G 
 
Intron 3 0.005 0.011 0.000 
11440 T>C 
 
Intron 3 0.016 0.021 0.010 
11472 C>A rs3211867 Intron 3 0.043 0.067 0.021 
11554 T>C rs3211868 Intron 3 0.048 0.076 0.021 
11618 A>G 
 
Intron 3 0.005 0.011 0.000 
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11684 T>A rs3211869 Intron 3 0.043 0.065 0.021 
11904 G>C 
 
Intron 3 0.005 0.000 0.010 
12145 G>A rs3211873 Intron 3 0.039 0.067 0.000 
12403 C>G rs3211875 Intron 3 0.039 0.068 0.011 
12642 G>A 
 
Intron 3 0.016 0.011 0.021 
12775 A>G rs3211876 Intron 3 0.026 0.000 0.052 
12936 A>T 
 
Intron 3 0.005 0.000 0.010 
13279 C>T 
 
Intron 3 0.006 0.000 0.011 
13456 A>G 
 
Intron 3 0.011 0.011 0.011 
14510 G>A 
 
Intron 3 0.005 0.000 0.010 
14903 G>A rs3211892 Intron 3 0.016 0.011 0.021 
15075 A>G 
 
Intron 4 0.005 0.011 0.000 
15833 C>T rs3212008 Intron 4 0.005 0.011 0.000 
15932 G>A rs1924 Intron 4 0.048 0.076 0.021 
16377 A>G 
 
Intron 4 0.016 0.011 0.021 
16385 C>T rs3212009 Intron 4 0.011 0.011 0.010 
16824 G>T 
 
Intron 4 0.005 0.000 0.010 
16983 G>A rs5956 
Exon 5 
(Synonymous) 0.042 0.043 0.042 
17274 A>T 
 
Intron 5 0.005 0.011 0.000 
17282_17823 insT 
 
Intron 5 0.005 0.011 0.000 
17641 G>A 
 
Intron 5 0.016 0.000 0.031 
17743 A>G rs3211905 Intron 5 0.016 0.011 0.021 
18137 delA 
 
Intron 5 0.016 0.011 0.021 
18463 C>T rs3211908 Intron 6 0.032 0.043 0.021 
18662 T>C rs3211909 Intron 6 0.016 0.011 0.021 
18724 A>C 
 
Intron 6 0.016 0.011 0.021 
18726 A>C 
 
Intron 6 0.022 0.000 0.043 
18966 G>A rs3211912 Intron 6 0.016 0.011 0.021 
19151 A>G rs3211913 Intron 6 0.01 0.000 0.024 
19228 A>C rs3211914 Intron 6 0.042 0.074 0.000 
19678 T>G 
 
Intron 6 0.016 0.011 0.021 
19810 G>A 
 
Intron 6 0.016 0.011 0.021 
20630 C>T rs3212013 Intron 7 0.021 0.032 0.010 
20758 C>G 
 
Intron 7 0.011 0.000 0.021 
20759 T>C 
 
Intron 7 0.005 0.011 0.000 
21084 C>T 
 
Intron 7 0.005 0.011 0.000 
21110 C>T rs3211922 Intron 7 0.016 0.000 0.031 
22830 C>T rs3212015 Intron 7 0.005 0.011 0.000 
22907 G>C 
 
Intron 7 0.005 0.011 0.000 
24071 A>T 
 
Intron 8 0.006 0.000 0.011 
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24104 A>G 
 
Intron 8 0.006 0.012 0.000 
24331 T>C 
 
Intron 8 0.005 0.011 0.000 
25575_25576 insA 
 
Intron 9 0.016 0.011 0.021 




synonymous) 0.005 0.011 0.000 
26822 A>C 
 




synonymous) 0.005 0.000 0.010 
27411 G>T 
 
Intron 12 0.026 0.032 0.021 
28080_28083 del4 
 
Exon- 3'UTR 0.021 0.032 0.010 
28375 T>G rs3211956 3' flanking 0.037 0.054 0.021 
28412 G>A 
 
3' flanking 0.005 0.011 0.000 
28572 G>T 
 
3' flanking 0.011 0.011 0.010 
29112 C>G 
 















Of the 281 variants identified in Blacks, 103 had a MAF ≥5%, 110 had a MAF 1-5%, and 68 had 
a MAF <1%. Of the variants identified in our study but not previously identified in the 
SeattleSNPs database the MAF range was 0.005-0.289%. Among the common variants (MAF 
≥5%), one variant had a statistically significant difference when comparing the allele frequencies 
between the high HDL-C and low HDL-C groups: 16568A>G (p=0.022). Of the relatively 
uncommon or rare variants (MAF<5%), 59 were present only in the low HDL-C group versus 32 
present only in the high HDL-C group. For Blacks: 32 out of 48 (66.7%) individuals with high 
HDL-C had more than two rare variants versus 34 out of 47 (72.3%) individuals with low HDL-
C; 28 out of 48 (58.3%) individuals with high HDL-C had more than three rare variants versus 
30 out of 47 (63.8%) individuals with low HDL-C; 22 out of 48(45.8%) individuals with high 
HDL-C had more than four rare variants versus 24 out of 47 (51.1%) individuals with low HDL-
C. Of 13 exonic variants identified, four were found only in the low HDL-C group (25048G>T, 
p=0.311; 25849T>G, p=0.311; 26692C>T, p=0.311; 10465G>A, p=0.311), one was found only 
in the high HDL-C group (25850A>T, p=0.087), and eight of them were found in both the high 
and low HDL-C groups (one of these variants was missense). Table 12 summarizes the 
distribution of common CD36 variants, and Table 13 summarized the distribution of relatively 
uncommon or rare CD36. Those variants highlighted in yellow are only found in the low HDL-C 





We particularly looked at variants causing nonsense and frameshift changes in the Black 
population. Except for two (10465G>A and 14701_15292del592), the remaining were not 
uniquely present in low HDL-C groups. 10465 was in exon 3 causing a nonsense change and was 
present in an individual in the low HDL-C group. 14701_15292 results in the partial removal of 
intron 3, total removal of exon 4, and partial removal of intron 4 was present in the individual 

















Table 12. Distribution of common CD36 variants in high HDL-C and low HDL-C 
groups in Blacks 
 








C (n=48) P value 
106 G>T rs3211805 5' flanking 0.063 0.042 0.085 0.218 
947_948 del2 
 
Intron 2 0.084 0.104 0.064 0.317 
949_950 insA 
 
Intron 2 0.084 0.104 0.064 0.317 
1021 T>C rs3211808 Intron 2 0.068 0.038 0.095 0.151 
1024 A>G rs3211809 Intron 2 0.244 0.256 0.232 0.716 
1547 T>G rs3211810 Intron 2 0.147 0.156 0.138 0.727 
1848 T>C rs3211811 Intron 2 0.058 0.031 0.085 0.112 
2162 A>G rs3211812 Intron 2 0.058 0.031 0.085 0.112 
2389 delT rs3211815 Intron 2 0.205 0.219 0.191 0.642 
2521 G>A rs3211816 Intron 2 0.100 0.115 0.085 0.498 
2638 T>G rs3211817 Intron 2 0.105 0.094 0.117 0.601 
2652 A>C rs3211818 Intron 2 0.084 0.104 0.064 0.317 
2996 C>A rs3211820 Intron 2 0.416 0.438 0.394 0.540 
3094 A>G rs3211821 Intron 2 0.295 0.292 0.298 0.925 
3157 G>A rs3211822 Intron 2 0.400 0.427 0.372 0.441 
3350 delA rs3211823 Intron 2 0.196 0.208 0.182 0.651 
3412 C>T rs3211824 Intron 2 0.054 0.031 0.080 0.149 
3714_3715 del2 rs3211826 Intron 2 0.168 0.177 0.160 0.747 
3991 A>C rs3211827 Intron 2 0.074 0.106 0.043 0.096 
4134 T>G rs3211828 Intron 2 0.221 0.229 0.213 0.785 
4249 C>T rs3211830 Intron 2 0.116 0.104 0.128 0.613 
4259 T>C rs3211831 Intron 2 0.089 0.104 0.074 0.473 
4366 A>T rs997906 Intron 2 0.095 0.115 0.074 0.345 
4648 C>A rs3211834 Intron 2 0.305 0.333 0.277 0.396 
4879 G>C rs3211836 Intron 2 0.094 0.117 0.070 0.279 
4990 C>T rs3211838 Intron 2 0.200 0.223 0.174 0.412 
4993 A>G rs3211839 Intron 2 0.489 0.511 0.465 0.542 
7167 G>A rs3211842 Intron 2 0.289 0.323 0.255 0.304 
7175 A>G rs3211843 Intron 2 0.106 0.106 0.106 1.000 
7430 C>A rs3211845 Intron 2 0.054 0.031 0.078 0.160 
7854 A>G rs3211849 Intron 2 0.489 0.489 0.489 1.000 
7947 G>A rs3211850 Intron 2 0.063 0.062 0.064 0.970 
7988 A>C rs3211851 Intron 2 0.191 0.213 0.170 0.458 
8595 T>A rs3211855 Intron 2 0.210 0.217 0.202 0.798 
8796 A>G rs3211856 Intron 2 0.055 0.054 0.056 0.972 
9152 delC rs3211857 Intron 2 0.065 0.096 0.033 0.087 
9473 T>C rs1054516 Intron 2 0.277 0.250 0.307 0.390 
9474 G>A rs3211858 Intron 2 0.056 0.054 0.057 0.942 
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9505 T>A rs3211859 Intron 2 0.054 0.052 0.056 0.916 
9534 C>T rs1054517 Intron 2 0.261 0.312 0.205 0.096 
9600 G>A rs1133344 Intron 2 0.394 0.402 0.385 0.818 
9786 delA 
 
Intron 2 0.193 0.217 0.167 0.395 
9794_9799 del6 
 
Intron 2 0.051 0.033 0.071 0.243 
10381 T>C rs3173798 Intron 2 0.189 0.208 0.170 0.503 
11137 delG rs3211865 Intron 3 0.069 0.096 0.043 0.151 
11472 C>A rs3211867 Intron 3 0.300 0.302 0.298 0.950 
11554 T>C rs3211868 Intron 3 0.189 0.208 0.170 0.503 
11684 T>A rs3211869 Intron 3 0.188 0.207 0.170 0.526 
11741 C>T rs3211870 Intron 3 0.371 0.402 0.340 0.383 
12132 T>C 
 
Intron 3 0.072 0.098 0.045 0.175 
12143_12144 del2 
 
Intron 3 0.088 0.120 0.056 0.127 
12145 G>A rs3211873 Intron 3 0.162 0.203 0.125 0.191 
12272_12274 del3 rs3211874 Intron 3 0.090 0.120 0.058 0.152 
12403 C>G rs3211875 Intron 3 0.101 0.139 0.066 0.141 
12919 G>A rs1358337 Intron 3 0.463 0.447 0.479 0.661 
12998 C>A rs3211878 Intron 3 0.058 0.031 0.085 0.112 
13094 T>A rs3211879 Intron 3 0.058 0.042 0.074 0.333 
13388 A>G rs3211881 Intron 3 0.056 0.034 0.076 0.219 
13528_13530 del3 rs3211882 Intron 3 0.109 0.130 0.087 0.343 
13577 A>T rs3211883 Intron 3 0.363 0.359 0.367 0.911 
13758 T>C rs3211884 Intron 3 0.060 0.033 0.087 0.120 
13936 C>T rs3211885 Intron 3 0.311 0.344 0.277 0.317 
13973 G>A rs3211886 Intron 3 0.079 0.115 0.043 0.066 
14081 C>A rs3211888 Intron 3 0.058 0.031 0.085 0.112 
14299 A>G rs3173799 Intron 3 0.189 0.208 0.170 0.503 
14455 A>T rs3173800 Intron 3 0.105 0.125 0.085 0.370 
14482 T>G rs3211890 Intron 3 0.080 0.096 0.064 0.419 
14882 T>C rs3211891 Intron 3 0.063 0.031 0.096 0.068 
14903 G>A rs3211892 Intron 3 0.321 0.333 0.309 0.714 
15554_15557 del3 
 
Intron 4 0.063 0.031 0.096 0.068 
15932 G>A rs1924 Intron 4 0.237 0.250 0.223 0.666 
15975 A>G rs3211895 Intron 4 0.068 0.042 0.096 0.140 
16040 G>T rs3211896 Intron 4 0.068 0.052 0.085 0.367 
16163 G>A rs3211897 Intron 4 0.090 0.106 0.074 0.446 
16568 A>G rs3211899 Intron 4 0.059 0.021 0.100 0.022 
17743 A>G rs3211905 Intron 5 0.080 0.062 0.098 0.372 
17807_17813 del7 rs3211906 Intron 5 0.280 0.255 0.304 0.456 
18137 delA 
 
Intron 5 0.352 0.302 0.412 0.127 
18662 T>C rs3211909 Intron 6 0.335 0.267 0.405 0.058 
18911 T>G rs3211911 Intron 6 0.084 0.104 0.064 0.317 
19151 G>A rs3211913 Intron 6 0.494 0.545 0.446 0.181 
19386 T>C rs3211916 Intron 6 0.289 0.260 0.319 0.372 
19678 T>G 
 
Intron 6 0.333 0.277 0.391 0.097 
19810 G>A 
 
Intron 6 0.389 0.333 0.447 0.109 
19877 T>C rs3211917 Intron 6 0.053 0.052 0.053 0.973 
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20644 T>G rs3211920 Intron 7 0.089 0.083 0.096 0.764 
22296 C>G rs3211928 Intron 7 0.174 0.125 0.223 0.073 
22351 A>C rs3211930 Intron 7 0.079 0.062 0.096 0.396 
22749 C>T rs3211931 Intron 7 0.170 0.125 0.217 0.092 
23463 T>C rs3211932 Intron 7 0.165 0.117 0.213 0.077 
23533 G>A rs3173802 Intron 7 0.069 0.052 0.087 0.346 
23689 G>A rs3173803 Intron 7 0.168 0.125 0.213 0.106 
24080 T>C 
 
Intron 8 0.059 0.031 0.087 0.104 
24166 G>A rs3211933 Intron 8 0.054 0.062 0.045 0.610 
24426 T>A rs3173804 Intron 8 0.168 0.125 0.213 0.106 
25025 T>G rs3211938 
Exon 9 
(Nonsense) 0.226 0.234 0.217 0.786 
25580 T>C rs3173805 Intron 9 0.060 0.043 0.078 0.314 
25945 C>A rs3211942 Intron 10 0.063 0.031 0.096 0.068 
26512 C>A rs1405747 Intron 10 0.207 0.160 0.256 0.108 
27003 C>T rs3211952 Intron 11 0.111 0.094 0.128 0.456 
28685 A>G rs3211958 3' flanking 0.082 0.053 0.111 0.151 
29225 A>G rs3211960 3' flanking 0.059 0.042 0.078 0.297 














Table 13. Distribution of relatively uncommon or rare variants in high HDL-C and 
low HDL-C groups in Blacks 
 











Intron 1 0.005 0.010 0.000 
861 T>C rs1527463 Intron 2 0.037 0.052 0.021 
1466 G>T 
 
Intron 2 0.005 0.000 0.011 
1529 G>A 
 
Intron 2 0.005 0.000 0.011 
1675 C>A 
 
Intron 2 0.005 0.000 0.011 
2092 A>G 
 
Intron 2 0.005 0.000 0.011 
2273 T>G rs3211813 Intron 2 0.037 0.042 0.032 
2298 C>A 
 
Intron 2 0.026 0.031 0.021 
2306 A>G rs3211814 Intron 2 0.037 0.000 0.074 
2702 T>C 
 
Intron 2 0.005 0.000 0.011 
2856 A>G 
 
Intron 2 0.005 0.010 0.000 
3079 C>G 
 
Intron 2 0.032 0.031 0.032 
3505 C>G 
 
Intron 2 0.005 0.000 0.011 
3835 delA 
 
Intron 2 0.026 0.010 0.043 
3852 G>A 
 
Intron 2 0.005 0.010 0.000 
4039 C>T 
 
Intron 2 0.005 0.010 0.000 
4046 G>T 
 
Intron 2 0.005 0.010 0.000 
4133 T>G 
 
Intron 2 0.005 0.000 0.011 
4266 C>T 
 
Intron 2 0.005 0.000 0.011 
4308 A>G 
 
Intron 2 0.005 0.000 0.011 
4752 C>A rs3211835 Intron 2 0.016 0.014 0.019 
5081 C>T 
 
Intron 2 0.005 0.000 0.011 
5241 G>C rs3211840 Intron 2 0.022 0.022 0.023 
5290 G>A 
 
Intron 2 0.006 0.000 0.011 
5504 T>A 
 
Intron 2 0.005 0.000 0.011 
5913 delA 
 
Intron 2 0.016 0.032 0.000 
5950 C>T 
 
Intron 2 0.005 0.000 0.011 
6007 C>T rs3211841 Intron 2 0.016 0.010 0.021 
6238 A>G 
 
Intron 2 0.005 0.000 0.011 
6638 G>T 
 
Intron 2 0.032 0.031 0.032 
6877 G>A 
 
Intron 2 0.005 0.010 0.000 
7037_7038 insA 
 
Intron 2 0.032 0.031 0.032 
7046 G>C 
 
Intron 2 0.005 0.011 0.000 
7265 G>T rs3211844 Intron 2 0.021 0.010 0.032 
7351 T>A 
 
Intron 2 0.005 0.000 0.011 
7414 C>T 
 
Intron 2 0.005 0.000 0.011 
7486 C>A rs3211846 Intron 2 0.021 0.010 0.033 
7663 C>T rs3211848 Intron 2 0.038 0.052 0.022 
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8152 G>A rs3211852 Intron 2 0.021 0.031 0.011 
8228 G>A 
 
Intron 2 0.005 0.011 0.000 
8414 A>T 
 
Intron 2 0.011 0.011 0.011 
8427 C>A 
 
Intron 2 0.016 0.011 0.021 
8583 C>T rs3211854 Intron 2 0.043 0.054 0.032 
8873 A>G 
 
Intron 2 0.011 0.021 0.000 
9045 T>A 
 
Intron 2 0.032 0.031 0.033 
9117 T>G 
 
Intron 2 0.033 0.022 0.044 
9291 G>A 
 
Intron 2 0.005 0.000 0.011 
9699 T>C 
 
Intron 2 0.021 0.021 0.021 
10045 C>T 
 
Intron 2 0.011 0.000 0.022 
10103 T>C 
 
Intron 2 0.005 0.000 0.011 
10342 T>C 
 
Intron 2 0.005 0.000 0.011 
10423_10424 del2 rs3211861 
Exon 3 




(Nonsense) 0.005 0.000 0.011 
10654 C>A 
 
Intron 3 0.005 0.010 0.000 
10876 A>G rs3211864 Intron 3 0.037 0.042 0.032 
10975 G>A 
 
Intron 3 0.005 0.010 0.000 
11155 C>T rs3211866 Intron 3 0.021 0.011 0.032 
11640 G>A 
 
Intron 3 0.011 0.010 0.011 
11890 A>G rs3211871 Intron 3 0.026 0.042 0.011 
11943 C>T 
 
Intron 3 0.021 0.000 0.043 
12124 T>C rs3211872 Intron 3 0.021 0.010 0.032 
12125_12126 ins2 
 
Intron 3 0.033 0.021 0.044 
12609 G>C 
 
Intron 3 0.011 0.010 0.011 
12691 A>T 
 
Intron 3 0.016 0.021 0.011 
12745 A>C 
 
Intron 3 0.005 0.000 0.011 
13346 T>C rs3211880 Intron 3 0.034 0.034 0.033 
13479 C>G 
 
Intron 3 0.027 0.022 0.033 
13548 C>T 
 
Intron 3 0.005 0.011 0.000 
14075 C>T 
 
Intron 3 0.005 0.010 0.000 
14076 G>A 
 
Intron 3 0.011 0.000 0.021 
14190 T>C rs3211889 Intron 3 0.016 0.000 0.032 
14500 T>C 
 




Intron 4 0.005 0.000 0.011 
15062 T>C rs3211893 Intron 4 0.043 0.043 0.043 
15405 A>G 
 
Intron 4 0.005 0.000 0.011 
15425 G>A 
 
Intron 4 0.026 0.021 0.032 
15676 A>G 
 
Intron 4 0.016 0.010 0.021 
16051 T>C 
 
Intron 4 0.005 0.000 0.011 
16295 C>T 
 
Intron 4 0.016 0.021 0.011 
16565 T>G 
 
Intron 4 0.011 0.021 0.000 
16741 A>G 
 




(Nonsense) 0.011 0.010 0.011 
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17093 T>A rs3173801 Intron 5 0.042 0.042 0.043 
17282 T>A 
 
Intron 5 0.042 0.042 0.043 
17292 G>A 
 
Intron 5 0.005 0.000 0.011 
17421_17433 del13 rs3211903 Intron 5 0.047 0.052 0.043 
17437 T>G 
 
Intron 5 0.005 0.000 0.011 
17462 delT rs3211904 Intron 5 0.042 0.042 0.043 
18119 G>A 
 
Intron 5 0.009 0.000 0.018 
18364_18367 del4 rs3211907 Intron 6 0.042 0.042 0.043 
18463 C>T rs3211908 Intron 6 0.012 0.000 0.024 
18596_18597 insT 
 
Intron 6 0.006 0.011 0.000 
18650_18651 ins3 
 
Intron 6 0.006 0.011 0.000 
18659 T>C 
 
Intron 6 0.005 0.010 0.000 
18784 C>T 
 
Intron 6 0.005 0.000 0.011 
18785 G>A rs3211910 Intron 6 0.043 0.042 0.044 
18821_18833 del13 
 
Intron 6 0.005 0.000 0.011 
18825 G>A 
 
Intron 6 0.005 0.010 0.000 
18966 G>A rs3211912 Intron 6 0.011 0.000 0.021 
19260_19261 ins4 
 
Intron 6 0.016 0.031 0.000 
19426 C>T 
 
Intron 6 0.005 0.010 0.000 
19673 A>T 
 
Intron 6 0.016 0.021 0.011 
19742 A>G 
 
Intron 6 0.005 0.010 0.000 
20108 T>G 
 
Intron 6 0.011 0.000 0.021 
20119_20120 ins23 
 
Intron 6 0.016 0.021 0.011 
20141 T>A 
 
Intron 6 0.005 0.010 0.000 
20440 A>G rs3211919 Intron 7 0.032 0.031 0.032 
20584 A>T 
 
Intron 7 0.026 0.021 0.032 
20843 T>C 
 
Intron 7 0.005 0.010 0.000 
21034 G>A 
 
Intron 7 0.011 0.010 0.011 
21111 G>A rs3211923 Intron 7 0.011 0.010 0.011 
21138 G>A 
 
Intron 7 0.021 0.021 0.021 
21174 T>C 
 
Intron 7 0.011 0.010 0.011 
21320_21321 ins4 
 
Intron 7 0.005 0.010 0.000 
21728 C>T 
 
Intron 7 0.007 0.000 0.015 
21882 G>A 
 
Intron 7 0.027 0.031 0.022 
21891 G>A rs3211926 Intron 7 0.011 0.010 0.011 
21927 C>T rs3211927 Intron 7 0.011 0.010 0.011 
21984 T>C 
 
Intron 7 0.026 0.031 0.021 
22338 A>G rs3211929 Intron 7 0.011 0.010 0.011 
22614 T>C 
 
Intron 7 0.011 0.010 0.011 
23008 G>C 
 
Intron 7 0.005 0.000 0.011 
23219 G>A 
 
Intron 7 0.005 0.000 0.011 
23345 G>C 
 
Intron 7 0.005 0.010 0.000 
23459_23488 del30 
 
Intron 7 0.005 0.010 0.000 
23780 G>A 
 
Intron 7 0.026 0.031 0.021 
24071 A>T 
 
Intron 8 0.011 0.000 0.022 
24165 C>T rs3211933 Intron 8 0.033 0.042 0.023 
24186 C>G rs3211935 Intron 8 0.011 0.010 0.012 
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24427 A>T rs3211936 Intron 8 0.037 0.021 0.053 
24496 A>G 
 
Intron 8 0.005 0.000 0.011 
24545 C>T 
 
Intron 8 0.021 0.042 0.000 
24657 T>C 
 




synonymous) 0.005 0.000 0.011 
25276 T>C rs3211939 Intron 9 0.037 0.021 0.053 
25305 C>T 
 
Intron 9 0.005 0.000 0.011 
25550 G>A rs3211940 Intron 9 0.037 0.043 0.032 








synonymous) 0.016 0.031 0.000 
26016_26019 del4 
 
Intron 10 0.011 0.000 0.021 
26076 G>A rs1527483 Intron 10 0.011 0.000 0.021 
26089 G>T rs3211944 Intron 10 0.047 0.042 0.053 
26158 T>C 
 
Intron 10 0.016 0.010 0.021 
26160 G>T rs3211945 Intron 10 0.011 0.010 0.011 
26262 T>C 
 
Intron 10 0.016 0.010 0.021 
26305 G>A rs3211946 Intron 10 0.011 0.010 0.011 
26346 C>T rs3211947 Intron 10 0.016 0.021 0.011 
26446_26449 del4 
 
Intron 10 0.005 0.000 0.011 
26484 G>A 
 




synonymous) 0.005 0.000 0.011 
26740 G>C 
 
Intron 11 0.005 0.010 0.000 
26776 T>C rs3211949 Intron 11 0.011 0.010 0.011 
26927 A>G rs3211951 Intron 11 0.016 0.021 0.011 
26948_26984 del37 rs3211950 Intron 11 0.011 0.000 0.021 
27041 A>G rs3211953 Intron 11 0.011 0.010 0.011 
27163 A>T 
 
Intron 11 0.021 0.031 0.011 
27234_27239 del6 
 
Intron 11 0.005 0.000 0.011 
27494 A>G 
 
Intron 12 0.005 0.000 0.011 
28080_28083 del4 
 
Exon- 3'UTR 0.016 0.021 0.011 
28278 G>T 
 
Exon- 3'UTR 0.016 0.021 0.011 
28302 A>G rs8956 Exon- 3'UTR 0.037 0.021 0.053 
28314_28329 del16 rs3212018 Exon- 3'UTR 0.037 0.042 0.032 
28375 T>G rs3211956 3' flanking 0.011 0.000 0.021 
28507_28508 ins4 
 
3' flanking 0.016 0.000 0.032 
28509 A>T 
 
3' flanking 0.016 0.000 0.032 
28747 C>G 
 
3' flanking 0.011 0.022 0.000 
28947 G>A rs3211959 3' flanking 0.021 0.010 0.032 
28969_28974 del6 
 
3' flanking 0.016 0.010 0.021 
28971 A>G 
 
3' flanking 0.005 0.000 0.011 
29082 G>A 
 
3' flanking 0.043 0.043 0.043 
29186_29187 ins4 
 
3' flanking 0.021 0.031 0.011 
29281_29945 del665 
 
3' flanking 0.006 0.000 0.011 
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29344_29347 del4 
 
3' flanking 0.005 0.000 0.011 
29706 C>A 
 
3' flanking 0.011 0.000 0.022 
29815 G>A 
 
3' flanking 0.011 0.010 0.011 
29963 G>A 
 
3' flanking 0.016 0.021 0.011 
30040 C>G 
 























3.3 LD AND TAGGER ANALYSES OF CD36 VARIANTS 
SNPs that are lie close to one another along the same chromosome are often inherited together, 
also known as linkage disequilibrium (LD). These SNPS that are transmitted together can be 
grouped into haplotypes, and uniquely identifying “tag” SNPs can be used to identify these 
haplotypes. Tagger analysis can be used to identify these tagSNPs in a group of SNPs, which 
helps to reduce the number of SNPs needed for genotype screening.  
3.3.1 Non-Hispanic Whites 
LD and Tagger analysis of the 44 common variants (MAF ≥5%) found in NHWs using an r2 
cutoff of 0.9 identified 8 tagSNP bins. Strong pair wise LD was detected for common variants in 
NHWs. Table 14 summarizes the Tagger results with variants genotyped in our entire NHW 
population underlined, and Figure 6 shows the LD plot obtained by analysis. 
 
Table 14. Tagger results using Haploview of CD36 common variants in NHWs 
Bin Variants Included in Bin 
1 2521, 2996, 3157
2 
, 3991, 4366, 4648, 11890, 12132, 12143_12144del2, 
12272_12274del3, 13528_13530del3, 13973, 14455 
22296, 22749, 23463, 23533, 23689, 24426, 25580, 26512
3 




, 4993, 7167, 7854, 9473, 9534, 11741, 12919, 13936 
9794_9799del6, 10876, 13094, 13388 
5 4249, 14299 
6 9600, 13577 
7 19307_19335del29 





Figure 6. LD analysis for NHWs 
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3.3.2 Blacks 
LD and Tagger analysis of the 103 common variants (MAF ≥5%) found in Blacks using an r2 
cutoff of 0.9 identified 57 tagSNP bins. Table 15 summarizes the Tagger results with variants 




















Table 15. Tagger results using Haploview of CD36 common variants in Blacks 
 
Bin Variants Included in Bin 
1  106, 1021, 1848, 2162, 3412, 7430, 12998, 13758, 14081 
2  2389delT, 4990, 7988, 9786delA, 10381, 11554, 11684, 14299 
3  947_948del2, 2949_950insA , 2652, 4259, 4879, 14482 
4 22296, 22749, 23463, 23689, 24426 
5  3991, 12132, 12272_12274del3, 13973 
6 9794_9799del6, 13094, 13388 
7  18137delA, 18662, 19678 
8  8796, 9505, 9474 
9  1024, 3350delA, 8595 
10  2996, 3157 
11  2521, 4366 
12  17807_17813del7, 19386 
13 13528_13530del3, 14455 
14  24080, 25945 
15  25580, 29225 
16  7167, 13936 
17  9152delC, 11137delG 
18  12145, 12403 
19  3094 
20  9473 
21  20644 
22  15932 
23  4993 
24  14882, 15554_15557del3, 15975, 
25  19151 
26  16163 
27  7854 
28  12919 
29  7947 
30  28685 
31  12143_12144del2 
32  25025 
33  27003 
34  16040 
35  4648 
36  4249 
37  19810 
38  3714_3715del2 
39  7175 
40  19877 
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41  16568 
42  11741 
43  29894_29902del9 
44  23533 
45  14903 
46  26512 
47  4134 
48  2638 
49  22351 
50  1547 
51  17743 
52  11472 
53  18911 
54  9534 
55  9600 
56  13577 






Figure 7. LD analysis for Blacks 
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3.4 GENOTYPING OF IDENTIFIED VARIANTS IN THE ENTIRE NHW AND 
BLACK POPULATIONS 
3.4.1 Taqman SNP Genotyping 
We genotyped 18 variants in Blacks and 18 variants in NHWs using pre-made Taqman SNP 
Genotyping Assays to date. Genotyping call rates for a total of 19 assays (17 common to both 
populations) is listed in Table 16. 
 
Table 16. Genotyping call rates for TaqMan 
CD36 Reference 
SNP ID 
Position Location NWH (%) Black (%) 
rs3211822 3157 Intron 99.36 97.20 
rs3211842 7167 Intron 98.24 96.70 
rs3211881 13094 Intron 100.00 99.04 
rs1924 15932 Intron 99.20 98.34 
rs3211908 18463 Intron 99.84 96.57 
rs3173804 24426 Intron 99.84 98.48 
rs1527483 26076 Intron 98.72 98.73 
rs1405747 26512 Intron 99.04 98.60 
rs3211956 28375 Intron 98.88 99.11 
rs1334511  Intron* 98.72 97.59 
rs1537593  Intron* 99.04 97.46 
rs9641866  Intron 98.88 96.44 
rs1194182  Exon* 98.24 99.23 
rs17154155  Intron* 99.04 98.60 
rs10499858  Intron* -- 97.84 
rs1049654  Exon* 99.36 96.82 
rs1194181  Intron* 99.04 98.48 
rs4731642  Intron* 99.36 -- 
rs7755  Exon* 99.04 97.07 
* SNPS falling outside of our sequenced region 
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None of the variants in the NWH group deviated from HWE (p>0.05). In the Black 
population, one variant (rs3173804) slightly deviated from HWE (p=0.0212). This SNP was also 
found to be out of HWE in the SeattleSNPs database for their Caucasian population. For the 
variants screened using TaqMan assays, the LD analysis was repeated (shown in Figures 8 and 
9), and the LD patterns were similar to those observed in the high and low HDL populations used 
for sequencing.  
 
Color Scheme for r2      
r2 = 0    White 
0< r2 <1 Shades of Grey 
r2 =1 Black 
 





Color Scheme for r2      
r2 = 0    White 
0< r2 <1 Shades of Grey 
r2 =1 Black 
 




3.4.2 Association Analysis of the Variants Screened in the Entire NWH and Black 
Samples for their Effect on Plasma HDL Levels 
Tables 17 and 18 show the genotype counts, covariate adjusted mean HDL-C levels (for each 
genotype), and adjusted p-values for each variant screened in the entire NHW and Black sample 
populations, respectively. The model used for this analysis was either dominant or additive 
depending on the MAF. We did not find any p-values that would indicate association between 
any significant association with HDL-C levels for the variants screened to date in the entire 
NHW and Black samples. The genotyping of remaining variants is under way using either 

















Table 17.  Genotype distribution, mean HDL-C levels, and adjusted p-values for 18 
CD36 variants in NHWs 
 
Variant Males*     Females**     All***     
rs1049654_Add CC  (94) AC  (146) AA  (51) CC  (102) AC  (152) AA  (72) CC  (196) AC  (298) AA  (123) 
HDL-C Adjusted Mean ± 
SE 45.26±1.05 43.19±0.85 44.38±1.43 56.63±1.36 56.8±1.11 57.57±1.61 50.98±0.88 50.03±0.71 50.93±1.11 
p-value 0.447 
 
  0.7 
 
  0.769 
 
  






   GG  (276) GA/AA  (49) GG  (531) GA/AA  (84) 
HDL-C Adjusted Mean ± 
SE 43.94±0.64 44.54±1.72   56.41±0.82 59.13±1.95 50.20±0.53 51.94±1.34   
p-value 0.703 
 
  0.19 
 
  0.226 
 
  
                    
rs1194182_Add  GG  (89) CG  (150) CC  (48) GG  (100) CG  (155) CC  (68) GG  (189) CG  (305) CC  (116) 
HDL-C Adjusted Mean ± 
SE 45.63±1.08 42.95±0.83 45.49±1.47 56.65±1.37 56.85±1.1 56.47±1.67 51.15±0.89 49.97±0.70 50.72±1.14 
p-value 0.627 
 
  0.85 
 
  0.579 
 
  
                    
rs1334511_Dom  AA  (263) AG  (27)   AA  (288) AG  (35)   AA  (551) AG  (62)   
HDL-C Adjusted Mean ± 
SE 43.83±0.63 45.80±1.96   56.44±0.8 58.3±2.31   50.16±0.52 52.08±1.56   
p-value 0.319 
 
  0.41 
 
  0.201 
 
  
                    
rs1405747_Add  CC  (101) CA  (136) AA  (53) CC  (101) CA  (151) AA  (73) CC  (202) CA  (287) AA  (126) 
HDL-C Adjusted Mean ± 
SE 44.09±1.02 43.48±0.88 45.40±1.40 56.45±1.37 56.6±1.12 57.53±1.61 50.23±0.86 50.06±0.73 51.58±1.10 
p-value 0.493 
 
  0.63 
 
  0.365 
 
  
                    
rs1527483_Dom  GG  (263) GA  (25)   GG  (284) GA  (41)   GG  (547) GA  (66)   
HDL-C Adjusted Mean ± 
SE 44.09±0.63 42.34±2.04   56.94±0.81 56.26±2.14 50.50±0.52 49.71±1.51   
p-value 0.528 
 
  0.94 
 
  0.892 
 
  
                    
rs1537593_Dom  CC  (255) CT/TT  (36) CC  (273) CT/TT  (51) CC  (528) CT/TT  (87) 
HDL-C Adjusted Mean ± 
SE 43.93±0.64 44.31±1.70   56.75±0.83 58.1±1.92   50.36±0.53 51.30±1.32   
p-value 0.778 
 
  0.47 
 
  0.465 
 
  
                    
rs17154155_Add  GG  (98) GT  (147) TT  (45) GG  (113) GT  (150) TT  (62) GG  (211) GT  (297) TT  (107) 
HDL-C Adjusted Mean ± 
SE 44.88±1.03 43.42±0.85 44.44±1.53 56.95±1.29 56.46±1.12 57.46±1.74 50.94±0.85 50.01±0.71 50.79±1.19 
p-value 0.676 
 
  0.97 
 
  0.689 
 
  
                    
rs1924_Dom  GG  (263) GA/AA  (27) GG  (291) GA/AA  (35) GG  (554) GA/AA  (62) 
HDL-C Adjusted Mean ± 
SE 43.84±0.63 45.69±1.96   56.77±0.8 57.77±2.32 50.34±0.52 51.57±1.56   
p-value 0.359 
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rs3173804_Add  TT  (101) TA  (138) AA  (54) TT  (103) TA  (151) AA  (73) TT  (204) TA  (289) AA  (127) 
HDL-C Adjusted Mean ± 
SE 44.11±1.01 43.41±0.87 45.52±1.39 56.58±1.35 56.66±1.12 57.53±1.61 50.31±0.86 50.04±0.72 51.65±1.09 
p-value 0.459 
 
  0.68 
 
  0.363 
 
  
                    
rs3211822_Add  GG  (111) GA  (140) AA  (42) GG  (118) GA  (153) AA  (53) GG  (229) GA  (293) AA  (95) 
HDL-C Adjusted Mean ± 
SE 45.02±0.97 43.57±0.86 43.03±1.57 56.84±1.26 56.46±1.11 57.88±1.88 50.95±0.81 50.04±0.72 50.53±1.26 
p-value 0.215 
 
  0.8 
 
  0.501 
 
  
                    
rs3211842_Add  GG  (100) GA  (138) AA  (48) GG  (113) GA  (146) AA  (65) GG  (213) GA  (284) AA  (113) 
HDL-C Adjusted Mean ± 
SE 44.81±1.03 43.93±0.88 43.24±1.48 56.35±1.29 56.65±1.13 58.2±1.7 50.61±0.85 50.30±0.73 50.87±1.16 
p-value 0.398 
 
  0.43 
 
  0.993 
 
  
                    
rs3211881_Dom  AA  (256) AG/GG  (37) AA  (293) AG/GG  (35) AA  (549) AG/GG  (72) 
HDL-C Adjusted Mean ± 
SE 43.65±0.63 46.75±1.67   57.27±0.79 53.19±2.31 50.52±0.52 50.04±1.45   
p-value 0.19 
 
  0.14 
 
  0.875 
 
  
                    
rs3211908_Dom  CC  (277) CT  (16)   CC  (300) CT  (27)   CC  (577) CT  (43)   
HDL-C Adjusted Mean ± 
SE 44.05±0.61 43.90±2.55   56.87±0.79 56.09±2.63 50.49±0.51 49.86±1.88   
p-value 0.92 
 
  0.89 
 
  0.933 
 
  
                    
rs3211956_Dom  TT  (264) TG/GG  (26) TT  (280) TG/GG  (44) TT  (544) TG/GG  (68) 
HDL-C Adjusted Mean ± 
SE 44.17±0.63 42.88±2.00   57.06±0.82 55.71±2.07 50.60±0.53 49.60±1.47   
p-value 0.677 
 
  0.82 
 
  0.804 
 
  
                    
rs4731642_Add  AA  (77) AG  (142) GG  (72) AA  (93) AG  (163) GG  (70) AA  (170) AG  (305) GG  (142) 
HDL-C Adjusted Mean ± 
SE 44.65±1.16 43.44±0.86 44.89±1.20 56.69±1.42 56.37±1.07 57.82±1.64 50.62±0.94 49.90±0.70 51.48±1.03 
p-value 0.809 
 
  0.65 
 
  0.559 
 
  
                    
rs7755_Add  GG  (98) GA  (138) AA  (54) GG  (102) GA  (151) AA  (72) GG  (200) GA  (289) AA  (126) 
HDL-C Adjusted Mean ± 
SE 44.15±1.03 43.48±0.87 45.53±1.39 56.67±1.36 56.83±1.12 57.4±1.62 50.37±0.87 50.16±0.72 51.58±1.10 
p-value 0.457 
 
  0.74 
 
  0.408 
 
  
                    
rs9641866_Dom  TT  (262) TA/AA  (27) TT  (291) TA/AA  (33) TT  (553) TA/AA  (60) 
HDL-C Adjusted Mean ± 
SE 43.81±0.63 44.90±1.96   56.74±0.8 58.27±2.39 50.31±0.52 51.56±1.59   
p-value 0.59     0.52     0.418     
 
* Mean and p-values adjusted for BMI 
** Mean and p-values adjusted for BMI, age, and smoking 




Table 18. Genotype distribution, mean HDL-C levels, and adjusted p-values for 18 
CD36 variants in Blacks 
 
Variant Males*     Females**     All***     
rs1049654_Add  AA (208) AC (202) CC (51) AA (96) AC (140) CC (41) AA (304) AC (341) CC (92) 
HDL-C Adjusted Mean 
± SD 47.20±0.84 45.43±0.85 46.00±1.70 50.68±1.26 52.02±1.04 48.18±1.94 48.59±0.70 48.05±0.66 46.38±1.28 
p-value 0.2 
 
  0.5176 
 
  0.127 
 
  
                    
rs10499858_Add  AA (304) AG (151) GG (13) AA (188) AG (76) GG (14) AA (491) AG (227) GG (27) 
HDL-C Adjusted Mean 
± SD 46.34±0.69 45.38±0.99 45.18±3.37 51.41±0.91 50.79±1.44 47.60±3.34 48.26±0.55 47.26±0.82 46.52±2.37 
p-value 0.46 
 
  0.4037 
 
  0.3066 
 
  
                    
rs1194181_Add  AA (153) AG (224) GG (95) AA (86) AG (130) GG (62) AA (239) AG (354) GG (156) 
HDL-C Adjusted Mean 
± SD 46.50±0.99 45.56±0.81 47.00±1.25 50.32±1.33 52.20±1.08 50.46±1.57 48.00±0.80 48.02±0.65 48.20±0.98 
p-value 0.99 
 
  0.8113 
 
  0.949 
 
  
                    
rs1194182_Add  CC (313) CG (149) GG (13) CC (174) CG (94) GG (13) CC (487) CG (242) GG (26) 
HDL-C Adjusted Mean 
± SD 46.44±0.69 45.44±1.00 45.69±3.38 51.44±0.95 50.60±1.30 52.21±3.48 48.27±0.56 47.46±0.79 48.27±2.42 
p-value 0.35 
 
  0.8519 
 
  0.462583 
 
  
                    
rs1334511_Add  AA (262) AG (182) GG (22) AA (168) AG (92) GG (17) AA (429) AG (274) GG (39) 
HDL-C Adjusted Mean 
± SD 46.73±0.75 44.93±0.90 48.94±2.59 52.13±0.97 49.89±1.31 51.78±3.06 48.76±0.60 46.80±0.75 49.90±2.00 
p-value 0.51 
 
  0.3506 
 
  0.277 
 
  
                    
rs1405747_Add  CC (315) CA (141) AA (14) CC (179) CA (94) AA (8) CC (493) CA (235) AA (22) 
HDL-C Adjusted Mean 
± SD 46.70±0.68 44.71±1.02 49.31±3.23 51.24±0.94 51.06±1.30 49.70±4.45 48.39±0.55 47.17±0.80 49.67±2.62 
p-value 0.33 
 
  0.7915 
 
  0.4023 
 
  
                    
rs1527483_Dom  GG (464) GA (9)   GG (272) GA (7)   GG (735) GA (16)   
HDL-C Adjusted Mean 
± SD 46.19±0.56 44.56±4.05   51.34±0.74 48.61±4.63   48.11±0.45 46.14±3.05   
p-value 0.64 
 
  0.5346 
 
  0.4876 
 
  
                    
rs1537593_Add  CC (170) CT (241) TT (53) CC (104) CT (133) TT (42) CC (273) CT (374) TT (95) 
HDL-C Adjusted Mean 
± SD 46.78±0.93 45.71±0.78 44.78±1.67 52.34±1.22 50.22±1.08 52.45±1.92 48.84±0.74 47.46±0.64 47.85±1.27 
p-value 0.28 
 
  0.685 
 
  0.3076 
 
  
                    
rs17154155_Add  GG (141) GT (250) TT (80) GG (96) GT (128) TT (56) GG (237) GT (377) TT (136) 
HDL-C Adjusted Mean 
± SD 47.09±1.02 45.13±0.77 47.87±1.35 50.77±1.29 51.80±1.11 49.70±1.68 48.59±0.80 47.46±0.63 48.47±1.06 
p-value 0.97 
 
  0.7829 
 
  0.7825 
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Table 18 Continued 
rs1924_Add  GG (264) GA (173) AA (30) GG (168) GA (96) AA (19) GG (431) GA (269) AA (49) 
HDL-C Adjusted Mean 
± SD 46.26±0.75 45.57±0.93 47.21±2.22 51.95±0.97 49.87±1.28 50.43±2.90 48.41±0.59 47.27±0.75 48.35±1.77 
p-value 0.96 
 
  0.243 
 
  0.4786 
 
  
                    
rs3173804_Add  TT (394) TA (68) AA (10) TT (206) TA (65) AA (7) TT (599) TA (133) AA (17) 
HDL-C Adjusted Mean 
± SD 46.51±0.61 44.04±1.48 45.49±3.85 51.60±0.86 49.96±1.54 60.43±4.68 48.39±0.50 46.36±1.07 52.22±2.98 
p-value 0.16 
 
  0.8192 
 
  0.4913 
 
  
                    
rs3211822_Add  GG (141) GA (233) AA (88) GG (102) GA (130) AA (46) GG (243) GA (362) AA (134) 
HDL-C Adjusted Mean 
± SD 46.60±1.02 44.54±0.79 48.41±1.29 50.61±1.25 51.66±1.10 51.05±1.86 48.03±0.79 47.22±0.65 49.51±1.06 
p-value 0.46 
 
  0.731 
 
  0.4044 
 
  
                    
rs3211842_Add  GG (214) GA (204) AA (42) GG (131) GA (123) AA (22) GG (345) GA (326) AA (64) 
HDL-C Adjusted Mean 
± SD 45.93±0.82 45.90±0.84 46.92±1.86 51.08±1.10 51.44±1.13 48.38±2.67 47.85±0.66 48.00±0.68 47.70±1.53 
p-value 0.59 
 
  0.6202 
 
  0.823199 
 
  
                    
rs3211881_Dom  AA (411) 
AG/GG 
(62)   AA (236) 
AG/GG 
(47)   AA (647) AG/GG (108) 
HDL-C Adjusted Mean 
± SD 46.29±0.60 44.95±1.54   51.25±0.81 50.63±1.83   48.11±0.48 47.40±1.18   
p-value 0.36 
 
  0.8942 
 
  0.6092 
 
  
                    
rs3211908_Dom  CC (453) CT (6)   CC (270) CT (7)   CC (722) CT (13)   
HDL-C Adjusted Mean 
± SD 46.15±0.57 41.23±4.98   51.38±0.76 47.73±4.74   48.13±0.46 43.75±3.42   
p-value 0.28 
 
  0.4576 
 
  0.188402 
 
  
                    
rs3211956_Dom  TT (467) TG (6)   TT (276) TG (6)   TT (742) TG (12)   
HDL-C Adjusted Mean 
± SD 46.14±0.56 41.21±4.96   51.31±0.75 46.04±5.11   48.08±0.45 43.15±3.55   
p-value 0.27 
 
  0.2993 
 
  0.1484 
 
  
                    
rs7755_Add  GG (374) GA (87) AA (6) GG (192) GA (75) AA (6) GG (565) GA (162) AA (12) 
HDL-C Adjusted Mean 
± SD 46.46±0.63 44.65±1.31 48.09±4.99 51.59±0.90 49.92±1.45 55.25±5.08 48.35±0.52 46.66±0.97 51.17±3.55 
p-value 0.35 
 
  0.6729 
 
  0.3677 
 
  
                    
rs9641866_Add  TT (263) TA (178) AA (23) TT (154) TA (101) AA (16) TT (416) TA (279) AA (39) 
HDL-C Adjusted Mean 
± SD 47.12±0.74 44.02±0.90 47.43±2.50 51.05±0.98 52.38±1.21 45.52±3.01 48.60±0.59 47.09±0.73 46.36±1.94 
p-value 0.1     0.5947     0.0947     
 
* Mean and p-values adjusted for waist measurement 
** Mean and p-values adjusted for waist measurement, smoking, and exercise 




4.0  DISCUSSION 
CD36 is a class B scavenger receptor which is known to act as a receptor for FA, LDL-C, HDL-
C, and VLDL. Mutations in the CD36 gene have been found to be associated with platelet 
glycoprotein IV deficiency, which is an autosomal recessive condition. Patients with this 
deficiency have been found to have an altered lipid profile, with elevated LDL-C and TG with 
but reduced HDL-C levels (Miyaoka et al., 2001 and Yanai et al., 2000). A list of the seven 
mutations reported to date in CD36 causing the protein deficiency is located in Online Mendelian 
Inheritance in Man (http://www.ncbi.nlm.nih.gov/omim), one of which (rs3211938, T>G) was 
identified in this study.  
In addition to this association with a Mendelian disorder, further studies are needed to 
determine the associations of rare and common variants in CD36 with complex genetic 
traits/diseases. Some studies have hypothesized atheroprotective roles for CD36 (Nagy et al., 
1998; Tontonoz et al., 1998; Masuda and Ross, 1990; Endemenn et al., 1993), however, other 
studies have implicated CD36 in alterations in the lipid profile that may increase risk for CVD 
(Ma et al., 2004). To date, GWA studies have not identified CD36 as a major gene associated 
with HDL levels. However, several genomewide linkage scans have linked a region of 
chromosome 7 (7q11.2–7q21.11) with components of the Metabolic Syndrome, including insulin 
resistance and dyslipidemia (Love-Gregory et al., 2008). This region harbors the CD36 gene, 
which has prompted researchers to further investigate the relationship of common SNPs and 
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haplotypes with the lipid profile and other components of MetS (Love-Gregory et al., 2008; 
Madden et al., 2008; Goyenechea et al., 2008). The rare variant hypothesis has not been tested to 
our knowledge, and the only study that has sequenced the CD36 gene did not investigate 
genotype-phenotype correlations (Gelhaus et al., 2001). In order to fully understand the 
correlation of CD36 with the lipid profile, HDL-C in particular, deep sequencing of this gene is 
the next step to clarify its association with HDL-C levels and expand the catalogue of variants 
known to be responsible for variation in lipid levels. 
In our study, we evaluated the role of CD36 genetic variation by resequencing the entire 
gene (covering all coding exons and their flanking regions as well as introns) in a subset of 
samples from healthy individuals with HDL-C levels in the upper and lower 5th percentiles. The 
portion of the CD36 gene sequenced in our study was ~30kb in length. There is an alternative 
splice-form that was not sequenced in this study, which includes additional non-coding exons 
and alternative introns. This alternative splice form spans ~79kb, which is ~49kb longer than the 
portion that we screened. The purpose was to catalogue the rare and common variation in this 
gene by using those individuals with extreme HDL-C levels, followed by comprehensive 
analysis of identified variants to test both the “common variant-common disease” and “rare 
variant-common disease” hypotheses. 
4.1 COMPARISON OF OUR STUDY RESULTS WITH SEATTLESNPS DATABASE 
We compared our sequencing data with one published study (Gelhaus et al., 2001) along with the 
publicly available SeattleSNPs data. Gelhaus et al. (2001) resequenced  the promoter region up 
to -253bp relative to the transcriptional start site and all 15 exons in 12 individuals from Ghana, 
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who were selected by their spleen size and hypothesized susceptibility to malaria. Gelhaus et al. 
(2001) identified 24 variants, with 5 of those variants affecting the amino acid sequence. Among 
these 5 variants they found to affect amino acid sequence, only 1 (1264) was also detected in our 
study.  
SeattleSNPs also completely sequenced the CD36 gene  in 24 and 23 randomly selected 
African-American and European adults, respectively that were unselected for HDL-C levels. A 
total of 95 African adults and 95 American NHWs, selected based on their extreme HDL-C 
levels (in the upper and lower 5th percentiles), were sequenced in this study. We noted several 
differences between the data we obtained through resequencing and the information available in 
the SeattleSNPs database which are likely due to differences in sample selection criteria and 
sample sizes. There is a greater likelihood of admixture with other ethnic groups in African 
American samples (used by SeattleSNPs) when compared to African samples (used in our 
study), which may be responsible for some sequence differences. Any variants identified in our 
study but not reported in the SeattleSNPs database may be a result of our larger sample size and 
selection factors, or they may be a result of their association with HDL-C levels. 
All variant and exon locations are given using SeattleSNPs database nomenclature. A 
total of 187 variants were reported in the SeattleSNPs database, with 115 have a MAF<5% and 
72 having a MAF≥5%.  A total of 343 variants were identified in this study, however we do not 
have combined population frequency data so we cannot break down the number of variants with 
a MAF<5% and a MAF≥5% for our combined populations. A total of 80 sequence variants were 
reported in the SeattleSNPs database for the European population (19 with MAF<5% and 61 
with MAF≥5%). By comparison, a total of 131 sequence variants were identified in this study in 
NHWs (87 with MAF<5% and 44 with MAF≥5%) . A total of 167 sequence variants were 
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reported in the SeattleSNPs database for the African-American population (69 with MAF<5% 
and 98 with MAF≥5%) , and a total of 281 variants were identified in this study (178 with 
MAF<5% and 103 with MAF≥5%). Aside from the variants at position 20028 and 27418 (one of 
which we believe may be a sequencing artifact in the SeattleSNPs sequence), we found all 
common variants reported by the SeattleSNPs database for the African-American and European 
populations. However, several rare variants reported in their study were not identified in our 
study and vice versa, and we have several suspicious variants identified in our study but not 
present in the SeattleSNPs database that need to be confirmed with other methods. We also 
found some common variants that were not reported by SeattleSNPs, which may be due to a 
sequencing gap from 19590-19849 that we did not have. 
Five variants affected the coding sequence were reported in the SeattleSNPs database 
data, including 10423del2 (frameshift, exon 3), 10425delG (frameshift, exon 3), 16983G>A 
(prolineproline, exon 5), 25025T>G (tyrosinestop, exon 9), and 25054insAAG (premature 
protein truncation, exon 9) of which 10423del2 and 25025insT>G were present only in the 
African American population, 16983G>A and 25054insAAG were present only in the European 
population, and 10425delG was present in both the African American and European populations. 
By comparison, a total of 12 coding variants were identified in our study, including 10423del2 
(frameshift, exon 3), 10465G>A (tryptophanstop), 14701del592 (deletion of exon 4), 
16983G>A (prolineproline, exon 5), 16986C>A (tyrosinestop, exon 5), 25025T>G 
(tyrosinestop, exon 9), 25048G>T (cysteinephenylalanine, exon 9), 25849T>G 
(tyrosineaspartic acid, exon 10), 25850A>T (tyrosinephenylalanine, exon 10), 26669G>T 
(glycinevaline, exon 11), 26692C>T (argininetryptophan, exon 11), and 27309T>C 
(tyrosinehistidine, exon 12) of which 16983, 26669 and 27309  were present only in NHWs 
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and  10423, 10465, 14701del592, 16986, 25025, 25048, 25849, 25850, and 26692 were present 
only in Blacks. Nine of the coding variants identified in our study were non-synonymous, one 
was frameshift, and one resulted in the total deletion of exon 4. Of the five variants affecting the 
coding sequence reported in the SeattleSNPs database, we identified three in our study 
(10423del2, 16983G>A, and 25025T>G). 
Altogether, we identified a total of 168 variants in our sequencing sample that were 
previously unreported in the SeattleSNPs database; 53 were present in NHWs and 138 were 
present in Blacks (listed in Tables 8 and 9 in sections 3.1.1 and 3.1.2, respectively). The 
identification of these variants not reported in the SeattleSNPs database could be due to our 
larger sample size allowing a higher detection rate, or it could be due to their association with 
extreme HDL-C levels (these variants may be unique to the extreme HDL-C groups).  
The SeattleSNPs database reported 20 variants unique to their European population and 
107 variants unique to their African-American population, while we identified 61 variants unique 
to our NHW population and 212 variants unique to our African population. As in the 
SeattleSNPs database, our study also identified a higher number of sequence variants in Blacks 
versus NHWs for the CD36 gene.  
We also identified a large number of indels in the CD36 gene in our sequencing sample. 
Levy et al. (2007) sequenced the human genome and reported ~290,000 indels spanning 3 billion 
bases, while Sjodin et al (2010) found 3,850 indels spanning 20.3Mb. Based on these numbers, 
we would expect to find ~3-5.6 indels located in the 30kb that we sequenced in our study. 
However, we found 46 indels, which is much higher than expected, indicating that CD36 is a 
gene enriched with indel polymorphisms. In addition to indels, we also identified two exonic 
stop codon polymorphisms: 10465 (tryptophanstop) and 25025 (tyrosinestop). Both were 
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found only in our Black population, and 25025 was relatively common with a MAF of 0.226. 
250250 (rs3211938) is also one of the seven variants reported in OMIN to cause platelet 
glycoprotein IV deficiency. Aitman et al. (2000) reported this mutation as one of the most 
common in the African population he studied. Fry et al. (2009) have argued that this SNP might 
have recently undergone positive selection in certain African populations, possibly due to an 
association of the minor allele (G) with less severe malaria. It is intriguing that deleterious 
variants that interrupt the transcription of CD36, such as the rs3211938 variant identified in our 
Black population, do not show a severe phenotype and undergo positive selection, possibly due 
to some advantage caused by resistance to certain infections such as malaria. 
4.2 DISTRIBUTION OF CD36 VARIANTS IN HIGH AND LOW HDL-
CHOLESTEROL GROUPS 
We performed a preliminary analysis of the variants identified by resequencing the CD36 gene. 
In NHWs, we observed 21 relatively uncommon or rare variants (MAF<5%) present only in the 
low HDL-C group, and 25 relatively uncommon or rare variants present only in the high HDL-C 
group. Eighty-six variants were present in both high HDL-C and low HDL-C groups. For 
NHWs: 14 out of 47 (29.8%) individuals with high HDL-C had more than two rare variants 
versus 16 out of 48 (33.3%) individuals with low HDL-C; and 11 out of 47 (23.4%) individuals 
with high HDL-C had more than three rare variants versus 6 out of 48 (12.5%) individuals with 
low HDL-C:, and 8 out of 47 (17.0%) individuals with high HDL-C had more than four rare 
variants versus 5 out of 48 (10.4%) individuals with low HDL-C. In Blacks, we observed 59 
relatively uncommon or rare variants (MAF<5%) present only in the low HDL-C group, and 32 
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relatively uncommon or rare variants present only in the high HDL-C groups. One hundred and 
ninety variants were present in both high HDL-C and low HDL-C groups For Blacks: 32 out of 
48 (66.7%) individuals with high HDL-C had more than two rare variants versus 34 out of 47 
(72.3%) individuals with low HDL-C; 28 out of 48 (58.3%) individuals with high HDL-C had 
more than three rare variants versus 30 out of 47 (63.8%) individuals with low HDL-C; 22 out of 
48(45.8%) individuals with high HDL-C had more than four rare variants versus 24 out of 47 
(51.1%) individuals with low HDL-C. We observed that in NHWs, the differences in percentage 
of rare variants in high and low HDL-C groups increased as the variant cut-off increased, with 
there being more individuals in the high HDL-C group with rare variants when compared to 
individuals in the low HDL-C. This does not seem suggestive of the “rare variant” hypothesis 
proposed by Cohen et al. (2004), which suggests that an excess of sequence variants in subjects 
with low HDL-C reflects an accumulation of damaging alleles in this group. We also did not 
observe any differences in the number of rare variants in individuals with high HDL-C versus 
low HDL-C for our Black population.  
Statistically significant differences in MAF between the low and high HDL-C groups 
were observed for some common variants (MAF≥5%) in the sequencing data from a small 
sample, but have not been confirmed yet by genotyping in the entire NHW and Black 
populations. These variants include: 4249C>T/rs3211830 (increase, p=0.047), 
13094T>A/rs3211879 (decrease, p=0.040), and 14299A>G/rs3173799 (increase, p=0.047) in 
NHWs; 16568A>G/rs3211899 (increase, p=0.022) in Blacks. In the NHW population, 4249C>T 
and 14299A>G were found to be linked to one another in LD analysis, while 13094 was located 
in a different bin. Out of these four variants that demonstrated significant differences in MAF 
between the low and high HDL-C groups, none have been reported in the literature as being 
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studied for an association with HDL-C. Thirteen of the common variants had a p-value of 
between 5-10%, which may be statistically significant due to the small sample size.  
We used our sequencing data to compare our results with several SNPs that were reported 
in to be associated with HDL-C levels in the literature but not yet genotyped in our entire 
population: rs3211810, rs3211849, rs1054516, rs3173798, rs3211868, rs3211870, rs1358337, 
rs3211938, and rs3211913 (Love-Gregory et al., 2008). Table 19 is a summary of those SNPs 
whose minor allele is reported to be associated with increase in HDL-C levels. All minor allele 
associations are in the context of the minor allele in our study. Even though none of the p-values 
we obtained in our sequencing samples were significant, the MAFs obtained in three of our 
sequencing samples supported the associations reported by Love-Gregory et al. (2008): 
rs3211849, rs1358337, and rs3211913. The directions of the reported associations in Love-
Gregory et al. (2008) along with the MAF obtained for both populations in our sequencing 










Table 19. Variants in literature reported to have an association with HDL-C (Love-





With the minor 
allele 











0.489 0.489 0.415 0.469 
rs1358337 Decrease 
p=0.00066 
0.447 0.479 0.415 0.458 
rs1054516 Increase 
p=0.003 
0.250 0.307 0.420 0.479 
rs3211913 Increase 
p=0.039 
0.545 0.446 0.01 0.00 
rs3211810 Decrease 
p=0.044 
0.156 0.138 -- -- 
rs3211870 Decrease 
p=0.0079 
0.402 0.340 0.415 0.546 
 
rs3211938 Increase  
p=0.00018 
0.234 0.217 -- -- 
rs3173798 Decrease 
p=0.033 
0.208 0.17 0.074 0.021 
rs3211868 Decrease 
p=0.011 






4.3 COMPARISON OF OUR STUDY RESULTS WITH PUBLISHED LITERATURE 
So far we have screened a total of 19 variants have been screened in the  entire NHW (n=623) 
and Black (n=788) populations with TaqMan SNP genotyping assays (Table 6). No association 
with fasting HDL-C levels was observed either the NHW or Black samples for these 19 variants. 
Nine out of these 19 variants genotyped in our study were investigated in the literature including: 
rs1334511, rs1049654, rs3211822, rs3211842, rs3173804, rs7755, rs1924, rs1527483, rs1537593 
(Ma et al., 2004; Love-Gregory et al., 2008). The literature reported no association of SNPs 
rs1924, rs1527483, rs1537593, rs1334511, rs3211822, rs3173804, and rs7755 with HDL-C 
levels, and our study confirmed these findings. Reports of the association of rs1049654 with 
HDL-C levels were inconsistent, with Ma et al (2004) reporting no association with HDL-C in 
Caucasians, and Love-Gregory (2008) reporting an increase in HDL-C levels associated with the 
minor allele (C) in African-Americans. Our results were consistent with Ma et al. (2004) for 
rs1049654, and did not support the association reported by Love-Gregory et al. (2008). Love-
Gregory also reported that rs3211842 was associated with a decrease in HDL-C levels, but our 
data did not support that conclusion (2008). This comparison of SNPs genotyped in our entire 
samples so far with the published literature is shown in Table 20, indicating whether the study 
found a statistically significant association with an increase in HDL-C, a statistically significant 
association with a decrease in HDL-C, or no statistically significant association with HDL-C 





Table 20. Comparison of our TaqMan genotyping results with published literature. 
 
SNP ID Study 
Ma et al. (2004) Love-Gregory et al. (2008) 
 
Our Study 
585 Caucasians, male and 
female 
2020 African Americans: 737 
males, 1283 females 
95 NHW, 95 Black 
rs1049654 No association Minor allele with high HDL-C 
(p= 0.0028) 
No association 
rs1924 No association -- No Association 
rs7755 No association No association No Association 
rs1527483 No association -- No Association 
rs1537593 No association -- No Association 
rs3211822 -- No Association No Association 
rs3173804 -- No Association No Association 
rs1334511 -- No Association No Association 




 There are several SNPs that have been reported as being associated with HDL-C levels in 
the literature that we haven’t genotyped and do not have sequencing data because they fall in the 
region that is ~44 kb 5’ further upstream (*) or ~3kb 3’ further downstream (**) from our 
targeted region for sequencing, corresponding to the largest CD36 sequence available in 
Genbank (NC_000007.13) that harbors additional alternative noncoding exons. These SNPs are: 
rs10499859, rs9784998, 13438282, rs3211909, and rs13246513.  
4.4 CONCLUSIONS AND FURTHER DIRECTIONS 
Heart disease is a major public health concern, with over 16 million people living with CHD, and 
80 million people living with CVD. One risk factor for these health problems is decreased HDL-
C levels. Although the reported GWA studies have not implicated CD36 as a main candidate 
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gene affected HDL-C levels, recent studies have implicated the locus on chromosome 7 
harboring CD36 with components of MetS, including HDL-C. Few studies have been done 
looking at common SNPs and their association with HDL-C levels and the data from these 
studies has been inconsistent. This lack of consistency prompts further studies to elucidate the 
role of CD36. Also, to date there have been no efforts to deeply sequence the CD36 gene to 
identify both common and rare variants. We undertook this study in order to investigate the 
reported associations of CD36 with HDL-C levels, as well as develop a comprehensive catalogue 
of CD36 variation through deep sequencing.  
We recently completed our sequencing, and we’ll be using this data to complete 
screening of all common TagSNPs and validate the rare variants that we have identified. 
Completion of this comprehensive screening will reveal the extent to which common and rare 
variants in CD36 contribute to HDL-C regulation in NHWs and Blacks. However, final 
determination of causative effects will involve performing functional studies.  
Preliminary analysis of our data did not confirm any previous associations with CD36 
and HDL-C levels through TaqMan genotyping analysis; however, our sequencing data did 
support one association with a marginally significant p-value. We identified several common 
variants with significant MAF differences between our high and low HDL-C levels, and 
additional genotyping of these variants in our entire populations needs to be completed in order 
to determine the validity of these associations. Confirmation of these findings is necessary by 
other groups because we are the first to undergo such a comprehensive study. Additional studies 
of CD36 with larger population sizes are needed as well to analyze variants that may only have a 
small effect of HDL-C levels, and further studies of rare variation in this gene are required to 
better understand the genetics of HDL-C cholesterol in relation to the rare allele hypothesis.  
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